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ABSTRACT
Mesoporous silica nanoparticle (MSNP) supported-lipid bilayers, termed
‘protocells,’ represent a potentially transformative class of therapeutic and
theranostic delivery vehicles. The field of targeted drug delivery poses
considerable challenges that cannot be addressed with a single ‘magic bullet’.
Consequently, the protocell has been designed as a modular platform composed
of interchangeable biocompatible components. The mesoporous silica core can
have variable size and shape to direct biodistribution and controlled pore size
and surface chemistry to accommodate diverse cargos. The encapsulating
supported lipid bilayer can be modified with targeting and trafficking ligands as
well as polyethylene glycol (PEG) to effect selective binding, endosomal escape
of cargo, drug efflux prevention, and potent therapeutic delivery, while
maintaining in vivo colloidal stability. Many nanocarrier cancer therapeutics
currently under development, as well as those used in the clinical setting, rely
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upon the enhanced permeability and retention (EPR) effect to passively
accumulate in the tumor microenvironment and kill cancer cells. In leukemia,
where leukemogenic stem cells and their progeny circulate within the peripheral
blood or bone marrow, the EPR effect may not be operative. Thus, for leukemia
therapeutics, it is essential to target and bind individual circulating cells. Here,
we investigate protocells, an emerging class of nanocarriers, and establish the
synthesis conditions and lipid bilayer composition needed to achieve highly
monodisperse protocells that remain stable in complex media as assessed in
vitro by dynamic light scattering and cryo-electron microscopy and ex ovo by
direct imaging within a chick chorioallantoic membrane (CAM) model. We show
that for vesicle fusion conditions where the lipid surface area exceeds the
external surface area of the MSNP and the ionic strength exceeds 20 mM, we
form monosized protocells (polydispersity index < 0.1) on MSNP cores with
varying size, shape, and pore size, whose conformal zwitterionic supported lipid
bilayer confers excellent stability as judged by circulation in the CAM and minimal
opsonization in vivo in a mouse model. Having established protocell formulations
that are stable colloids, we further modified them with anti-EGFR antibodies as
targeting agents and re-verified their monodispersity and stability. Then using
intravital imaging in the CAM we directly observed in real time the progression of
selective targeting of individual leukemia cells (using the established REH
leukemia cell line transduced with EGFR) and delivery of a model cargo. Overall
we have established the effectiveness of the protocell platform for individual cell
targeting and delivery needed for leukemia and other disseminated disease.
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GOALS AND SUMMARY OF CONTRIBUTIONS
Acute lymphoblastic leukemia (ALL), is a disease characterized by
malignant lymphocyte proliferation resulting in the suppression of normal
hematopoiesis, and is the most common type of childhood cancer, generally
occurring between the ages of 3 and 5. Treatment of pediatric leukemias have
been described as one of the true success stories of modern medicine, with
current treatment strategies resulting in survival rates exceeding 90 %. 1 The
success of ALL treatment has come through the progressive increase in
chemotherapy and the development of a risk classification scheme to identify
children to more dose-intensive regimes based on calculated probability of
relapse based on a specific set of identified prognostic factors including age and
white blood cell counts.2 Regardless of these advances, standard treatment
methods lead to complications due to the non-specific action of
chemotherapeutic agents on healthy normal cells.3 In addition, the ~ 10 % of
children that do not respond to therapy, or those who relapse, have poor
prognostic outcomes despite efforts to intensify therapy including stem cell
transplantation.4-6 Next generation therapies must be developed to improve
survival rates and quality of life. The pharmacological properties of traditional
chemotherapeutics can be improved through targeted delivery using
nanocarriers.7-9 Passive targeting strategies, utilizing the enhanced permeability
and retention (EPR) effect,10 whereby the permeability of the tumor vasculature
can direct the accumulation of nanoparticles, have overcome many of the
problems associated with ‘free’ drugs, however they still lack cell-specific
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interactions which can result in off-target effects.11 More importantly, not all
tumors exhibit an EPR effect; for example, in leukemia, leukemogenic stem cells
and their progeny circulate within the peripheral blood or bone marrow, thus the
EPR effect may not be operative.12 The ability to target, bind, internalize, and
delivery therapeutic cargo to individual circulating cells is critical to the future of
leukemia treatment.
Early generation (i.e. polydisperse) mesoporous silica nanoparticlesupported lipid bilayers (protocells) displayed multiple promising characteristics
with enhanced efficacy in vitro relative to liposome formulations alone, including
highly specific and efficient delivery of multiple classes and combinations of
cargos to several cell types.9, 13, 14 However, the polydispersity of the first
generation protocell severely limited the in vivo utility. Therefore, the principal
goal of my graduate work was to develop, characterize, and optimize an in vivo
stable nanocarrier platform capable of therapeutic delivery to individual leukemia
cells with a high degree of selectivity and minimal side-effects, enabling a major
step forward in leukemia treatment. To achieve this goal, I needed a platform
that could simultaneously address the numerous requirements of targeted
delivery, including cell specificity, nanoparticle stability, effective cargo capacity,
multicomponent delivery, biocompatibility, size/shape control, prolonged
circulation, and immune evasion. Although the majority of protocell studies
conducted had reported in vitro efficacy,13-15 more recently, reports had shown
promising in vivo results, where passive and active targeting to solid tumors via
the EPR effect had been demonstrated.16-19 Prior to the work reported in my
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dissertation, the targeting of individual cells in vivo or in living systems had yet to
be reported, and there had been no direct observations/determinations of in vivo
colloidal stability.
The work detailed in Chapter 1 and Chapter 6, was published as a review
article, Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid
Bilayers for Drug Delivery, in the scientific journal Small. As the co-first author, I
shared the majority of the literature research, writing, and revisions of this review
equally with Dr. Kimberly Butler. Dr. Christophe Theron, helped research
protocell targeting chemistries, and Dr. C. Jeffrey Brinker assisted in manuscript
writing, review, and approval.
The work detailed in Chapters 2 – 6, was published as a research article,
Mesoporous Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active
Targeting and Delivery to Individual Leukemia Cells, in the scientific journal ACS
Nano. As the primary author of this article, I performed the majority of this
research at the University of New Mexico. I wish to acknowledge contributions
made by the following individuals. The original protocell concept was conceived
of by Dr. C. Jeffrey Brinker and engineered for use in biomedical application for
transfection by Dr. Juewen Liu, and further developed for targeted cargo delivery
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1.1 Overview
Targeted delivery of drugs incorporated within nanoparticles can
potentially ameliorate a number of problems exhibited by conventional ‘free’
drugs, including poor solubility, limited stability, rapid clearing, and, in particular,
lack of selectivity, which results in non-specific toxicity to healthy cells and
precludes dose escalations needed to combat multiple drug resistance. An ideal
targeted nanoparticle drug carrier, or “nanocarrier” should have the following
combined features: 1) the capacity for carrying high levels of multiple diverse
molecular cargos (small molecules, drugs with varying physiochemical
properties, siRNAs, peptides, imaging agents); 2) the ability to circulate in the
blood in vivo for extended periods without elimination by the immune or excretory
systems; 3) specificity for binding only to target disease cells; 4) controlled
release and intracellular trafficking of the cargo; and 5) low immunogenicity and
toxicity. Additionally, as the optimal biodistribution and biological interactions of
the nanocarrier can vary between different diseases (and individuals), an ideal
nanocarrier should also have physical and chemical properties that can be
controlled and essentially tuned for the specific application. Finally, the potential
to include imaging agents as well as therapeutics presents the possibility of
creating theranostics, which could allow both drug delivery and the monitoring of
the course of therapy to be achieved with a single nanocarrier. In the context of
creating a tunable nanocarrier that can address this wide range of requirements,
nanoparticle-supported lipid bilayer constructs have a distinctive combination of
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features that could potentially enable their development as a ‘universal’
nanocarrier that is both drug and disease agnostic.
1.2 Challenges in Nanomedicine for Nanostructured Platforms
A wide variety of nanocarrier systems have been developed for the
delivery of therapeutic cargo all of which have both advantages and
disadvantages, which present challenges for their ultimate clinical use. Major
challenges to the successful development of nanotherapeutics include:
biocompatibility, ability to load and release varied therapeutic cargos, high cargo
loading capacity, the ability to circulate in blood for extended periods of time,
evasion of elimination by the immune or excretory systems, specific targeting of
and delivery to diseased cells, and low immunogenicity. One of the most
successful nanocarrier-based approaches to date is liposomal-based drug
delivery, for which there are over a dozen U.S. Food and Drug Administration
(FDA) approved formulations and five approved for use in cancer. 1-4 The
advantages to liposomal nanocarriers are their high biocompatibility, low
immunogenicity, flexible formulation, and easy and scalable synthesis. 5-7
Additionally, the specificity of liposomal formulations can be increased by
addition of targeting moieties, such as antibodies, directly to the surface of the
liposomes.2, 5-9 However, it has proven difficult to identify stable lipid formulations
that allow drug encapsulation but prevent leakage, making liposomes poor
‘universal’ nanocarriers.10, 11 Polymeric based therapeutic nanocarriers have also
been developed, and several formulations are currently undergoing clinical
trials.2 Similar to lipid formulations, many polymer based nanocarriers are
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biocompatible and easy to manufacture, however they also suffer from limited
stability in in vivo systems and dose dependent toxicity.12, 13 In addition to the
issues specific to each carrier type, both liposomes and polymer based
nanoparticles share the issues of invariant size and shape, uncontrollable
release profiles, and highly interdependent properties, whereby changing one
property, such as loading efficiency, affects numerous other properties, such as
size, charge, and stability.5-7, 9
Many of the challenges of nanocarrier delivery can be addressed by
mesoporous silica nanoparticles (MSNP). MSNP have controllable size and
shape and exhibit a high internal surface area (> 1000 m 2/g) resulting from
uniform periodic arrangements of internal nanopores (ranging in diameter from 2
to > 20 nm) embedded within a silica framework.14, 15 The major advantage of
using MSNP as therapeutic nanocarriers is that their pore size and pore surface
chemistries can be easily modified to accommodate a variety of cargos and that
their high surface areas result in high loading capacities (vide infra).15
Additionally, MSNP are biocompatible and degrade overtime with in a biological
system into non-toxic silicic acid (Si(OH)4) by-products.16 However, MSNP use
as a nanocarrier is limited by the rapid clearance of the particles by immune and
excretory systems after injection.16-18
To address the limitations of liposomes, polymer conjugates, and MSNP,
while taking advantage of their strengths, we developed a flexible modular
nanocarrier we term a “protocell” (Figure 1.1).15, 19-24 Protocells are formed by
the encapsulation of MSNP cores within supported lipid bilayer (SLB)
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Figure 1.1 – Protocell Schematic

Figure 1.1 – Schematic illustration of the protocell construct. Disparate types
of therapeutic and diagnostic agents, such as smaller nanoparticles, toxins,
oligonucleotides and drugs, can be loaded within the mesoporous silica core.
Targeting ligands, such as peptides or antibodies, and fusogenic peptides can
be chemically conjugated to phosphatidylethanolamine 1,2-dioleoyl-snglycero-3-phosphoethanolamine

(DOPE)

or

1,2-dipalmitoyl-sn-glycero-3-

phosphoethanolamine (DPPE), present in the limited amounts (usually 1 – 5
%) in the supported lipid bilayer (SLB), by a heterobifunctional crosslinker with
a polyethylene glycol (PEG) spacer arm. The SLB can be composed of either
fluid DOPC or non-fluid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)
zwitterionic phosphatidylcholine lipids along with cholesterol and can be
further modified with phosphatidylethanolamine PEG-2000, or other agents, to
enhance colloidal stability and decrease nonspecific interactions.
and reproduced with permission.19 © 2011, The Authors.

Adapted
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membranes which can then be modified by conjugation with targeting/trafficking
ligands and polyethylene glycol (PEG).18-20, 22, 25-32 They synergistically combine
the advantages of liposomes (low inherent toxicity, immunogenicity, and long
circulation times) with MSNPs (stability and enormous capacity for multiple
cargos and disparate cargo combinations).19, 20, 22, 24 In addition to combining the
independent advantages of the MSNP and the liposome systems, the adhesion
energy between the MSNP and SLB suppresses large scale membrane bilayer
fluctuations responsible for liposome instability and leakage, while the SLB
serves to retain soluble cargos within the MSNP. The earliest conceptual
protocell was synthesized using micron-sized mesoporous silica particles.33, 34
The first-generation nanosized protocell consisted of a hydrophilic, spherical
MSNP core prepared by aerosol-assisted evaporation-induced silica-surfactant
self-assembly35 fused with either zwitterionic/cationic (1,2-dioleoyl-sn-glycero-3phosphocholine (DOPC) / 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP))
or zwitterionic/anionic (DOPC/ 1,2-dioleoyl-sn-glycero-3-phospho-L-serine
(DOPS)) liposomes24 which served to simultaneously load and seal negatively
charged cargo within the MSNP and allow it to be delivered across the cell
membrane. Since that time many variations of the protocell design have been
reported including: lipid monolayer encapsulated hydrophobic MSNP, 18, 30
covalent attachment of lipids to enable chemically triggered release under
disulfide reducing conditions,36 polymer additives to the SLB or monolayer,29, 30
native cell membrane encapsulated particles,37, 38 and red blood cell mimicking
lipid compositions.39
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1.3 Modular Design and Combined Functions of Protocells
The modular design and synergistic characteristics of the protocell confer
a unique combination of properties that can be further independently engineered
or tuned for specific applications (Figure 1.1): 1) the MSNP core size can be
varied from 25 nm to over 250 nm and the MSNP shape can be varied from
prismatic to spherical to toroidal to rod-like;17, 26, 35, 40-43 2) through self-assembly,
the MSNP pore diameter can be varied from 2 nm to over 20 nm, 14 and, using
silane coupling chemistry, the pore surface chemistry can be varied to
accommodate high concentrations of disparate cargos;14, 44-46 3) SLB formation,
by spontaneous liposome fusion with the silica core, seals and protects sensitive
cargo (Figure 1.2A), while SLB destabilization under acidic conditions provides
for pH-triggered cargo release from the endosome;19, 20, 22, 27-29 4) lateral bilayer
diffusivity enables recruitment of targeting ligands to cell surface receptors
thereby achieving high avidity with low targeting ligand density and reducing
immunogenicity and non-specific binding (Figure 1.2B);19, 47 5) the reconfigurable SLB surface supports complex biomolecular interactions with the
cell surface, involving, for example, targeting, immune cell evasion, and
endosomal escape ligands;18-20, 22, 27-29 6) the silica dissolution rate and hence
release of cargo can be modulated by controlling the extent of siloxane
condensation during the synthesis of MSNP;48-51 7) both therapeutic compounds
and imaging agents can be incorporated to create a theranostic nanocarrier,
allowing assessment of protocell stability, biodistribution, co-localization with

Figure 1.2 – Cryogenic TEM and Lateral Bilayer Diffusivity
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Figure 1.2 – A) Cryogenic TEM image of the protocell, the white arrows
highlight the lipid bilayer on the surface of the MSNP core. Scale bar = 25 nm.
B) Recruitment of Alexa Fluor 647-labelled peptide (white) to the surface of a
HCC cell when peptides are displayed on a mesoporous silica thin filmsupported lipid bilayer (green) composed of fluid DOPC (open circles) or solid
DPPC (closed circles). Cells were labeled with CellTracker Red CMTPX (red)
and Hoechst 33342 (blue). Inset scale bars = 5 µm. Adapted and reproduced
with permission.19 © 2011, The Authors.
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target cells, toxicity, and efficacy at the cellular/intracellular level as well as in the
whole organism.19, 27, 28, 52, 53
1.3.1 MSNP Core Synthesis
Mesoporous silica nanoparticles are synthesized by colloidal or aerosolbased self-assembly employing surfactants or block co-polymers as structure
directing agents. Using solution based colloidal self-assembly processes
derived, for example, from the original Stöber process for preparing spherical
colloidal silica particles, the synthesis of micrometer- and sub micrometer-size
spheres of ordered mesoporous oxide (MCM-41),54 or a dendritic process
referred to as colloidal stable mesoporous silica nanoparticles (CMS),55 it is
possible to synthesize uniformly sized populations of MSNP with spherical,
prismatic, toroidal, rod-like, or hollow shapes with dimensions spanning 25 nm to
over 250 nm,26, 40-43 while in many cases maintaining low polydispersity indices
(PdI) of < 0.1.23 Using evaporation induced self-assembly (EISA),35 it is possible
to generate in a single-step spherical MSNP with a predictable power law particle
size distribution spanning 25 nm to over 250 nm. The highly tunable synthesis of
MSNP allows for the selection of the size, size distribution, and shape most
applicable based on the proposed delivery route and target biodistribution. The
MSNP pore and particle surface chemistry can be readily modified via reactions
with silanol groups (≡Si-OH) present both within the pore interiors and on the
exterior surface. Silanol groups (which are partially deprotonated to form anionic
≡Si-O-) are chemically accessible and can be reacted with alkoxy or chlorosilane
derivatives to introduce organic functionality. Modification performed in single-
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step or multi-step procedures provides an unlimited ability to ‘tune’ the charge,
polarity, and hydrophobic/hydrophilic character of the pore and exterior particle
surfaces additionally providing sites for further chemical conjugation or chelation
with targeting and control ligands as well as imaging agents.
1.3.2 Cargo Content and Loading
The controlled pore size and surface chemistry allow multiple cargo types
to be efficiently loaded within the MSNP, where the loading efficiency scales with
the drug accessible surface area for surface chemistries with attractive drug
interactions arising from electrostatic, hydrophobic, hydrogen-bonding, or other
generally non-covalent forces.15 The most common cargos are small molecule
drugs like doxorubicin (DOX) that can access and interact electrostatically with
the negatively charged ~ 2 nm diameter pores characteristic of MCM-41-type
MSNP.25, 27-29 Loading of hydrophilic small molecule drugs is typically done by
incubating the MSNP core with the drug of interest prior to centrifugation, resuspension in buffer and fusion of liposomes to the surface of the MSNP. 19, 27-29
To load negatively charged cargos, such as nucleic acid or proteins, the MSNP
framework can be modified with aminosilanes to produce a positively charged
framework.19, 20, 22 Once the MSNP is positively charged, cargo can be loaded by
incubation of the modified MSNP with the cargo of interest prior to liposome
fusion. Other methods of drug loading have also been explored, including
simultaneous drug loading and liposome fusion24 as well as simultaneous SLB
assembly and drug loading using a solvent exchange method.25 To facilitate
loading of larger cargo, such as plasmid DNA,56 larger pore sizes can be
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achieved with block copolymer templating agents, micro-emulsion procedures,22
and swelling agents.57
The loading of hydrophobic cargo can be achieved in several ways. Using
the standard protocell formulation with a SLB, the hydrophobic cargo can be
loaded in the interbilayer domain of the SLB.27 The use of the hydrophobic
domain of the SLB limits the amount of hydrophobic cargo that can be loaded,
but does allow for the loading of both a hydrophilic drug in the MSNP core as well
as a hydrophobic drug within the same protocell.27 Hydrophobic cargos can also
be loaded from organic solvents like DMSO (or mixtures of DMSO and alcohol)
followed by vacuum drying and re-suspension in buffer for liposome fusion.58
Hydrophobic drug cargos have also been loaded in hybrid protocells composed
of organosilane modified MSNP with a single lipid monolayer interacting with
molecules directly on the surface of the MSNP.18, 30, 59
1.3.3 Liposomal Components and Protocell Assembly
The earliest protocell lipid formulations consisted zwitterionic/cationic
(DOPC/DOTAP),24, 25 zwitterionic/anionic (DOPC/DOPS),24 or zwitterionic lipids
alone (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or DOPC).25
Since these initial formulations, the complexity of protocell lipid formulations has
increased and, as depicted in Figure 1.1, a large variety of lipid and membrane
bound components can be incorporated into the SLB. Most commonly, the major
component of the SLB remains a zwitterionic lipid,19, 20, 22, 27-29, 31, 39 although the
cationic lipid, DOTAP, is still occasionally utilized.32 In the selection of the
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primary lipid component, the important design considerations are the lipid melting
transition temperature, which controls the SLB fluidity/diffusivity and stability, 19
and charge, which controls non-specific interactions with cells and tissues and
can affect the fusion of the SLB to the MSNP.21, 24, 25, 60 The lipid melting
transition temperature correlates with the length and degree of saturation of the
alkane tails, ranging from 55˚C for the saturated 18-carbon chain lipid 1,2distearoyl-sn-glycero-3-phosphocholine (DSPC) to -17˚C for the single
unsaturated 18-carbon chain lipid DOPC. Higher transition temperature lipids
increase stability and reduce leakage but can limit the diffusion of targeting
ligands conjugated to the lipid head groups (vide infra) reducing multivalent
interactions and binding avidity with the target cell surface.19
In addition to the primary lipid composition, auxiliary components can be
added to control the fluidity of the SLB, increase the colloidal stability and
circulation time in vivo, and/or add functionality to the protocell. In many
formulations, cholesterol is added to control the fluidity and leakage of the SLB, 19,
20, 22, 27, 28, 39

and PEG-modified (PEGylated) lipids are commonly added to

increase colloidal stability and circulation time in vivo.19, 20, 22, 27, 28, 32 In addition
to cholesterol and PEGylated lipids, functional lipids which provide a site for
chemical conjugation are included in protocell lipid formulations to allow addition
of targeting ligands.19, 20, 22, 28, 32 The most common functional lipids utilized for
addition of targeting are phosphoethanolamine lipids,19, 20, 22, 28, 32 although other
functional lipids incorporating nickel chelating agents have been demonstrated. 31
In addition to adding targeting ligands, lipids modified with polymers such as
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pluronic-P123 and D-α-tocopherol polyethylene glycol 1000 succinate (TPGS)
have been used to block drug resistance proteins and thereby add functionality to
the lipid bilayer itself.29, 30
The most common method of protocell assembly is liposomal fusion, in
which mixtures of lipids suspended in organic solvents are dried then hydrated in
aqueous buffer, followed by extrusion through a filter to produce liposomes of the
desired size. Liposomes spontaneously fuse to the surface of MSNP upon
mixing due to the highly lipophilic nature of silica.60 This phenomenon has been
demonstrated using Cryo-TEM to observe the successive steps of SLB formation
on a solid silica nanoparticle.60 After fusion, excess liposomes are removed by
centrifugation and the resulting protocells are resuspended.19, 22, 28 Protocells
can also be assembled by solvent exchange, wherein MSNP are dissolved in
ethanolic solution followed by addition of water, which causes transfer of the lipid
bilayer directly to the MSNP.25 A third method of assembly involves adding
MSNP in saline to a dried lipid film accompanied by probe sonication, wherein a
SLB forms directly or through a liposomal pathway.27 A critical consideration is
the extent of drug leakage during the assembly process and the integrity of the
supported lipid bilayer that can be assessed by drug leakage after assembly.19, 27
1.3.4 Targeting Chemistry
The multifunctionality of the protocell platform allows for the presentation
of targeting agents, including peptide, molecule, and/or antibodies via lipid head
group-modification, while maintaining biocompatibility and prolonging circulation
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times by the incorporation of PEGylated and/or other modified lipids. The major
concerns surrounding targeting chemistry are the choice of ligand, the chemical
conjugation method, and determination of what stage in the protocell assembly
process to perform the conjugation. To date, small molecule ligands such as
folate and hyaluronan,18, 28, 32, 59 and peptides19, 20, 22 have been used for protocell
targeting. Full antibodies, as well as partial antibodies, have been utilized for
liposome targeting2, 8, 61, 62 and recently have been applied to protocells as well.63
After selection of the targeting ligand, a conjugation strategy can then be
employed to link the ligand to the protocell. Multiple conjugation strategies that
covalently or non-covalently associate the targeting ligand with the functional lipid
are possible and the conjugation strategy should be carefully selected to
maintain functionality of the targeting ligand. The most common functional lipids
utilized for addition of targeting ligands to protocells are phosphoethanolamine
lipids, which are linked to the ligand utilizing covalent heterobifunctional linkers. 19,
20, 22, 28, 32

Additionally, non-covalent association of a targeting ligand with the

protocell has been performed utilizing lipids with incorporated nickel chelating
agents and histidine (His)-tagged targeting ligands.31 This conjugation method is
convenient because it occurs in a single-step with suitable yields, but the ligandprotocell binding interaction is weaker than other covalent strategies, risking the
potential dissociation of the targeting ligand. Although only a limited number of
conjugation chemistries have been utilized for targeting protocells, additional
targeting strategies have been employed for liposome targeting and could be
applied to protocells as well. For example, simple thiol groups can be added to
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both the targeting antibodies and lipids in the liposomes, these thiol groups can
be used to conjugate the targeting antibody to the liposome through disulfide
bonds or maleimide crosslinking chemistry. This method has been utilized with
targeting antibodies such as anti-HER2 or anti-My9, to create targeted
liposomes.64, 65 Other potential chemistries include click-chemistry66 and
avidin/biotin chemistries that have previously been employed with liposome
based carriers67, 68 and have recently been translated to protocells.63
Finally, the timing of lipid modification with the targeting moiety must be
selected; lipids can be modified before creation of the liposome, before liposomal
fusion with the MSNP, or after formation of the supported lipid bilayer. Among
the earliest reported methods for the addition of targeting moieties involved
modification of lipids with a folate derivative, prior to addition to the MSNP. 18, 59
This approach allows the synthesis of large quantities of targeted lipids and
works well for the creation of lipid monolayer coated MSNP. However, this
method is problematic for the creation of protocells as it is impossible to control
the inward and outward orientation of the folate modified lipids on the liposome.
To address this concern, preformed liposomes were modified prior to fusion with
MSNP.28 This method assumes the original liposome orientation to be
maintained throughout MSNP fusion, which may not be the case. Most
commonly, targeting moieties are conjugated to completely assembled
protocells, resulting in surface-only displayed targeting ligands.19, 22 Modification
of completely assembled protocells is also amenable to non-covalent conjugation
chemistries employing, for example, nickel chelating lipids that bind to His-
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terminated ligands.31 Another unique approach to targeting ligand modification
involves the insertion of ligand-functionalized lipids, e.g. folate-modified lipids,
after the protocell assembly.32 Although addition of functionalized lipids after
assembly is potentially simple and economical, it is difficult to predict and control
the final proportion of ligand-modified lipid incorporation. Perhaps the most
promising method for complete outward orientation of targeting ligand display
involves a hybrid bilayer constructed by lipid monolayer deposition on an
organosilane modified MSNP.18, 59 Hybrid bilayers form via hydrocarbon rich tail
group interaction with the hydrophobic MSNP cores, positioning targeting ligands
with the correct outward orientation. This approach was demonstrated using
folate-modified lipids and resulted in selective uptake in vitro. While many
methods of protocell surface modification have been described, many other
methods have yet to be reported. Thus, with the multitude of different lipid head
group modifications and numerous unexplored functionalization techniques,
protocell targeting remains an active area of research.
1.4 In Vitro Performance of Protocells
Figure 1.3 depicts the successive stages of (step 1) protocell binding,
(step 2) internalization, (step 3) endosomal escape, and (step 4) nuclear
targeting of desired cargo(s) by which targeted protocells selectively deliver
encapsulated cargos to a cell of interest. Importantly, the fluid but stable SLB
promotes lateral diffusivity and enables targeting peptides introduced at low
concentrations (important for avoiding non-specific binding and immunogenicity)
to be recruited to cell surface receptors (see Figure 1.2B), promoting high avidity

Figure 1.3 – Protocell Internalization Schematic
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Figure 1.3 – Schematic diagram depicting the successive steps of the
multivalent binding [1], internalization [2], endosomal escape [3], and delivery
of cargo to the nucleus [4] of peptide targeted protocells. Adapted and
reproduced with permission.19 © 2011, The Authors.
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multivalent binding and internalization by receptor mediated endocytosis (Figure
1.3, step 1). Dissociation constants (Kd, where Kd is inversely related to affinity)
were used to quantify surface binding of SP94-targeted protocells to human
hepatocellular carcinoma cell line (Hep3B), normal hepatocytes, endothelial cells,
and immune cells.19 Protocells modified with a calculated average of only six
SP94 peptides per particle exhibit a 10,000-fold greater affinity for Hep3B than
for normal hepatocytes, and other control cells suggesting the specificity
necessary for efficacious targeted delivery in vivo. Furthermore, SP94-modified
protocells have a 200-fold higher affinity for Hep3B than free SP94, a 1000-fold
higher affinity for Hep3B than nanoparticles bearing a non-targeting control
peptide, and a 10,000-fold higher affinity for Hep3B than unmodified particles.19
The affinity of protocells is a function of both peptide density and the fluidity of
the supported lipid bilayer; therefore, the Kd can be precisely controlled by
changing the composition of the bilayer to include varying amounts of fluid and
non-fluid lipid components (e.g. Figure 1.1), which is envisioned to be important
for translation to in vivo conditions.19 To demonstrate that binding results in
internalization and cytosolic delivery (Figure 1.3, steps 2 and 3) of multiple
cargos, Figure 1.4 shows hyperspectral confocal images of four categories of
fluorescently labelled cargo mimics delivered by a single targeted protocell. After
15 minutes (reference19 data not shown) calcein (a drug mimic), ds-DNA (an
siRNA mimic), red fluorescent protein (a toxin mimic), and quantum dots appear
as punctate spots co-localized with fluorescently-labelled silica and lipid
indicating incorporation into endosomes consistent with the receptor-mediated

Figure 1.4 – Hyperspectral Confocal Imaging of Multicomponent Delivery
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Figure 1.4 – Hyperspectral confocal imaging of targeted delivery of
multicomponent cargo by protocells to Hep3B cells for 12 hours at 37 °C.
Alexa Fluor 532-labeled mesoporous silica cores (yellow) were loaded with
calcein, dsDNA oligonucleotide (magenta), Red Fluorescent Protein (orange),
and CdSe/ZnS quantum dots (teal). Cargos were sealed in the cores by fusion
of Texas Red-labeled DOPC liposomes (red). The calcein and dsDNA
oligonucleotide were modified with a nuclear localization signal and show
accumulation in the nucleus by 12 hours, while the RFP and the quantum dots
remain in the cytosol. Scale bar = 20 μm. Adapted and reproduced with
permission.19 © 2011, The Authors.
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endocytotic process depicted in Figure 1.3 steps 1 and 2. Within 12 hours
(Figure 1.4), calcein, ds-DNA, red fluorescent protein, and quantum dots are
delivered into the cytosol, and calcein and dsDNA (both conjugated with a
nuclear localization sequence) are further delivered into the nucleus (Figure 1.3,
step 4). Delivery of the drug from the endosome into the cytosol is crucial for
therapeutic efficacy and has emerged as a major problem in nanocarrier-based
drug delivery. For the protocell, the natural acidification of the endosome initiates
three pH-triggered events insuring endosomal escape (Figure 1.3, step 3). First,
it reduces the SLB adhesion energy allowing leakage of cargo as confirmed in
vitro, second, below its pKa, the endosomolytic peptide H5WYG serves as a
proton sponge resulting in endosome swelling and disruption, third, for partially
aminated silica cores, lowered pH increases the silica solubility, which along with
diffusion controls cargo release. Thus, for protocells, delivery profiles may be
tuned/optimized through variation of pore size, charge, and solubility of the silica
core along with the extent of SLB modification with the endosomolytic peptide. In
vitro delivery has also been demonstrated for other cargos including: siRNA, 22 a
variety of anti-cancer drugs,19, 25, 27-29 a photodynamic therapeutic,59 and multiple
anticancer drugs within a single protocell.19, 27
In addition to delivery of cargo, visualization of protocells in an in vitro
system has been utilized to demonstrate targeting specificity and functional
cellular response to drug delivery (e.g. Figure 1.5). Addition of targeting
peptides was shown to provide specificity by demonstrating binding and
internalization of protocells, shown in white in the merged images in Figure 1.5,
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Figure 1.5 – Confocal Microscopy Imaging of Cellular Response to Drug
Delivery

Figure 1.5 – Confocal microscopy images of Hep3B hepatocellular carcinoma
cells and normal hepatocytes after exposure to an excess peptide targeted
protocells loaded with an anti-cyclin siRNA cocktail for 1 hour or 48 hours at
37 °C. Cells were fixed and then imaged by confocal microscopy, protocells
are shown in white, cyclins in green and nuclei in blue. Scale bar = 20 μm.
Adapted and reproduced with permission.22 © 2012, The American Chemical
Society.
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to HCC cells but not to normal hepatocytes.22 These peptide targeted protocells
delivered a cocktail of siRNAs to knockdown the expression of a selection of
cyclin proteins. Confocal microscopy showed not only specific binding and
uptake only in HCC cells but also reduction in cyclin protein expression only in
the targeted cancer cells, while leaving the normal hepatocytes unaffected
(Figure 1.5). In vitro imaging has been used to demonstrate specific targeting of
protocells utilizing small molecule ligands, such as folic acid,18, 32, 59 soluble
protein ligands, such as epidermal growth factor,32 polysaccharides, such as
hyaluronan28 and complex proteins, such as cell surface receptors, Ephrin-B2
and Ephrin-B3.31
In vitro systems have also been used to evaluate the therapeutic efficacy
of small molecule chemotherapeutic cargo delivery. Delivery of DOX or a
cocktail of DOX, 5-fluorouracil, and cisplatin by peptide-targeted protocells
demonstrated killing of multidrug resistant HCC cells while sparing normal
hepatocytes (Figure 1.6A).19 When the targeted-protocells were compared to
liposomes containing the same drugs, the liposomes resulted in reduced cell
killing of the HCC cells and increased toxicity to normal hepatocytes compared to
targeted-protocell delivery (Figure 1.6A), presumably due to the leakiness of
liposomal formulations.19 The delivery of a variety of drugs by non-targeted
protocells has been demonstrated in vitro including: colchicine,25 gemcitabine,27
paclitaxel,27 docetaxel,28 irinotecan,29 and DOX,30 both as single drugs25, 28-30 and
as drug cocktails.27 In vitro delivery of 8-hydroxyquinoline,28 DOX,19 5fluorouracil,19 protoporphyrin IX,59 and cisplatin19 by targeted protocells both

Figure 1.6 – Evaluation of Therapeutic Efficacy
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Figure 1.6 – A) Left axis (bars in grey and black): The percentage of multidrug
resistant positive (MDR+) Hep3B hepatocellular carcinoma cells and normal
hepatocytes that remained viable after exposure to free doxorubicin (DOX),
targeted-protocell encapsulated DOX, liposomal DOX, targeted protocells
containing a cocktail of chemotherapeutics or liposomes containing a cocktail
of chemotherapeutics for 24 hours at 37 °C at the LC90 value for free DOX.
Right axis (bars in red): The percentage of MDR + Hep3B cells that remain
viable after exposure to free DOX, protocell encapsulated DOX, liposomal
DOX, targeted protocells containing a cocktail of chemotherapeutics or
liposomes containing a cocktail of chemotherapeutics for 24 hours at 37 °C at
the LC50 value for free DOX. Adapted and reproduced with permission.19 ©
2011, The Authors. B) Induction of apoptosis by exposure to peptide targeted
protocells loaded with an anti-cyclin siRNA cocktail. Cells were classified for
early apoptosis (annexin V positive) or late apoptosis (annexin V and
Propidium Iodide positive). Adapted and reproduced with permission. 22
2012, The American Chemical Society.
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individually19, 28, 59 and as cocktail19 has also been demonstrated. In addition to
the therapeutic delivery of drugs, in vitro efficacy and cytotoxicity of siRNA cargo
has also been examined (Figure 1.6B).22 Peptide targeted protocells were able
to deliver a cocktail of siRNAs to reduce expression of cyclin proteins. The
reduction in cyclin proteins resulted in apoptosis of HCC cells but did not cause
apoptosis of the normal hepatocytes.22 In vitro systems have also been used to
assess the efficacy of potential therapeutic additions to the lipid bilayer such as
Pluronic-123 and TPGS.29, 30 Pluronic-123 and TPGS, when released from the
lipid bilayer on the surface of the protocell, blocks drug efflux pumps present in
tumor cells that result in multidrug resistance and results in increased killing of
cancer cells in vitro.29, 30 In addition to delivery of therapeutic cargo, in vitro
testing has been utilized to test novel therapeutic technologies which utilize
protocells such as specific cargo release by red-light photoactivation,32 and even
the expansion of protocell technology beyond cancer treatment to antiviral
therapy.31
Finally, in vitro assessment provides a rapid method to evaluate the
biocompatibility of various lipid compositions and protocell components prior to
progressing to evaluation of toxicity, biocompatibility or therapeutic delivery in an
in vivo system. For example, hemotoxicity testing demonstrated that a
combination of phosphatidylcholine, phosphatidylserine and cholesterol,
designed to mimic red blood cell membranes, was more biocompatible than
phosphatidylcholine alone for the SLB formulation.39 In vitro testing for
biocompatibility, such as hemocompatibility, serves two major functions in the
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evaluation of a nanocarrier such as the protocell. First, in vitro testing, including
hemocompatibility, is required prior to FDA approval. Secondly, in vitro testing
can be used to select only those formulations likely to be biocompatible for
testing in in vivo systems.
1.5 In Vivo Use and Testing of Protocells
1.5.1 In Vivo Biocompatibility and Toxicity
A critical issue for any nanocarrier is in vivo toxicity and biocompatibility.
Toxicity from protocells can arise from either the MSNP core or from the SLB.
Although the formulations may vary and individual formulations will need to be
tested for biocompatibility and toxicity, liposomes that are biocompatible and nontoxic are FDA-approved for delivery of chemotherapeutic drugs.8 The toxicity of
silicon dioxide has been studied for more than a century and amorphous silica is
Generally Recognized as Safe (GRAS) by the FDA. Recently, the toxicity of
silica nanoparticles has been extensively investigated, because the high surface
to volume ratio of nanoparticles could lead to enhanced cellular interactions and
different pathways of toxicity compared with coarse grained silica.69 Based on
the high surface to volume ratio of silica NPs, it might be anticipated that they
would show higher toxicity compared with their bulk counterparts. However, the
majority of evidence supports lack of toxicity and the biocompatibility of silica
nanoparticles prepared by low temperature colloidal synthesis. Recently
amorphous silica nanoparticle ‘C-dots’ (Cornell Dots) were FDA approved for
diagnostic applications in a stage I human clinical trial.70 The FDA approval for a
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clinical trial of silica nanoparticles should accelerate the acceptance of
amorphous, colloidally derived silica particles in medical applications.
In the case of MSNP, the intrinsic porosity of the MSNP surface reduces
the extent of hydrogen bonding or electrostatic interactions with cell membranes,
a potential cause of silica nanoparticle toxicity.50 Although the porosity of MSNP
should decrease their toxicity, studies of MSNP toxicity have shown variable and
occasionally high toxicity. One potential reason for the variability in toxicity
studies is the surfactant used to template the pores is toxic and variable amounts
of this surfactant can remain within the pores of the MSNP depending on the
processing.49 However, a study which used Fourier Transform Infrared
Spectroscopy (FTIR) to confirm that the template surfactant had been removed
prior to toxicity testing of the MSNP found survival of all mice treated with up to
1000 mg/kg by IV injection and followed for 14 days.48 The survival of all the
animals treated with a very high dose of MSNP that did not retain surfactant
shows the lack of intrinsic toxicity of the silica framework of the MSNP.
In addition to toxicity, biocompatibility must also be taken into account. In
this area, the porous structure of the MSNP further enhances their
biocompatibility as the high surface area and low extent of condensation of the
MSNP siloxane framework promotes a high rate of dissolution into soluble silicic
acid species, which are nontoxic.49 The breakdown of the MSNP overtime into
nontoxic species supports the potential of repeat and long term use of protocells
to deliver drugs as the MSNP core can be cleared from the biological system
overtime in a nontoxic way. Examination of animals treated with both PEG-
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coated and unmodified MSNP showed excretion of the silica in both feces and
urine without any signs of significant organ damage.17 Although assessment of
toxicity and biocompatibility will be important for each individual protocell
formulation that is developed, biocompatibility of the individual components of the
protocell should greatly reduce the potential toxicity and enhance the
biocompatibility of the complete protocell. Potential toxicity is further mitigated by
the high drug loading capacity of MSNP and protocells, which greatly reduces
needed dosages and therefore the potential for toxicity. Finally, the ability to add
cell specific targeting will further mollify potential toxicity as the protocells are
directed specifically to the cells or tissues of interest and will have reduced
nonspecific interactions within the body.
1.5.2 In Vivo Application of Protocell Technology
The most common area of research for therapeutic protocells is cancer,
due to the highly toxic and non-specific nature of most cancer therapeutics.
Increased specific delivery of encapsulated cancer therapeutics would address
the lack of selectivity, which results in non-specific toxicity to healthy cells and
prevents the dose escalation necessary to eradicate diseased cells and
overcome drug resistance. The tunable nature of protocells makes them highly
adaptable nanocarriers which can be easily altered to fit the needed
biodistribution and drug release profile of the specific cancer. Therapeutic
protocells have been used to take advantage of the EPR effect which leads to
accumulation of nanosized materials in tumors. The EPR effect is due to the
rapid growth of tumor vessels which are often abnormal in form and architecture.
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Due to the abnormal architecture, nanosized carriers are released into the tumor
tissue and trapped due to impaired lymphatic drainage often present in tumors.
Although many nanocarriers can take advantage of the EPR effect, the
addition of a lipid bilayer to the surface of a drug loaded MSNP greatly increased
the EPR effect compared to uncoated MSNP.29 In addition, a comparison of
uncoated MSNP to protocells both loaded with irinotecan showed a significant
increase in survival and a reduction in tumor growth in mice treated with the
protocells.29 Protocells created to treat breast cancer have been further modified
to address a common breast cancer resistance pathway. The tumor cells were
modified to express the breast cancer resistance protein (BCRP), which confers
resistance by pumping chemotherapy agents out the cells. To counteract this
pump, the protocell lipid bilayer was modified with Pluronic-123, which can block
the action of the BCRP. The combined delivery of Pluronic-123 with the
chemotherapy agent resulted in the greatest reduction in tumor growth as well as
an increase in survival.29 The ability to both load drugs as well as modify the
components in the surface of the protocell to address the BCRP demonstrates
the customizability of the protocell platform. Protocell therapeutic delivery has
been applied to pancreatic cancer, a notoriously difficult to treat disease, with
dual drug loaded protocells.27 Gemcitabine and paclitaxel were loaded into
protocells to treat mice with both subcutaneous and orthotopic pancreatic cancer
xenografts. The combined therapy protocells were more effective than single
agent gemcitabine protocells or the combined free-drug treatment at tumor
growth retardation in the subcutaneous tumors and in prevention of metastasis in
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the orthotopic model.27 The dual therapeutic protocells utilize the high surface
area MSNP core to carry the hydrophilic drug, gemcitabine, and the hydrophobic
space within the lipid bilayer to encapsulate the hydrophobic drug, paclitaxel,
which can be used in low quantities in combination therapy.
In addition to studies focusing on the EPR effect, targeting moieties have
been used to enhance the delivery of protocells (Figure 1.7). Protocells
containing 8-hydroxyquinoline (8-HQ) were optimized to target breast cancer
xenografts by the addition of hyaluronan to the surface. 28 Hyaluronan targets
CD44, a surface marker highly expressed in breast cancer stem cells. 8-HQ
alone is not toxic, but has a synergistic effect when present with a secondary
chemotherapy agent and may help overcome chemoresistance. In addition to
the targeted protocells loaded with 8-HQ, a non-targeted set of protocells
containing docetaxel and relying on the EPR effect were also used as
combination therapy. While the docetaxel loaded protocells and the targeted
protocells loaded with 8-HQ had limited effect on tumor growth alone, when
combined, the effect was stronger than the combined free-drugs (Figure 1.8A).
Additionally, free- docetaxel was very toxic, resulting in significant weight loss,
and this toxicity was avoided by inclusion of the drug within the protocell (Figure
1.8B).28 Targeted delivery, utilizing folate, of photodynamic therapeutic
protoporphyrin IX loaded protocells to mice bearing subcutaneous melanoma
tumors has also been demonstrated. Delivery of the free-protoporphyrin IX alone

Figure 1.7 – Hyaluronan Targeting Modification Schematic
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Figure 1.7 – Targeted and non-targeted protocells for treatment of breast
cancer xenografts.

Schematic of protocells (MSS) both targeted with

hyaluronan (HA-MSS) and loaded with 8-HQ and non-targeted protocells
loaded with docetaxel (DTX). Adapted and reproduced with permission. 28 ©
2013, Elsevier.

Figure 1.8 – Anti-tumor Activity of Protocells
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Figure 1.8 – A) Antitumor activity of free drugs in comparison to drug-loaded
protocells alone or in combination with each other and free drug as shown by
tumor size after 43 days. Treatments were given 4 times between day 15 and
day 25. B) Assessment of toxicity by the change in body weight ratio. At day
43, the body weight change ratio was compared to saline injection by the
Student’s t-test. **P < 0.01, *** P < 0.001 and n.s. represents not significant (P
> 0.05). Adapted and reproduced with permission.28 © 2013, Elsevier.
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or in the absence of phototherapy resulted in no response. However, delivery of
the protoporphyrin in the protocell in combination with light irradiation resulted in
significant reduction in tumor burden.59
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CHAPTER 2
PROTOCELL COMPONENT SYNTHESIS AND ASSEMBLY

This chapter was adapted from
Durfee, P. N.; Lin, Y-S.; Dunphy, D. R.; Muñiz, A. J.; Butler, K. S.; Humphrey, K.
R.; Lokke, A. J.; Agola, J. O.; Chou, S. S.; Chen, I-M.; Wharton, W.; Townson, J.
L.; Willman, C. L.; Brinker, C. J. Mesoporous Silica Nanoparticle-Supported
Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual
Leukemia Cells. ACS Nano 2016, DOI: 10.1021/acsnano.6b02819. © 2016
American Chemical Society.

49
2.1 Overview
Given the unique challenge of nanoparticle-based delivery to leukemic
cells, it is worthwhile to consider the optimal drug delivery platform. An
effectively targeted nanocarrier for leukemia treatment would ideally possess the
following combined characteristics: 1) uniform and controllable particle size and
shape; 2) high colloidal stability under physiological and storage conditions; 3)
minimal non-specific binding interactions, uptake by the MPS, or removal by
excretory systems, allowing extended circulation time; 4) high specificity to
diseased cells or tissues; 5) high capacity for and precise release of diverse
therapeutic cargos; and 6) low cytotoxicity. Liposomes are one of the most
successful classes of nanocarriers for achieving both passive and active targeted
delivery, and numerous U.S. Food and Drug Administration (FDA) approved
formulations exist.1-4 Of candidate nanocarriers, liposomes exhibit many
advantageous properties, including ease of synthesis, high biocompatibility,
flexible formulation, targetability, and increased circulation times compared to
free drugs.5-9 However, it has proven difficult to identify stable lipid formulations
that allow drug encapsulation but prevent leakage.10, 11 Polymeric-based
therapeutic nanocarriers have also been developed and several formulations are
currently being tested in clinical trials.3 Similar to liposomes, many polymerbased nanocarriers are biocompatible and easy to manufacture, however they
also suffer from limited stability in vivo and dose dependent toxicity.12-14
Furthermore, both liposomes and polymer-based nanoparticles suffer the issues
of invariant size and shape, uncontrollable, often burst release profiles, and
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highly interdependent properties, whereby changing one property, such as
loading efficiency, affect numerous other properties, such as size, charge, and
stability.5, 7-9 By comparison, MSNPs have controlled size and shape, and are
composed of high surface area (500 to > 1000 m 2/g) networks of uniformly sized
pores whose size and surface chemistry can be varied widely to accommodate
high payloads of disparate cargos.15, 16 Furthermore, colloidal mesoporous silica
is biodegradable and GRAS by the FDA.17 The drawbacks of MSNP are that
often coatings are required to contain the cargo and shield surface silanols (SiOH) and deprotonated silanols (Si-O-) that are highly lipophilic and known to
promote non-specific binding and mononuclear phagocytic system uptake.18-20 In
this context, MSNP-supported lipid bilayers (protocells), a rapidly emerging class
of nanocarriers, have unique attributes (Figure 2.1). Protocells are formed by
the encapsulation of the MSNP core within a SLB followed optionally by
conjugation of polymers, such as PEG, and targeting and/or trafficking ligands to
the surface of the SLB.21-35 Protocells synergistically combine the advantages of
liposomes, viz. low inherent toxicity and immunogenicity, and long circulation
times, with the advantages of MSNP, viz. size and shape control and an
enormous capacity for multiple cargos and disparate cargo combinations.
Moreover, many studies have revealed that protocells and related MSNP
supported bilayer nanocarriers are stable at neutral pH but exhibit pH triggered
cargo release under endosomal conditions.22-28, 33

Figure 2.1 – SLB Fusion and Protocell Targeting Modification Schematic
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Figure 2.1 – Schematic depicting lipid vesicle fusion onto mMSNP to form
mMSNP-supported lipid bilayers (protocells). Drug (gemcitabine) and/or
fluorescent molecular cargo (YO-PRO®-1) loaded protocells were assembled
by soaking nanoparticle cores with cargo for 24 hours in aqueous buffer
followed by fusion of (DSPC:chol:DSPE-PEG2000-NH2 – 49:49:2 mol ratio
(targeted formulation) or (DSPC:chol:DSPE-PEG2000 – 54:44:2 mol ratio (nontargeted formulation) vesicles. Leukemia cell targeting was achieved by
NeutrAvidin modification followed by binding to biotinylated EGFR antibodies.
SLB thickness is nearly identical to that of the vesicle used for protocell
synthesis as shown in Cryo-TEM images. Adapted and reproduced with
permission.36 © 2016, The American Chemical Society.
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2.2 Results and Discussion
2.2.1 Synthesis Criteria for Monosized Protocells
Protocells were formed by fusion of zwitterionic lipid-based vesicles on
monosized MSNP (mMSNP) cores synthesized with varying size, shape, and
pore morphologies (See Materials and Methods section below for detailed
synthesis procedures). Vesicle fusion on silica glass substrates to form planar
supported lipid bilayers has been extensively studied using atomic force
microscopy, quartz crystal microbalance, deuterium nuclear magnetic resonance,
surface plasmon resonance, fluorescence microscopy and ellipsometry, 37-42
where the fusion process has been shown to involve vesicle adsorption followed
(in some cases at a critical surface coverage) by vesicle rupture and desorption
of excess lipid to form a bilayer separated from the glass surface by an
intervening 1 to 2 nm thick water layer. Generally, the process of phospholipid
vesicle fusion with smooth glass supports is governed by the same DerjaguinLandau-Verwey-Overbeek (DLVO) forces that are responsible for colloid
aggregation; hence, both vesicle-substrate and vesicle-vesicle interactions need
to be considered. DLVO theory models the forces in such systems as consisting
of an electrostatic interaction combining with a van der Waals attraction; as such,
SLB fusion depends on pH, which controls the extent of deprotonation of surface
silanol groups to form anionic Si-O- species above pH 2, and the ionic strength
and cationic component of the buffer, which dictate, respectively, the Debye
length (mediating electrostatic interactions) and the cation hydration diameter. 43
Cremer and Boxer studied fusion of positively charged, neutral and negatively
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charged vesicles onto glass as a function of pH (3-12) and ionic strength (0-90
mM). They found neutral and positively charged vesicles fuse under all
conditions, whereas negatively charged vesicles fuse only above a critical ionic
strength, which increased with pH (negative charge of silica surface). This is in
keeping with expectations of DLVO theory as increasing ionic strength reduces
electrostatic repulsion between vesicles and the glass surface.43
Although considerably fewer studies have been performed on vesicle
fusion on silica nanoparticles, we anticipate that the mechanism and governing
forces would be comparable but further influenced by the nanoparticle curvature.
Using differential scanning calorimetry (DSC) in combination with dynamic light
scattering (DLS), Savarala et al. studied the fusion of the zwitterionic 1,2dimyristoyl-sn-glycero-3-phosphocholine (DMPC) vesicles on silica beads with
diameters ranging from 100 to 4 – 6 nm at neutral pH and ionic strengths ranging
from 0 to 0.75 mM NaCl. For a critical limiting ratio of lipid surface area to silica
surface area of 1 (SAlipid:SAsilica = 1), they found no (or very slow) vesicle fusion
to occur in pure water and that higher ionic strengths were required to achieve
fusion on successively smaller particles (100-20 nm).44 Silica beads sized
between 4 – 6 nm did not form supported lipid bilayers; rather, these beads
appeared to associate with the exterior surfaces of the vesicles.44 These results
differ somewhat from flat surfaces and, in keeping with DLVO theory, suggest
that, for progressively smaller particles, possible repulsive electrostatic
interactions must be reduced by increasing ionic strength and/or attractive
electrostatic interactions promoted by cation association with phosphocholine to
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compensate for increased membrane curvature (assuming conformal SLBs).
This result is consistent with a study by Garcia-Manyes et al. that showed the
surface charge of zwitterionic DMPC liposomes at neutral pH is negative at < 100
mM NaCl solution and positive at higher ionic strength. Excess lipid i.e.,
SAlipid:SAsilica > 1 appears to promote SLB formation on silica nanoparticles. 45
Mornet et al. studied the fusion of 30 – 50 nm diameter negatively charged
DOPC / DOPS vesicles on ~ 110 nm diameter spherical silica colloids by direct
Cryo-TEM. For SAlipid:SAsilica = 15 and a buffer ionic strength of 152 mM, they
observed conformal ~ 5 nm thick SLBs to form by a process involving conformal
vesicle adsorption followed by rupture to form SLB patches. 46 Multiple
adsorption and fusion events resulted in complete SLBs that conformed to the
moderate surface roughness / microporosity of the Stöber silica nanoparticle
surface.46
Numerous researchers have studied vesicle fusion on mesoporous silica
macroparticles and nanoparticles as a means to form cell-like biomimetic
materials47 and lipid bilayer encapsulated nanoparticles for drug delivery. 22-29, 33
To date, nanoparticle studies have employed primarily spherical
cetyltrimethylammonium bromide (CTAB)-templated MSNP formed by aerosolassisted EISA22, 23, 28, 34, 35, 48 or colloidal processing and characterized by wormlike or isotropic mesopores with diameters of about 2-3 nm.24-27, 29, 33 Direct CryoTEM observations of protocells have shown the bilayer thickness to range from ~
4 – 7 nm,25, 28, 35, 48 corresponding to that measured for solid silica nanoparticle
SLBs46 or planar SLBs.41 SLBs span the surface mesopores and remain
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conformal to the MSNP surface, as we. and others, have shown by Cryo-TEM
imaging (see, for example, Figure 2.1). With respect to SLB formation, surface
porosity decreases the areal fraction of silica at the nanoparticle surface and,
assuming spanning lipid bilayers, reduces accordingly the possible magnitude of
both van der Waals and electrostatic interactions that drive vesicle fusion.
2.3 Materials and Methods
2.3.1 Materials
All chemicals and reagents were used as received. Ammonium hydroxide
(NH4OH, 28 – 30 %), 3-aminopropyltriethoxysilane (98 %, APTES), ammonium
nitrate (NH4NO3), benzyldimethylhexadecylammonium chloride (BDHAC), ncetyltrimethylammonium bromide (CTAB), Cetyltrimethylammonium chloride
(CTAC), N,N-dimethyl formamide (DMF), rhodamine B isothiocyanate (RITC),
tetraethyl orthosilicate (TEOS), cyclohexane, and triethanolamine (-TEA) were
purchased from Sigma-Aldrich (St. Louis, MO). Hydrochloric acid (36.5 – 38 %,
HCl) was purchased from EMD Chemicals (Gibbstown, NJ). Absolute (99.5 %)
and 95 % ethanol were obtained from PHARMCO-AAPER (Brookfield, CT). 1,2dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-snglycero-3phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000] (ammonium salt) (DOPE-PEG2000), 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (ammonium salt) (DSPE-PEG2000), 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2000-NH2)
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phospholipids and cholesterol (chol, ovine wool, >98 %) were purchased from
Avanti Polar Lipids (Birmingham, AL). Phosphate buffered saline (PBS) was
purchased from Gibco (Logan, UT).
2.3.2 Synthesis of mMSNP Composed of Hexagonally Arranged Cylindrical
Pores (2.8 nm pore size), Hexagonal mMSNP
To prepare monosized dye-labeled mMSNP (~ 95 nm in diameter, ~ 130
nm in hydrodynamic size in D.I. water), 3 mg of RITC was dissolved in 2 mL of
DMF followed by addition of 1.5 μL APTES.49 The synthesis conditions of
Hexagonal mMSNP is based on reported literature.50 See Figure 2.2 for
schematic description of synthesis. The RITC-APTES solution was incubated at
room temperature for at least 1 hour. Next, 290 mg of CTAB was dissolved in
150 mL of 0.51 M ammonium hydroxide solution in a 250 mL beaker, sealed with
parafilm (Neenah, WI), and placed in a mineral oil bath at 50 °C. After
continuously stirring for 1 hour, 3 mL of 0.88 M TEOS solution (prepared in
ethanol) and 1 mL of RITC-APTES solution were combined and added
immediately to the surfactant solution. After another 1 hour of continuous
stirring, the particle solution was stored at 50 oC for ~ 18 hours under static
conditions. Next, solution was passed through a 1.0 μm Acrodisc 25 mm syringe
filter (PALL Life Sciences, Ann Arbor, MI) followed by a hydrothermal treatment
at 70 oC for 24 hours. Followed procedure for CTAB removal was as described
in literature.51 Briefly, mMSNP were transferred to 75 mM ammonium nitrate
solution (prepared in ethanol) then placed in an oil bath at 60 oC for 1 hour with
reflux and stirring. The mMSNP were then washed in 95 % ethanol and

Figure 2.2 – Hexagonal MSNP Synthesis Schematic
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Figure 2.2 – Schematic depicting Hexagonal mMSNP synthesis process. [1]
Silica precursor (TEOS) is mixed with surfactant (CTAB) under basic
conditions, [2] Cooperative self-assembly of silicate micelles, [3] Silica
condenses around cylindrical CTAB micelles to form mMSNP framework, and
[4] Hydrothermal treatment and surfactant extraction results in mMSNP cores
that can be loaded with cargo and used to support lipid bilayers.
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transferred to 12 mM HCl ethanolic solution and heated at 60 °C for 2 hours with
reflux and stirring. Lastly, Hexagonal mMSNP were washed in 95 % ethanol,
then 99.5 % ethanol, and stored in 99.5 % ethanol.
2.3.3 Synthesis of Spherical mMSNP with Isotropic Pores (2.8 nm pore size)
To prepare monosized spherical mMSNP composed of isotropic
mesopores, we used the same procedure described above for synthesis of
mMSNP with hexagonally arranged pore structure. However, we substituted
cationic surfactant BDHAC for CTAB as the template. The 3-dimensional
isotropic pore arrangement is due to a larger micelle packing parameter of
BDHAC, compared to CTAB surfactant.52 See Figure 2.3 for schematic
description of synthesis.
2.3.4 Synthesis of Spherical mMSNP Composed of Dendritic Large Pores (5
nm, 9 nm, and 18 nm pore size)
The large pore spherical mMSNP were synthesized by a published
biphase method.53-55 Syntheses of 5 nm, 9 nm, and 18 nm pore mMSNP are
based on a modified condition reported by Zhao et al.55 For preparation of 5 nm
dendritic pore mMSNP, 0.18 g of TEA was dissolved in 36 mL of D.I. water and
24 mL of 25 w/w % CTAC in a 100 mL round bottom flask. The surfactant
solution was stirred at 150 rpm and heated at 50 oC in an oil bath. After 1 hour,
20 mL of 20 v/v % TEOS (in cyclohexane) was added to the CTAC-TEA aqueous
solution. After 12 hours, the particle solution was washed with D.I. water twice
by centrifugation. Further surfactant removal achieved by following the

Figure 2.3 – Spherical Small-pore MSNP Synthesis Schematic
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Figure 2.3 – Schematic depicting synthesis of spherical mMSNP with an
anisotropic pore structure. [1] Silica precursor (TEOS) is mixed with surfactant
(BDHAC) under basic conditions, [2] Cooperative self-assembly of silicate
micelles, [3] Silica condenses around three-dimensional worm-like BDHAC
micelles to form mMSNP framework, and [4] Hydrothermal treatment and
surfactant extraction results in mMSNP cores that can be loaded with cargo
and used to support lipid bilayers.
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previously described conditions used in preparation of small pore mMSNP. For
synthesis of 9 nm dendritic pore mMSNP, the stirring rate and organic phase
concentration were adjusted to 300 rpm and 10 v/v % TEOS, respectively. For
synthesis of 18 nm dendritic pore mMSNP, the TEOS concentration in the
organic phase was changed to 5 v/v %. All other steps were identical. See
Figure 2.4 for schematic description of synthesis.
2.3.5 Synthesis of Rod-shaped mMSNP with Hexagonally Arranged
Cylindrical Pores (2.8 nm pore size)
The shape of mMSNP can be simply tuned to rod-like morphology by
altering the CTAB concentration, stirring rate, and ammonia concentration. 56, 57
Briefly, 0.5 g CTAB was dissolved in 150 mL of 0.22 M ammonium hydroxide
solution at 25 oC under continuous stirring (300 rpm). Next, of 1 mL TEOS was
added (drop wise) to the surfactant solution with stirring. After 1 hour, the
particle solution was aged under static conditions for 24 hours, then
subsequently transferred to a sealed container and heated to 70 oC for 24 hours.
The removal of surfactant was followed the same procedures described
previously. See Figure 2.5 for schematic description of synthesis.
Figure

2.3.6 Liposome Preparation
Lipids and cholesterol ordered from Avanti Polar Lipids were
presolubilized in chloroform at 25 mg/mL and were stored at -20 oC. To prepare
liposomes, lipids were mixed at different mol % ratios including (54:44:2) for

Figure 2.4 – Spherical Large-Pore MSNP Synthesis Schematic
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Figure 2.4 – Schematic depicting synthesis of mMSNP with larger pore
structure (5, 9, and 18 nm pore diameter). [1] Silica precursor (TEOS) is mixed
with cyclohexane in either 5, 10, 20 v/v % ratio (ratio influences pore size) and
layered over surfactant (CTAC) dissolved in aqueous buffer, [2] Cooperative
self-assembly of silicate micelles and pore swelling by cyclohexane entering
the hydrophobic region of the CTAC micelles, occurring at the organic /
aqueous interface, [3] Silica condenses around CTAC micelles to form
mMSNP framework, and [4] Hydrothermal treatment and surfactant extraction
results in large pore mMSNP cores that can be loaded with cargo and used to
support lipid bilayers.

Figure 2.5 – Rod-Shaped MSNP Synthesis Schematic
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Figure 2.5 – Schematic depicting synthesis of rod-shaped mMSNP with
hexagonally arranged isotropic pore structure. [1] Silica precursor (TEOS) is
mixed with surfactant (CTAB) under basic conditions, [2] Cooperative selfassembly of silicate micelles, [3] Silica condenses around cylindrical CTAB
micelles to form mMSNP framework, and [4] Hydrothermal treatment and
surfactant extraction results in mMSNP cores that can be loaded with cargo
and used to support lipid bilayers.

63
DOPC:chol:DOPE-PEG2000 and DSPC:chol:DSPE-PEG2000, and (49:49:2) for
DSPC:chol:DSPE-PEG2000-NH2 (Table 2.1). Lipid films were prepared by drying
lipid mixtures (in chloroform) under high vacuum to remove the organic solvent.
Then the lipid film was hydrated in 80 mM PBS and bath sonicated for 30
minutes to obtain a liposome solution. Finally, the liposome solution was further
passed through a 0.1 μm polycarbonate filter membrane (minimum 21 passes)
using a mini-extruder to produce uniform and unilamellar vesicles with
hydrodynamic diameters less than 100 nm. See Figure 2.6 for schematic
description of liposome preparation.
2.3.7 Protocell Assembly
To form protocells, mMSNP are transferred to D.I. water at 1 mg/mL
concentration by centrifugation (15,000 x g, 10 minutes) and added to liposome
solution (2 mg/mL) in 80 mM PBS (1:1 v/v and 1:2 w/w ratios). The mixture was
bath sonicated ~ 10 s and non-fused liposomes were removed by centrifugation
(15,000 x g, 10 minutes). Pelleted protocells were redispersed in 160 mM PBS
via bath sonication, this step is repeated twice.
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Table 2.1 – Hydrodynamic Size Comparison of Liposomes
Sample

Medium

Mol
ratio
(%)

DOPC:chol:DOPEPEG2000

PBS

54:44:2

75.0 ± 0.9

0.139 ±
0.041

DSPC:chol:DSPEPEG2000

PBS

55:44:2

88.5 ± 4.2

0.142 ±
0.017

DSPC:chol:DSPEPEG2000-NH2

PBS

49:49:2

93.5 ± 7.1

0.148 ±
0.023

Hydrodynamic
Diameter (nm)

PdI

Table 2.1 – Composition and representative hydrodynamic size data of
liposomes used for preparation of protocells. Data represent mean ± SD, n=3.
Adapted and reproduced with permission.36 © 2016, The American Chemical
Society.

Figure 2.6 – Liposome Preparation Schematic
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Figure 2.6 – Schematic depicting the preparation of liposomes for SLB fusion.
Individual liposome components are mixed together in chloroform. [1] Solvent
is evaporated under high vacuum.

[2] Dried lipid films is rehydrated in

aqueous buffer (PBS) then bath sonicated to produce polydisperse and
multilamellar liposomes. [3] Sonicated liposomes are then extruded through a
0.1 μm polycarbonate filter membrane to produce small, uniform, unilamellar
liposomes.

66
2.4 References
1.

Allen, T. M.; Cullis, P. R. Drug Delivery Systems: Entering the
Mainstream. Science 2004, 303, 1818-1822.

2.

Iwamoto, T. Clinical Application of Drug Delivery Systems in Cancer
Chemotherapy: Review of the Efficacy and Side Effects of Approved
Drugs. Biol. Pharm. Bull. 2013, 36, 715-718.

3.

Egusquiaguirre, S.; Igartua, M.; Hernández, R.; Pedraz, J. Nanoparticle
Delivery Systems for Cancer Therapy: Advances in Clinical and Preclinical
Research. Clin. Transl. Oncol. 2012, 14, 83-93.

4.

Pattni, B. S.; Chupin, V. V.; Torchilin, V. P. Chem. Rev. Chemical Reviews
2015, 115, 10938-10966.

5.

Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle Therapeutics: An
Emerging Treatment Modality for Cancer. Nat Rev Drug Discov 2008, 7,
771-782.

6.

Deshpande, P. P.; Biswas, S.; Torchilin, V. P. Current Trends in the Use
of Liposomes for Tumor Targeting. Nanomedicine (London, U. K.) 2013, 8,
10.2217/nnm.13.118.

7.

Farokhzad, O. C.; Langer, R. Acs Nano. ACS Nano 2009, 3, 16-20.

8.

Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R.
Nanocarriers as an Emerging Platform for Cancer Therapy. Nat.
Nanotechnol. 2007, 2, 751-760.

9.

Torchilin, V. P. Recent Advances with Liposomes as Pharmaceutical
Carriers. Nat. Rev. Drug Discovery 2005, 4, 145-160.

10.

Çağdaş, M.; Sezer, A. D.; Bucak, S. Liposomes as Potential Drug Carrier
Systems for Drug Delivery. INTECH: 2014.

11.

Reynolds, J. G.; Geretti, E.; Hendriks, B. S.; Lee, H.; Leonard, S. C.; Klinz,
S. G.; Noble, C. O.; Lücker, P. B.; Zandstra, P. W.; Drummond, D. C.;
Olivier Jr, K. J.; Nielsen, U. B.; Niyikiza, C.; Agresta, S. V.; Wickham, T. J.
Her2-Targeted Liposomal Doxorubicin Displays Enhanced AntiTumorigenic Effects without Associated Cardiotoxicity. Toxicol. Appl.
Pharmacol. 2012, 262, 1-10.

12.

Elsabahy, M.; Wooley, K. L. Design of Polymeric Nanoparticles for
Biomedical Delivery Applications. Chem. Soc. Rev. 2012, 41, 2545-2561.

67
13.

Draz, M. S.; Fang, B. A.; Zhang, P.; Hu, Z.; Gu, S.; Weng, K. C.; Gray, J.
W.; Chen, F. F. Nanoparticle-Mediated Systemic Delivery of Sirna for
Treatment of Cancers and Viral Infections. Theranostics 2014, 4, 872-892.

14.

Williford, J.-M.; Wu, J.; Ren, Y.; Archang, M. M.; Leong, K. W.; Mao, H.-Q.
Recent Advances in Nanoparticle-Mediated Sirna Delivery. Annu. Rev.
Biomed. Eng. 2014, 16, 347-370.

15.

Li, Z.; Barnes, J. C.; Bosoy, A.; Stoddart, J. F.; Zink, J. I. Mesoporous
Silica Nanoparticles in Biomedical Applications. Chem. Soc. Rev. 2012,
41, 2590-2605.

16.

Vivero‐Escoto, J. L.; Slowing, I. I.; Trewyn, B. G.; Lin, V. S. Y. Mesoporous
Silica Nanoparticles for Intracellular Controlled Drug Delivery. Small 2010,
6, 1952-1967.

17.

Butler, K. S.; Durfee, P. N.; Theron, C.; Ashley, C. E.; Carnes, E. C.;
Brinker, C. J. Protocells: Modular Mesoporous Silica Nanoparticle‐
Supported Lipid Bilayers for Drug Delivery. Small 2016.

18.

Zhang, H.; Dunphy, D. R.; Jiang, X.; Meng, H.; Sun, B.; Tarn, D.; Xue, M.;
Wang, X.; Lin, S.; Ji, Z.; Li, R.; Garcia, F. L.; Yang, J.; Kirk, M. L.; Xia, T.;
Zink, J. I.; Nel, A.; Brinker, C. J. Processing Pathway Dependence of
Amorphous Silica Nanoparticle Toxicity: Colloidal Vs Pyrolytic. J. Am.
Chem. Soc. 2012, 134, 15790-15804.

19.

Meng, H.; Yang, S.; Li, Z.; Xia, T.; Chen, J.; Ji, Z.; Zhang, H.; Wang, X.;
Lin, S.; Huang, C.; Zhou, Z. H.; Zink, J. I.; Nel, A. E. Aspect Ratio
Determines the Quantity of Mesoporous Silica Nanoparticle Uptake by a
Small Gtpase-Dependent Macropinocytosis Mechanism. ACS Nano 2011,
5, 4434-4447.

20.

Brinker, C. J.; Scherer, G. W. Sol-Gel Science: The Physics and
Chemistry of Sol-Gel Processing. Academic press: 2013.

21.

Wang, L.-S.; Wu, L.-C.; Lu, S.-Y.; Chang, L.-L.; Teng, I. T.; Yang, C.-M.;
Ho, J.-a. A. Biofunctionalized Phospholipid-Capped Mesoporous Silica
Nanoshuttles for Targeted Drug Delivery: Improved Water Suspensibility
and Decreased Nonspecific Protein Binding. ACS Nano 2010, 4, 43714379.

22.

Ashley, C. E.; Carnes, E. C.; Epler, K. E.; Padilla, D. P.; Phillips, G. K.;
Castillo, R. E.; Wilkinson, D. C.; Wilkinson, B. S.; Burgard, C. A.; Kalinich,
R. M.; Townson, J. L.; Chackerian, B.; Willman, C. L.; Peabody, D. S.;
Wharton, W.; Brinker, C. J. Delivery of Small Interfering Rna by PeptideTargeted Mesoporous Silica Nanoparticle-Supported Lipid Bilayers. ACS
Nano 2012, 6, 2174-2188.

68
23.

Epler, K.; Padilla, D.; Phillips, G.; Crowder, P.; Castillo, R.; Wilkinson, D.;
Wilkinson, B.; Burgard, C.; Kalinich, R.; Townson, J.; Chackerian, B.;
Willman, C.; Peabody, D.; Wharton, W.; Brinker, C. J.; Ashley, C.; Carnes,
E. Delivery of Ricin Toxin a-Chain by Peptide-Targeted Mesoporous Silica
Nanoparticle-Supported Lipid Bilayers. Adv. Healthcare Mater. 2012, 1,
348-353.

24.

Cauda, V.; Engelke, H.; Sauer, A.; Arcizet, D.; Bräuchle, C.; Rädler, J.;
Bein, T. Colchicine-Loaded Lipid Bilayer-Coated 50 Nm Mesoporous
Nanoparticles Efficiently Induce Microtubule Depolymerization Upon Cell
Uptake. Nano Lett. 2010, 10, 2484-2492.

25.

Meng, H.; Wang, M.; Liu, H.; Liu, X.; Situ, A.; Wu, B.; Ji, Z.; Chang, C. H.;
Nel, A. E. Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform
for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic
Cancer in Mice. ACS Nano 2015, 9, 3540-3557.

26.

Wang, D.; Huang, J.; Wang, X.; Yu, Y.; Zhang, H.; Chen, Y.; Liu, J.; Sun,
Z.; Zou, H.; Sun, D.; Zhou, G.; Zhang, G.; Lu, Y.; Zhong, Y. The
Eradication of Breast Cancer Cells and Stem Cells by 8-HydroxyquinolineLoaded Hyaluronan Modified Mesoporous Silica Nanoparticle-Supported
Lipid Bilayers Containing Docetaxel. Biomaterials 2013, 34, 7662-7673.

27.

Zhang, X.; Li, F.; Guo, S.; Chen, X.; Wang, X.; Li, J.; Gan, Y.
Biofunctionalized Polymer-Lipid Supported Mesoporous Silica
Nanoparticles for Release of Chemotherapeutics in Multidrug Resistant
Cancer Cells. Biomaterials 2014, 35, 3650-3665.

28.

Ashley, C. E.; Carnes, E. C.; Phillips, G. K.; Padilla, D.; Durfee, P. N.;
Brown, P. A.; Hanna, T. N.; Liu, J.; Phillips, B.; Carter, M. B.; Carroll, N. J.;
Jiang, X.; Dunphy, D. R.; Willman, C. L.; Petsev, D. N.; Evans, D. G.;
Parikh, A. N.; Chackerian, B.; Wharton, W.; Peabody, D. S.; Brinker, C. J.
The Targeted Delivery of Multicomponent Cargos to Cancer Cells by
Nanoporous Particle-Supported Lipid Bilayers. Nat. Mater. 2011, 10, 389397.

29.

Liu, X.; Situ, A.; Kang, Y.; Villabroza, K. R.; Liao, Y.; Chang, C. H.;
Donahue, T.; Nel, A. E.; Meng, H. Irinotecan Delivery by Lipid-Coated
Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety
over Liposomes for Pancreatic Cancer. ACS Nano 2016, 10, 2702-2715.

30.

Huang, W.-C.; Burnouf, P.-A.; Su, Y.-C.; Chen, B.-M.; Chuang, K.-H.; Lee,
C.-W.; Wei, P.-K.; Cheng, T.-L.; Roffler, S. R. Engineering Chimeric
Receptors to Investigate the Size- and Rigidity-Dependent Interaction of
Pegylated Nanoparticles with Cells. ACS Nano 2016, 10, 648-662.

31.

Mackowiak, S. A.; Schmidt, A.; Weiss, V.; Argyo, C.; von Schirnding, C.;
Bein, T.; Bräuchle, C. Targeted Drug Delivery in Cancer Cells with Red-

69
Light Photoactivated Mesoporous Silica Nanoparticles. Nano Lett. 2013,
13, 2576-2583.
32.

Porotto, M.; Yi, F.; Moscona, A.; LaVan, D. A. Synthetic Protocells Interact
with Viral Nanomachinery and Inactivate Pathogenic Human Virus. PloS
one 2011, 6, e16874.

33.

Han, N.; Zhao, Q.; Wan, L.; Wang, Y.; Gao, Y.; Wang, P.; Wang, Z.;
Zhang, J.; Jiang, T.; Wang, S. Hybrid Lipid-Capped Mesoporous Silica for
Stimuli-Responsive Drug Release and Overcoming Multidrug Resistance.
ACS Appl. Mater. Interfaces 2015, 7, 3342-3351.

34.

Liu, J.; Stace-Naughton, A.; Jiang, X.; Brinker, C. J. Porous Nanoparticle
Supported Lipid Bilayers (Protocells) as Delivery Vehicles. J. Am. Chem.
Soc. 2009, 131, 1354-1355.

35.

Liu, J.; Jiang, X.; Ashley, C.; Brinker, C. J. Electrostatically Mediated
Liposome Fusion and Lipid Exchange with a Nanoparticle-Supported
Bilayer for Control of Surface Charge, Drug Containment, and Delivery. J.
Am. Chem. Soc. 2009, 131, 7567-7569.

36.

Durfee, P. N.; Lin, Y.-S.; Dunphy, D. R.; Muñiz, A. J.; Butler, K. S.;
Humphrey, K. R.; Lokke, A. J.; Agola, J. O.; Chou, S. S.; Chen, I. M.;
Wharton, W.; Townson, J. L.; Willman, C. L.; Brinker, C. J. Mesoporous
Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active
Targeting and Delivery to Individual Leukemia Cells. ACS Nano 2016.

37.

Bayerl, T. M.; Bloom, M. Physical Properties of Single Phospholipid
Bilayers Adsorbed to Micro Glass Beads. A New Vesicular Model System
Studied by 2h-Nuclear Magnetic Resonance. Biophys. J. 1990, 58, 357362.

38.

Johnson, S. J.; Bayerl, T. M.; McDermott, D. C.; Adam, G. W.; Rennie, A.
R.; Thomas, R. K.; Sackmann, E. Structure of an Adsorbed
Dimyristoylphosphatidylcholine Bilayer Measured with Specular Reflection
of Neutrons. Biophys. J. 1991, 59, 289-294.

39.

Keller, C. A.; Glasmästar, K.; Zhdanov, V. P.; Kasemo, B. Formation of
Supported Membranes from Vesicles. Phys. Rev. Lett. 2000, 84, 54435446.

40.

Reviakine, I.; Brisson, A. Formation of Supported Phospholipid Bilayers
from Unilamellar Vesicles Investigated by Atomic Force Microscopy.
Langmuir 2000, 16, 1806-1815.

41.

Johnson, J. M.; Ha, T.; Chu, S.; Boxer, S. G. Early Steps of Supported
Bilayer Formation Probed by Single Vesicle Fluorescence Assays.
Biophys. J. 2002, 83, 3371-3379.

70
42.

Richter, R. P.; Brisson, A. R. Following the Formation of Supported Lipid
Bilayers on Mica: A Study Combining Afm, Qcm-D, and Ellipsometry.
Biophys. J. 2005, 88, 3422-3433.

43.

Cremer, P. S.; Boxer, S. G. Formation and Spreading of Lipid Bilayers on
Planar Glass Supports. J. Phys. Chem. B 1999, 103, 2554-2559.

44.

Savarala, S.; Ahmed, S.; Ilies, M. A.; Wunder, S. L. Formation and
Colloidal Stability of Dmpc Supported Lipid Bilayers on Sio2 Nanobeads.
Langmuir 2010, 26, 12081-12088.

45.

Garcia-Manyes, S.; Oncins, G.; Sanz, F. Effect of Ion-Binding and
Chemical Phospholipid Structure on the Nanomechanics of Lipid Bilayers
Studied by Force Spectroscopy. Biophys. J. 2005, 89, 1812-1826.

46.

Mornet, S.; Lambert, O.; Duguet, E.; Brisson, A. The Formation of
Supported Lipid Bilayers on Silica Nanoparticles Revealed by
Cryoelectron Microscopy. Nano Lett. 2005, 5, 281-285.

47.

Buranda, T.; Huang, J.; Ramarao, G.; Ista, L. K.; Larson, R. S.; Ward, T.
L.; Sklar, L. A.; Lopez, G. P. Biomimetic Molecular Assemblies on Glass
and Mesoporous Silica Microbeads for Biotechnology. Langmuir 2003, 19,
1654-1663.

48.

Dengler, E. C.; Liu, J.; Kerwin, A.; Torres, S.; Olcott, C. M.; Bowman, B.
N.; Armijo, L.; Gentry, K.; Wilkerson, J.; Wallace, J.; Jiang, X.; Carnes, E.
C.; Brinker, C. J.; Milligan, E. D. Mesoporous Silica-Supported Lipid
Bilayers (Protocells) for DNA Cargo Delivery to the Spinal Cord. J.
Controlled Release 2013, 168, 209-224.

49.

Townson, J. L.; Lin, Y.-S.; Agola, J. O.; Carnes, E. C.; Leong, H. S.;
Lewis, J. D.; Haynes, C. L.; Brinker, C. J. Re-Examining the Size/Charge
Paradigm: Differing in Vivo Characteristics of Size- and Charge-Matched
Mesoporous Silica Nanoparticles. J. Am. Chem. Soc. 2013, 135, 1603016033.

50.

Lin, Y.-S.; Haynes, C. L. Impacts of Mesoporous Silica Nanoparticle Size,
Pore Ordering, and Pore Integrity on Hemolytic Activity. J. Am. Chem.
Soc. 2010, 132, 4834-4842.

51.

Lin, Y.-S.; Abadeer, N.; Hurley, K. R.; Haynes, C. L. Ultrastable,
Redispersible, Small, and Highly Organomodified Mesoporous Silica
Nanotherapeutics. J. Am. Chem. Soc. 2011, 133, 20444-20457.

52.

Chen, P.-K.; Lai, N.-C.; Ho, C.-H.; Hu, Y.-W.; Lee, J.-F.; Yang, C.-M. New
Synthesis of Mcm-48 Nanospheres and Facile Replication to Mesoporous
Platinum Nanospheres as Highly Active Electrocatalysts for the Oxygen
Reduction Reaction. Chem. Mater. 2013, 25, 4269-4277.

71
53.

Nandiyanto, A. B. D.; Kim, S.-G.; Iskandar, F.; Okuyama, K. Synthesis of
Spherical Mesoporous Silica Nanoparticles with Nanometer-Size
Controllable Pores and Outer Diameters. Microporous Mesoporous Mater.
2009, 120, 447-453.

54.

Wang, J.; Sugawara-Narutaki, A.; Shimojima, A.; Okubo, T. Biphasic
Synthesis of Colloidal Mesoporous Silica Nanoparticles Using Primary
Amine Catalysts. J. Colloid Interface Sci. 2012, 385, 41-47.

55.

Shen, D.; Yang, J.; Li, X.; Zhou, L.; Zhang, R.; Li, W.; Chen, L.; Wang, R.;
Zhang, F.; Zhao, D. Biphase Stratification Approach to Three-Dimensional
Dendritic Biodegradable Mesoporous Silica Nanospheres. Nano Lett.
2014, 14, 923-932.

56.

Huang, X.; Li, L.; Liu, T.; Hao, N.; Liu, H.; Chen, D.; Tang, F. The Shape
Effect of Mesoporous Silica Nanoparticles on Biodistribution, Clearance,
and Biocompatibility in Vivo. ACS Nano 2011, 5, 5390-5399.

57.

Yu, T.; Malugin, A.; Ghandehari, H. Impact of Silica Nanoparticle Design
on Cellular Toxicity and Hemolytic Activity. ACS Nano 2011, 5, 57175728.

72
CHAPTER 3
OPTIMIZATION AND CHARACTERIZATION OF THE PROTOCELL
PLATFORM

This chapter was adapted from
Durfee, P. N.; Lin, Y-S.; Dunphy, D. R.; Muñiz, A. J.; Butler, K. S.; Humphrey, K.
R.; Lokke, A. J.; Agola, J. O.; Chou, S. S.; Chen, I-M.; Wharton, W.; Townson, J.
L.; Willman, C. L.; Brinker, C. J. Mesoporous Silica Nanoparticle-Supported
Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual
Leukemia Cells. ACS Nano 2016, DOI: 10.1021/acsnano.6b02819. © 2016
American Chemical Society.
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3.1 Overview
The fact that the modular MSNP features of size, shape, pore size, pore
volume, and pore morphology are important for their ultimate use as nanocarriers
prompts us to ask how MSNP physicochemical characteristics along with
processing conditions influence vesicle fusion to form MSNP-supported lipid
bilayers aka ‘protocells’ for use as nanocarriers - where key criteria are size
monodispersity, preservation of shape, and stability within physiologically
relevant complex biological media. To address this question we first chose to
study monosized ~ 107 nm (hydrodynamic diameter measured by DLS) singlecrystal-like mMSNP composed of close-packed cylindrical pores confined within
a hexagonally shaped nanoparticle that is disc-shaped in cross-section (Figure
3.1). This highly asymmetric mMSNP (referred to as Hexagonal mMSNP) has
opposing porous surfaces adjoined by grooved silica facets, thereby providing
two distinct surfaces for vesicle fusion.
3.2 Results and Discussion
3.2.1 Optimized MSNP-Supported Lipid Bilayer Fusion Conditions
To understand the roles of surface area (SA) SAlipid:SAsilica and ionic
strength on vesicle fusion, we assembled protocells by mixing Hexagonal
mMSNPs with ~90 nm hydrodynamic diameter liposomes (composition = DSPC,
cholesterol (-chol), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) – where the molar ratio of
DSPC:chol:DSPE-PEG2000 equaled 54:44:2 – Table 2.1). Liposomes were

Figure 3.1 – TEM Image of Hexagonal MSNPs Showing Asymmetry

Figure 3.1 – Representative TEM image of Hexagonal mMSNPs. A) TEM
image shows highly asymmetric particles with a narrow size distribution. B)
Enlarged region highlights hexagonal porous silica surface.
region highlights grooved disc-shaped solid silica surface.

C) Enlarged
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prepared by extrusion in a series of solutions consisting of 0 mM, 40 mM, 80
mM,120 mM, 160 mM, and 320 mM ionic strength phosphate buffered saline
(PBS). To complete the assembly process, the protocells were washed twice by
centrifugation and resuspended in the final buffer solution with bath sonication
and pipetting. Through variation of the lipid:silica ratio (wt:wt) and PBS
concentration, we were able to adjust the SAlipid:SAsilica from 0 (mMSNP alone
used as a control) to 4.22:1 and the ionic strength of the fusion conditions from 0
mM (water) to 160 mM spanning physiologically relevant ranges needed for in
vivo applications (vide infra). We used a shape applicable model to calculate the
external SAsilica from dimensional measurements of mMSNPs obtained from TEM
images (Table 3.1), using the pore volume obtained from nitrogen sorption data
(Table 3.1 and Figure 3.2), and assuming 2.0 g/cm3 as the silica framework
density;1 SAlipid was calculated assuming 0.59 nm2 as the phospholipid head
group area;2 and that cholesterol does not contribute to SAlipid (See calculation
details in Appendix A.1). Using a Malvern Zetasizer Nano ZS, we measured
the hydrodynamic diameter, PdI, and zeta-potential () of protocells. Figure 3.3
plots hydrodynamic diameter and PdI as a function of SAlipid:SAsilica and ionic
strength. Consistent with our expectations from DLVO theory, without lipid,
mMSNPs ( = - 28.1 mV, Table 3.2) aggregate with increasing ionic strength due
to the reduced Debye length and concomitant reduction in the range of
electrostatic repulsion. For samples prepared with SAlipid:SAsilica < 1, the critical
ratio needed to exactly cover the external surface of the mMSNP with a single
phospholipid bilayer, we observed severe aggregation that increases with ionic

Table 3.1 – MSNP Shape, Size, Surface Area, and Pore Morphology Analyses
Average hydrodynamic size comparison of mMSNPs of various size, shape, and pore morphology before and after
SLB fusion, data accompanies images in Figure 3.5, data represents mean ± SD, n = 3. Average mMSNP dimensions
from TEM images of mMSNPs, data represent mean ± SD, n = 50. Surface area and pore volume measurements
calculated from Nitrogen sorption data, * data from the literature. 3 Estimated numbers calculated from equations
described later in Appendix A.1 and image analysis in Appendix B.1. Adapted and reproduced with permission.4 ©
2016, The American Chemical Society.
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Figure 3.2 – Adsorption-desorption Isotherms

Figure 3.2 – N2 adsorption-desorption isotherms and pore size distribution
(inset) of A) Hexagonal mMSNPs with 2.8 nm pores, B) Spherical mMSNPs
with 2.8 nm pores, C) Spherical mMSNPs with 5, 9, or 18 nm pores, and D)
Rod-like mMSNPs with 2.8 nm pores. Adapted and reproduced with
permission.4

© 2016, The American Chemical Society.

description of calculations in Appendix A.2.

More detailed
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Figure 3.3 – Optimization of Surface Area Ratio and Ionic Strength in Protocell
Assembly

Figure 3.3 – Comparison of Hexagonal protocells prepared in differing ionic
strength conditions using different liposome to mMSNP mass ratios (w:w) –
bottom scale, and respective calculated inner liposome to outer mMSNP
surface area ratios – top scale. Hydrodynamic size (Left axis) corresponds to
bar graph with black dashed line indicating optimal protocell size range.
Polydispersity index (Right axis) corresponds to box plots with blue dashed
line indicating threshold for monodispersity, values below the dashed line are
considered monodisperse (PdI < 0.1). Green arrow identifies the optimal ionic
strength and liposome:mMSNP ratio fusion conditions used for subsequent
experiments.

Adapted and reproduced with permission. 4

© 2016, The

American Chemical Society. Surface area calculations described in detail in
Appendix A.1.
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Table 3.2 – Hydrodynamic Size and Zeta Potential of Protocell Components
Sample

Medium

Hydrodynamic
Diameter (nm)

PdI

Zeta
potential
(mV)

mMSNP

H2O

106.90 ± 0.54

0.50 ± 0.015

-41.0 ± 0.9

mMSNP

PBS

193.4 ± 2.83

0.292 ±
0.044

-28.1 ± 1.5

DSPC:chol:DSP
E-PEG2000
Liposomes

PBS

92.54 ± 0.26

0.112 ±
0.006

-2.9 ± 0.8

Protocell

PBS

137.30 ± 0.30

0.085 ±
0.013

-3.3 ± 0.9

Table

3.2

–

Hydrodynamic

size

characteristics

and

zeta

potential

measurements of modular protocell components. Liposome formulation
DSPC:chol:DSPE-PEG2000 (mol % 54:44:2). Data represent mean ± SD, n = 3.
Adapted and reproduced with permission.4 © 2016, The American Chemical
Society.
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strength indicative of aggregation of exposed silica surfaces accompanied by
liposome adsorption and possible bridging. For samples prepared with
SAlipid:SAsilica > 1, we observed much more uniformly sized particles (PdI < 0.1)
with hydrodynamic diameters ca 30 nm larger than the parent mMSNP and zetapotentials in the range ( = - 3.3 mV, Table 3.2) consistent with the formation of a
PEGylated zwitterionic SLB that shields the mMSNP charge and provides a
repulsive hydration barrier that stabilizes the protocells within biologically relevant
media (vide infra). The exception are samples prepared in pure water (ionic
strength = 0 mM) where for all SAlipid:SAsilica we observed diameters 50 to 60 nm
greater than the parent mMSNP along with a trend of increasing PdI (Table 3.3).
Samples prepared in pure water have a zeta potential comparable to the parent
mMSNP ( = - 41.0 mV) and aggregate when transferred to 160 mM PBS ( = 28.1 mV). These ionic strength effects indicate fusion to be inhibited in pure
water and are consistent with those obtained by Savarala et al. for fusion of
single component 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)
zwitterionic vesicles on solid 100 nm silica beads at SAlipid:SAsilica = 1, where ionic
strengths ≥ 0.05 mM NaCl were needed for fusion as assessed by DSC.5 Direct
Cryo-TEM observation of Hexagonal mMSNPs fused with DSPC-based
liposomes at SAlipid:SAsilica = 2.11:1 and ionic strength 40 mM show a conformal
SLB with thickness 4.7 ± 0.5 nm (Figure 2.1 and Figure 3.4) observed both on
the porous and grooved surfaces (Figure 3.1). We note the increased diameter
of ~ 10 nm determined by TEM is inconsistent with the ~ 25 nm increase
measured by DLS. Such discrepancies are often reported in the literature. 6, 7

Table 3.3 – Analysis of hydrodynamic size and PdI change in protocells prepared under differing PBS ionic strength
conditions and transferred to physiological ionic strength (160 mM) PBS. The size change of protocells prepared in the
absence of salt suggests that protocells do not form in pure water, since the size increase is clearly larger than all
protocells prepared in increasing ionic strength conditions. Data represent mean ± SD, n = 3. Adapted and reproduced
with permission.4 © 2016, The American Chemical Society.

Table 3.3 – Size Change of Protocells Assembled Under Differing Ionic Strength Conditions
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Figure 3.4 – Average Bilayer Thickness Measured by TEM

Figure 3.4 – Average lipid bilayer thickness measured from TEM images.
Data represent mean ± SD, n = 33.

Adapted and reproduced with

permission.4 © 2016, The American Chemical Society. See Appendix B.2 for
addition information on thickness measurements.
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Considering that the SAlipid of a 90 nm liposome is less than that of a Hexagonal
mMSNP, multiple liposome fusion events are required to create a complete SLB
(Figure 2.1). In time-dependent Cryo-TEM, Mornet et al. showed liposome
fusion on 100 nm colloidal silica nanoparticles to occur by a ‘two-step’ process
involving adsorption followed by deformation and rupture.8 Although we did not
conduct a time- dependent Cryo-TEM study, we did observe similarly evidence of
deformed vesicles that conform to the mMSNPs, which likely subsequently
rupture to form SLBs in a similar ‘two-step’ process. We should note that,
although it has been suggested that SLB formation on spherical, isotropic
MSNPs via probe sonication of dried lipid films in saline solution may proceed
through a pathway other than vesicle fusion, implementing the identical probe
sonication technique7, 9 for Hexagonal mMSNPs results in protocells
indistinguishable (i.e., nearly identical hydrodynamic diameter and PdI) from
those formed by fusion with DSPC-based liposomes at SAlipid:SAsilica = 4.22:1 and
ionic strength 40 mM (Table 3.4). Finally, to help avoid any accompanying
aggregation from occurring at the ionic strengths needed for vesicle fusion (and
ultimately for ex ovo and in vivo applications, vide infra), we propose that
conditions of excess of lipid and a low but sufficient ionic strength serve to
increase the relative rate of vesicle fusion with respect to aggregation thus
allowing the formation of monosized protocells with a low PdI (Figure 3.3).
Our results on vesicle fusion on Hexagonal mMSNP established a wide
processing window in which to synthesize rather monosized protocells. As noted
above, a SAlipid:SAsilica ≈ 2:1 and ionic strength 40 mM appeared to represent an
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Table 3.4 – Comparison of Assembly Conditions

Table 3.4 – Comparison of protocells assembled using the methods described
in our paper and those assembled using probe sonication conditions
described in the literature.7, 9 Both methods produced protocells of similar size
and monodispersity profile. Data represent mean ± SD, n = 3. Adapted and
reproduced with permission.4 © 2016, The American Chemical Society.
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optimal fusion condition resulting in the smallest combination of hydrodynamic
diameter and PdI (highlighted by a green arrow in Figure 3.3). To test how
this condition depended on bilayer fluidity or charge, we prepared vesicles
containing unsaturated or saturated phosphatidylcholine (e.g., DOPC or DSPC)
or the cationic lipid DOTAP based on liposomal formulations reported in the
literature (Table 3.5). We found, in general, that these conditions resulted in
monosized protocells for zwitterionic lipid based formulations, whereas DOTAP
resulted in aggregate formation. To further understand the influence of MSNP
physicochemical properties on protocell formation, we tested the optimized fusion
conditions on a ‘library’ of MSNPs with differing shapes (i.e., spherical or rodlike), particle size distributions (mMSNP or EISA MSNP), pore diameters (2.8 to
18 nm), and pore morphologies (aligned cylindrical, isotropic worm-like, and
dendritic).13-20 (See Figure 3.5 and Table 3.1 for a summary of the mMSNP and
EISA MSNP physicochemical properties). As observed by direct Cryo-TEM
observation, ~ 4 to 5 nm thick conformal SLBs formed on all of the tested
particles (Figures 3.5A-L and Figure 3.4), and DLS showed a consistent
increase in diameter of ~ 25 to 40 nm (Figure 3.5M). By visual examination, we
observed a well-suspended and transparent dispersion of protocells in PBS
contrasted with bare mMSNPs that settle under normal gravity (Figure 3.6). The
exception was for spherical mMSNPs prepared with dendritic pore diameters of ~
18 nm. In this case we observed, by Cryo-TEM, vesicle adsorption and
deformation on the mMSNP surface but little evidence of complete SLB fusion
(Figure 3.7). We propose that for this highly porous particle the magnitude of

Table 3.5 – Hydrodynamic size measurement and polydispersity index values of liposomes, Hexagonal
mMSNPs, and assembled protocells using techniques described in my dissertation paper with different
liposome formulations described in the literature.3, 7, 10-12 Data represent mean ± SD, n = 3. Adapted and
reproduced with permission.4 © 2016, The American Chemical Society.
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Table 3.5 –Size Comparison of Protocells Using Different SLB Formulations

Figure 3.5 – TEM and Cryo-TEM of MSNPs and Protocells of Varying Shape
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Figure 3.5 – Representative TEM and Cryo-TEM images of MSNPs and
corresponding protocells of various shape and pore morphology including A)
and B) Hexagonal mMSNPs and protocells, C) and D) Spherical 2.8 nm pore
mMSNPs and protocells, E) and F) Spherical 5 nm pore mMSNPs and
protocells, G) and H) Spherical 8 nm pore mMSNPs and protocells, I) and J)
Rod-like 2.8 nm pore mMSNPs and protocells, K) and L) Aerosol assisted
EISA MSNPs and protocells. Yellow arrows highlight the SLB (~ 4.6 nm) in
the Cryo-TEM images. M) Hydrodynamic size analysis by DLS shows an
increase in nanoparticle diameter following SLB fusion. DLS data represent
mean ± SD, n = 3. Scale bars = 50 nm. L) Cryo-TEM images of EISA
protocells were carried out at Baylor College of Medicine (Houston, TX) by C.
Jia-Yin Fu, H. Khant and W. Chiu. Adapted and reproduced with permission. 4
© 2016, The American Chemical Society.

Figure 3.6 – Visual Evidence of Protocell Stability in PBS
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Figure 3.6 – Fluorescent mMSNPs and protocells in cuvettes illustrate the
colloidal stability of mMSNPs in H2O and aggregation driven settling of
mMSNPs in 160 mM PBS, protocells remain suspended in 160 mM PBS.
Adapted and reproduced with permission.4 © 2016, The American Chemical
Society.

Figure 3.7 – Cryo-TEM of 18 nm MSNPs and Liposomes
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Figure 3.7 – Cryo-TEM image of 18 nm pore structured mMSNPs mixed with
liposomes under optimized fusion conditions as established in Figure 3.3
showing large lipid-associated aggregates. (Inset): conventional TEM of 18
nm pore structured mMSNPs. Yellow arrows highlight regions of liposome to
silica interactions, red arrows highlight exposed silica surfaces. Scale bar =
100 nm. Corresponding hydrodynamic size measurements: mMSNPs with 18
nm pore diameter, Z-average diameter = 123.0 ± 0.3 nm (Avg PdI = 0.056 ±
0.018); lipid associated aggregates Z-average diameter = 396.9 ± 13.0 nm
(Avg PdI = 0.139 ± 0.043). DLS data represent mean ± SD, n = 3. Adapted
and reproduced with permission.4 © 2016, The American Chemical Society.
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possible van der Waals and electrostatic interactions (that all scale nominally
with surface silica concentration) is insufficient to cause rupture/fusion to form a
SLB. Moreover, the topography of the silica surface is influential in the spreading
process of the SLB, where 10 – 30 nm deep scratches were found to arrest
spreading of egg phosphatidylcholine bilayers on borosilicate glass due to
unfavorable bending interactions needed to maintain conformity.21, 22 It is likely
that for mMSNPs there is a critical pore size above which the highly contoured
regions of the pore arrest spreading and fusion. This pore size should be
sensitive to the SLB composition, which dictates the bending modulus. Using
unsaturated lipids and, potentially, decreasing the cholesterol content might be
expected to make the membrane more flexible and promote SLB formation on
mMSNPs with larger pore size,23, 24 however, at the cholesterol concentration (44
%) used in our experiments, it is unlikely that the transition temperature (-Tm) of
the phosphatidylcholine SLB component is a major factor in size stability.25 It is
also conceivable that fusion might be promoted by doping the buffer with divalent
ions like Ca2+ or Mg2+ that, through several possible electrostatically mediated
pathways, are known to promote vesicle fusion on glass.26, 27 Finally adsorption
of drugs within the pores would in essence increase the solid fraction of the
surface and potentially promote attractive DLVO interactions and vesicle fusion.
3.2.2 Factors Influencing Colloidal Stability of Monosized Protocells for Use
In Vivo
Having established a generalized process by which to reliably form
monosized protocells in vitro, we next studied how the physicochemical

91
properties of the SLB influence colloidal stability in complex biological media. As
noted above, in vivo colloidal stability is crucial to the realization of both passive
and active targeting as any process that non-selectively removes nanoparticles
from circulation reduces concomitantly the number of particles that could
accumulate in the tumor microenvironment due to the EPR effect or those that
are available to selectively bind to target cells or tissues. Despite its importance,
few papers unambiguously establish the stability of nanocarriers, which may in
part explain inconsistent and unreproducible results in the literature, which are
now generally recognized.28-30 Problematic is that in vivo colloidal stability is
difficult to predict from in vitro measurements. For example, we recently showed
cationic MSNPs with identical size, shape, and surface charge (and therefore
indistinguishable according to National Cancer Institute – Nanotechnology
Characterization Laboratory standards)28 to have completely different circulation
and non-specific binding behaviors as elucidated by direct observation ex ovo in
a chicken embryo chorioallantoic membrane (CAM) model31 and SPECT imaging
in a rat model (Adolphi et.al. private communication). Here, we evaluated
colloidal stability by determination of hydrodynamic size and polydispersity index
in complex biological media and by direct observation in the CAM model.
First, we examined how the encapsulating SLB and its fluidity affected
long-term stability compared to the bare mMSNP surface. We prepared
liposomes with zwitterionic lipids using either unsaturated DOPC or saturated
DSPC as the major liposome component. Our comparison between DOPC and
DSPC is ideal because these lipids possess nearly identical molar mass, have
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the same acyl tail length, and yet exhibit Tm (-20 °C and 55 °C respectively)
below and above the storage and physiological temperatures (22 °C and 37 °C,
respectively). Additionally, the cis-configuration double bonds present in the
DOPC acyl chains (absent in DSPC) are highly susceptible to oxidation, which
can lead to structural instability.32 We prepared unsaturated DOPC-based
(composition = DOPC, chol, and 1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DOPE-PEG2000) –
DOPC:chol:DOPE-PEG2000 mol ratio of 54:44:2) and saturated DSPC-based
(composition = DSPC:chol:DSPE-PEG2000 mol ratio of 54:44:2) vesicles by
extrusion as previously described. Liposome compositions and hydrodynamic
diameters are summarized in Table 2.1, where all possessed a hydrodynamic
diameter < 100 nm and low PdI value < 0.2. Liposome to mMSNP fusion was
achieved in 40 mM PBS as described earlier; then protocells were finally
redispersed in 160 mM PBS. The formation of a complete SLB surrounding the
MSNP cores was verified by combined techniques: DLS measurements showed
the hydrodynamic diameter to increase uniformly by ~ 30 nm compared to
mMSNPs, while maintaining a low PdI (< 0.1) (Tables 3.1 and 3.2). Zetapotential measurements indicated the Hexagonal mMSNP protocells to have a
zeta potential (- 3.3 mV) similar to the corresponding zwitterionic liposomes (- 2.9
mV) and much lower than the mMSNP (- 28.1 mV) (Table 3.1). Direct
observation by Cryo-TEM (Figure 3.5B) showed the presence of a uniform
conformal SLB surrounding the mMSNP cores.
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Figure 3.8A shows changes in hydrodynamic size of protocells for 72
hours at 37 °C compared to bare mMSNP controls (see Table 3.6 for
corresponding PdI). Whereas the hydrodynamic size of bare mMSNPs increases
within minutes of transfer to PBS at room temperature, and more rapidly at 37
°C, both DOPC-based and DSPC-based protocells maintain uniform size for 24
hours. Our results suggest that the colloidal stability of the protocells is primarily
due to the zwitterionic SLB component rather than the PEG component, as the
trends observed for DOPC and DSPC-based protocells prepared with and
without PEG are nearly identical (Figure 3.8A). The stabilizing effect of the
zwitterionic SLB can be attributed to several factors. Zwitterionic coatings are
shown to increase nanoparticle stability in high salt concentration solutions due
to hydration repulsion which also minimizes non-specific protein adsorption in
serum containing solutions.33-36 In addition, the presence of both positively and
negatively charged functional groups on nanoparticle surfaces has been shown
to increase solubility in water over a wide pH range, limit non-specific interactions
with cultured cells, and display a non-toxic profile upon interaction with cells,
based on cell viability assessment.37 That the protocells are encapsulated
completely within a zwitterionic SLB is evidenced by the hydrodynamic size / PdI
change of bare mMSNPs, increasing from 106.9 nm / 0.050 to 193.4 nm / 0.292
in PBS after centrifugation (Table 3.2) along with their rapidly settling in PBS
solution (Figure 3.6); incomplete SLB coverage would similarly result in the
formation of irreversible aggregates via electrostatic destabilization and van der
Waals forces, vide supra.

Figure 3.8 – Comparison of SLB Formulation on Protocell Size Stability

Figure 3.8 – A) Hydrodynamic size of protocells prepared with differing SLB
formulations versus incubation time at 37 °C in 160 mM PBS. Trend in size
change appears dependent on the extent of saturation of the lipid component
of the SLB rather than PEGylation. B) Hydrodynamic size of PEGylated
protocells prepared with differing SLB formulations versus incubation time at
37 °C in DMEM + 10 % FBS. All data represent mean ± SD, n = 3. Adapted
and reproduced with permission.4 © 2016, The American Chemical Society.
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mean ± SD, n = 3. Adapted and reproduced with permission.4 © 2016, The American Chemical Society.

PBS or DMEM + 10 % FBS. Data corresponds to size data reported in Figures 3.7A and 3.7B. Data represent

Table 3.6 – Analysis of PdI of Hexagonal mMSNPs and protocells after incubation for 72 hours at 37°C in either

Table 3.6 – MSNP and Protocell PdI Measurements
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Concerning the influence of lipid bilayer composition on long-term stability,
we find that, although both DOPC-based and DSPC-based protocells are stable
for 24 hours, the size of both PEGylated and non-PEGylated DOPC-based
protocells increases progressively from 24 to 72 hours in PBS. In comparison,
DSPC-based protocells remain stable for > 72 hours at 37 °C in PBS (Figure
3.8A) and for over 6 months at room temperature (Table 3.7). To assess the
possible role of lipid oxidation as being the cause of the instability of DOPCbased protocells, we prepared protocells in de-oxygenated PBS and determined
their hydrodynamic size during storage for 7 days at 37 °C. Interestingly, we find
DOPC-based protocells to remain stable in an oxygen reduced buffer, whereas
they aggregate in standard PBS. In comparison, the presence or absence of
oxygen made no difference in DSPC-based protocell size stability (Figure 3.9).
This result indicates that the double bonds present in the acyl chains of
unsaturated lipids are susceptible to oxidation and that lipid oxidation plays a
significant role in the long-term stability of the corresponding protocells, where
lipid oxidation presumably compromises the SLB leading to aggregation.
Storage of protocells prepared with unsaturated lipids in de-oxygenated solvents
should significantly increase ‘shelf-life’ needed for practical clinical translation.
Although, we have noted that colloidal stability of the protocells is primarily
due to the zwitterionic SLB component, modification of nanocarriers with
hydrophilic polymers have been widely shown to prolong in vivo circulation times,
reduce protein adsorption, and reduce phagocytosis by immune cells. 38
Therefore, we used only PEGylated protocells to examine the influence of Tm in a

mean ± SD, n = 3. Adapted and reproduced with permission.4 © 2016, The American Chemical Society.

under static conditions at 25 °C. SLB formulation DSPC:chol:DSPE-PEG2000 (mol % 54:44;2). Data represent

Table 3.7 – Hydrodynamic size characteristics of Hexagonal mMSNP and protocells after 6-month storage

Table 3.7 – Long-term Hydrodynamic Size Analysis
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Figure 3.9 – Protocell Stability Assessment under Deoxygenated Conditions

Figure 3.9 – Hydrodynamic size of A) DOPC-based protocells or B) DSPCbased protocells stored in either 160 mM standard PBS or deoxygenated PBS
at 37°C for 7 days. The presence of oxygen in solution appears to cause a
size increase likely due to the oxidation of the double bonds present in the acyl
chains of DOPC. Neither the presence nor absence of oxygen appears to
influence the size of DSPC-based protocells, as they do not contain any
double bonds in the acyl chains. Data represent mean ± SD, n = 3. Adapted
and reproduced with permission.4 © 2016, The American Chemical Society.
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more complex medium. We prepared protocells in PBS and then transferred
them to a cell culture medium containing fetal bovine serum. Similar to the
previous experiment, DSPC-based protocells maintain size stability for > 72
hours at 37 °C (Figure 3.7A), indicating minimal protein binding and
destabilization of the SLB. Interestingly, we observe the identical size stability for
DOPC-based protocells in complete media, suggesting that protein adsorption
stabilizes the DOPC-based SLB and/or provides a steric barrier toward fusion
and aggregation despite there being no measureable increase in hydrodynamic
diameter.
Overall, we find that the zwitterionic SLB confers excellent colloidal
stability to the protocell in physiologically relevant media. Both unsaturated and
saturated SLBs prepared with and without PEG have greatly enhanced stability
compared to the parent mMSNP. Nevertheless, the measured long-term stability
of DSPC-based monosized protocells, compatibility with the majority of mMSNP
cores tested, and potential to incorporate functional modifications to PEGylated
lipids, in particular amine terminated 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2000-NH2)
which can be chemically modified with a functional component, prompted us to
choose the DSPC-PEG-based protocell formulation for further in vitro, ex ovo,
and in vivo studies.
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3.2.3 Biocompatibility and Protocell Size Stability Ex Ovo and In Vivo
Previous studies have shown mesoporous silica to be a biocompatible
material; however, the interpretation of the overall biocompatibility of MSNPbased nanocarriers is complex due to several factors including methods of
synthesis, physicochemical properties, size distribution, and surface
modifications.39 Therefore, to assess the influence of the SLB on biocompatibility
and to determine the uniformity of the SLB coating, we incubated mMSNPs and
protocells with human red blood cells (hRBCs). We observed that the hemolytic
activity and potential toxicity of bare mMSNPs can be completely abolished with
a SLB (Figure 3.10). This result supports evidence of a complete (defect-free)
lipid bilayer coating that screens silanols (Si-OH) and anionic deprotonated
silanols (Si-O-) implicated in hemolysis40 and, thereby, provides enhanced
biocompatibility of the protocells vis-à-vis mMSNPs.
Earlier we established that monosized protocells maintain long-term
colloidal stability in PBS and complete cell culture media; however, we sought a
more rigorous test for our platform under more dynamic conditions. Protein
corona formation onto nanoparticle surfaces has been shown to occur
immediately upon exposure to a live animal system.41 Thus, we examined
protocell size stability after intravenous injection and circulation because, to the
best of our knowledge, no current reports have examined nanoparticle stability
post-injection. Fluorescent nanoparticle labeling provided useful qualitative
analysis of stability within the CAM vasculature, which led us to seek quantitative
measures of protocell size after separation from blood samples extracted post-
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Figure 3.10 – Hemolysis Assay

Figure 3.10 – A) Percentage of lysed human red blood cells (hRBCs) after
exposure to 25, 50, 100, 200, and 400 µg/mL of mMSNPs and protocells for 2
hours at 37 °C. Data represent mean ± SD, n = 3. B) Digital photographs of
hRBCs after 2 hours incubation with (top) mMSNPs or (bottom) protocells at
different particle concentrations (25 to 400 µg/mL).

Presence of red

hemoglobin in supernatant indicates membrane damaged hRBCs. Adapted
and reproduced with permission.4 © 2016, The American Chemical Society.
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injection from both CAM and in vivo mouse models. We detected fluorescent
protocells in whole blood samples extracted from the CAM (Figure 3.11A); we
then separated protocells from whole blood by centrifugation and the measured
hydrodynamic size. Remarkably, the average protocell size is nearly identical
pre- and post-injection (Figure 3.11B). In addition, we examined protocell size
after circulation for multiple time points and found only a modest, timedependent, average hydrodynamic diameter increase of 9 % at 30 minutes and
increasing to 23 % at 240 minutes (Figure 3.12). We further validated in vivo
stability characteristics by intravenous tail vein injection of protocells into a
BALB/c mouse. After 10 minutes of protocell circulation, we extracted blood from
the mouse, imaged fluorescent protocells in whole blood (Figure 3.11C),
separated protocells using centrifugation, and found protocells maintain size
stability in a mouse model (Figure 3.11D). Thus, we demonstrated qualitative
and quantitative confirmation of both ex ovo and in vivo protocell stability in
unique and separate model systems. While these data indicate that the protocell
platform possesses a distinctive ability to circulate and avoid aggregation in a
complex living system for a short period of time, we acknowledge the need for a
more comprehensive analysis of protocell circulation and biodistribution in
relevant in vivo animal models of disease in order to provide a more complete
pre-clinical understanding of in vivo protocell performance.

Figure 3.11 – Protocell Size Stability Post-Circulation
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Figure 3.11 – A) Red fluorescent protocells extracted from CAM 10 minutes
post-injection and imaged on glass slide with Zeiss AxioExaminer upright
microscope. We observed protocells in motion moving in and out of frame in a
Brownian pattern with no apparent direct association with red blood cells. B)
Hydrodynamic size and PdI of core Hexagonal mMSNPs, protocells, and
protocells separated from CAM blood. C) Fluorescent protocells injected and
pulled from Balb/c mouse 10 minutes post-injection. D) Hydrodynamic size
and PdI of core Hexagonal mMSNPs, protocells, and protocells separated
from mouse blood. Injected protocells were separated from blood by variable
speed centrifugation. Microscopy image scale bars = 20 µm and DLS data
represent mean ± SD, n = 3. Data provides evidence of size stability A) and
B) ex ovo and C) and D) in vivo as assessed by minimal change in
hydrodynamic size and PdI values.

Adapted and reproduced with

permission.4 © 2016, The American Chemical Society.

104
Figure 3.12 – Protocell Size Stability After Separation from CAM Blood

Figure 3.12 – Hydrodynamic size comparison of pre-injected protocells and
protocells separated from CAM blood at different time points. Data provides
evidence of size stability ex ovo as assessed by modest change in
hydrodynamic size over multiple times up to 240 minutes in circulation. Data
represent mean ± SD, n = 3. Adapted and reproduced with permission. 4 ©
2016, The American Chemical Society.
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3.3 Materials and Methods
3.3.1 Protocell Biocompatibility Assessment
Whole human blood was acquired from healthy donors with informed
consent and stabilized in K2EDTA tubes (BD Biosciences). Human RBCs were
purified following reported procedure,42 then incubated with either bare mMSNPs
or protocells (25, 50, 100, 200, and 400 µg/mL) at 37 oC. After 3 hours of
exposure, samples were centrifuged at 300 x g for 3 minutes, then 100 µL of
supernatant from each sample was transferred to a 96-well plate. Hemoglobin
absorbance was measured using a BioTek microplate reader (Winooski, VT) at
541 nm. The percent hemolysis of each sample was quantified using a reported
equation (Detailed equation in Appendix A.3).42
3.3.2 Cell-Nanoparticle Interactions in Ex Ovo Avian Embryos
Ex ovo avian embryos were handled according to published methods, 43
with all experiments conducted following an institutional approval protocol (11100652-T-HSC). This method included incubation of fertilized eggs (purchased
from East Mountain Hatchery-Edgewood, NM) in a GQF 1500 Digital
Professional egg incubator (Savannah, GA) for 3 to 4 days. Following initial in
ovo incubation, embryos were removed from shells by cracking into 100 mL
polystyrene weigh boats (VWR, Radnor, PA). Ex ovo embryos were then
covered and incubated (~ 39 oC) with constant humidity (~ 70 %). For
nanoparticle injections, ~ 50 µg (at 1 mg/mL) of bare mMSNPs or protocells in
PBS were injected into secondary or tertiary veins of the CAM via pulled glass
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capillary needles. CAM vasculature and fluorescent protocells were imaged
using a customized avian embryo chamber (humidified) and a Zeiss
AxioExaminer upright microscope modified with a heated stage. High speed
videos were acquired on the same microscope using a Hamamatsu Orca Flash
4.0 camera.
3.3.3 Post-Circulation Size and Stability Analyses
All animal care and experimental protocols were in accordance with the
National Institutes of Health and University of New Mexico School of Medicine
guidelines. Ten- to twelve-week-old female BALB/c mice (Charles River
Laboratories, Wilmington, MA) were administered dose of fluorescent protocells
(10 mg/mL) in 150 µL PBS via tail vein injection. After 10 minutes of circulation,
mice were euthanized and blood was drawn by cardiac puncture. Whole blood
was stabilized in K2EDTA microtainers (BD Biosciences) prior to analysis. Ex
ovo avian embryos were administered dose of fluorescent protocells (1 mg/mL)
in 50 µL PBS via secondary or tertiary veins of the CAM. After 10 minutes of
circulation, blood was drawn via pulled glass capillary needles and analyzed
immediately. Whole blood cells and protocell fluorescence in both mouse and
avian samples were imaged on a glass slide with Zeiss AxioExaminer fixed stage
microscope (Gottingen, Germany). To separate protocells from whole blood,
samples were centrifuged at low speed to remove blood cells, supernatant
fraction was transferred to a fresh tube then centrifuged at 15,000 x g for 10
minutes. The pellets were washed (15,000 x g for 10 minutes) twice in PBS,
then protocell size was analyzed on Malvern Zetasizer Nano-ZS equipment.
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3.3.4 Nanoparticle Imaging and Characterization Analyses
TEM images were acquired on a JEOL 2010 (Tokyo, Japan) equipped
with a Gatan Orius digital camera system (Warrendale, PA) under a 200 kV
voltage. The Cryo-TEM samples were prepared using an FEI Vitrobot Mark IV
(Eindhoven, Netherlands) on Quantifoil® R1.2/1.3 holey carbon grids (sample
volume of 4 µL, a blot force of 1, and blot and drain times of 4 and 0.5 seconds,
respectively). Imaging was taken with a JEOL 2010 TEM at 200 kV using a
Gatan model 626 cryo stage. Nitrogen adsorption-desorption isotherms of
mMSNPs were obtained from on a Micromeritics ASAP 2020 (Norcross, GA) at
77 K. Samples were degassed at 120 oC for 12 hours before measurements.
The surface area and pore size was calculated following the Brunauer-EmmetTeller (BET) equation in the range of P/Po from 0.05 to 0.1 and standard BarrettJoyer-Halenda (BJH) method. Hydrodynamic size and zeta potential data were
acquired on a Malvern Zetasizer Nano-ZS equipped with a He-Ne laser (633 nm)
and Non-Invasive Backscatter optics (NIBS). All samples for DLS measurements
were suspended in various media (D.I. water, PBS, and DMEM+10 % FBS) at 1
mg/mL. Measurements were acquired at 25 oC or 37 oC. DLS measurements for
each sample were obtained in triplicate. The Z-average diameter was used for
all reported hydrodynamic size measurements. The zeta potential of each
sample was measured in D.I. water or 1xPBS using monomodal analysis. All
reported values correspond to the average of at least three independent
samples. The fluorescence images were captured with a Zeiss AxioExaminer
fixed stage microscope (Gottingen, Germany).
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CHAPTER 4
INFLUENCE OF PARTICLE SIZE DISPERSITY ON PROTOCELL
CHARACTERISTICS

This chapter was adapted from
Durfee, P. N.; Lin, Y-S.; Dunphy, D. R.; Muñiz, A. J.; Butler, K. S.; Humphrey, K.
R.; Lokke, A. J.; Agola, J. O.; Chou, S. S.; Chen, I-M.; Wharton, W.; Townson, J.
L.; Willman, C. L.; Brinker, C. J. Mesoporous Silica Nanoparticle-Supported
Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual
Leukemia Cells. ACS Nano 2016, DOI: 10.1021/acsnano.6b02819. © 2016
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4.1 Overview
For the development of therapeutic nanocarriers specifically targeted to
leukemia cells, prolonged circulation times are needed to enhance the probability
of delivery to distributed cells within the blood, marrow, and other tissue spaces,
and, it is reported that particle size is an important determinant in delivery to
tissue sites characteristic of this disseminated disease.1 Therefore, it is of
interest to understand the effect of protocell size dispersity on in vivo
performance. Potentially, a broad particle size distribution could effect or direct
broad dissemination of protocells to differing body tissues in addition to the
peripheral vasculature and other tissues (liver, spleen, bone marrow) which may
harbor leukemic cells, or, protected tissues which serve as sanctuaries for
leukemic cells (testes, brain) and are frequent sites of recurrent or relapsed
disease following systemic chemotherapy treatment. However, it is presently
unclear as to how particle size polydispersity influences particle entrapment, nonspecific binding, and circulation time.
4.2 Results and Discussion
4.2.1 Influence of Protocell Size Dispersity on In Vitro and Ex Ovo
Performance
In order to assess the dependence of polydispersity on non-specific
binding and circulation, we compared monosized protocells with protocells
assembled from MSNP cores prepared by aerosol assisted EISA as previously
reported.2 EISA cores are characterized by spherical MSNPs with a power law

114
particle size distribution ranging from ~ 20 to ~ 800 nm (see TEM images in
Figures 3.5K, 3.5L, and 4.1) that results from the aerosol droplet size
distribution of the aerosol generator. EISA MSNPs have a pore diameter of ~ 2.5
nm and a zeta-potential of approximately - 31 mV,4 comparable to those of
Hexagonal mMSNPs, so the comparison of their behaviors depends principally
on polydispersity (See Table 3.1 for other physicochemical parameters of the
EISA MSNP and protocells). Hexagonal and EISA protocells were prepared by
fusion of vesicles with composition, DSPC:chol:DSPE-PEG2000 mol ratio of
54:44:2 according to methods described previously. The hydrodynamic diameter
and PdI of EISA protocells were ~ 715 nm and 0.434 compared to ~ 137 nm and
0.085 for hexagonal protocells (Figure 3.5M and Table 3.1).
To investigate the role of polydispersity on in vitro MSNP and protocell
non-specific binding interactions, we incubated human endothelial cells
(EA.hy926) with either fluorescently labelled EISA or mMSNP cores and their
corresponding protocells (20 µg/mL) for 4 hours with complete medium under
normal cell culturing conditions. Flow cytometry analysis showed both EISA and
mMSNP particles to have significant levels of non-specific binding to EA.hy926
cells (Figure 4.2) whereas for EISA MSNP the extended breadth of the FL2-H
intensity curve reflected the size, and therefore, fluorescence intensity
distribution of individual MSNPs. Correspondingly, the fluorescence intensity
binding curve for mMSNPs was rather monodisperse. For both EISA and
mMSNP derived protocells, we observe a 20-fold decrease in non-specific
binding relative to the parent core particle (Figure 4.2, see also fluorescence

Figure 4.1 – Comparison Between EISA and mMSNPs
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Figure 4.1 – A) Conventional TEM image of MSNPs prepared from EISA
synthesis route. B) Conventional TEM image of Hexagonal mMSNPs prepared
from colloidal solution-based synthesis route.

Scale bars = 200 nm.

C)

Histogram of particle size distributions of EISA and Hexagonal mMSNP cores
measured from TEM images.

Data represent mean ± SD, n = 220.

D)

Hydrodynamic size measurement comparison of EISA and Hexagonal
mMSNP cores and protocells. Data represent mean ± SD, n = 3. Adapted
and reproduced with permission.3 © 2016, The American Chemical Society.

Figure 4.2 – Flow Cytometry Comparison of Non-Specific Binding
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Figure 4.2 – Flow cytometry measurements of EA.hy926 endothelial cells
after incubation with 20 µg/mL of A) EISA MSNP, B) EISA protocell, C)
Hexagonal mMSNP, and D) monosized protocells for 4 hours.

Percent

population shift due to particle fluorescence (grey = control, no particle
exposure, blue outline = mMSNPs or protocells). Adapted and reproduced
with permission.3 © 2016, The American Chemical Society.
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microscopy images in Figure 4.3). This indicates that the conformal and
complete SLB serves to effectively shield lipophilic surface silanol groups (SiOH) and anionic deprotonated silanols (Si-O-) present on the bare MSNP and
known to promote internalization via macropinocytosis and other non-specific
endocytotic pathways.5 Our findings underscore the importance of the SLB in
helping to prevent non-specific cell binding events, and support previous reports
demonstrating minimal nonspecific cell binding affinity of polydisperse EISA
protocells in vitro.6, 7
However, as previously noted, in vitro studies of nanoparticle behavior
may be poor indicators of in vivo outcomes as they lack the complexities of in
vivo conditions which present major obstacles to nanoparticle stability and target
cell binding.8 These obstacles include flow dynamics within the diverging and
converging vasculature, opsonization by plasma proteins, uptake by the
mononuclear phagocyte system, and the need for translocation across the
capillary bed for tissue penetration. To assess MSNP and protocell behavior in a
more relevant model, we employed the CAM model as an in vivo (ex ovo) model
of the vascular system in which to observe nanoparticle circulation, flow
characteristics, non-specific interactions, and particle stability in a living system
using intravital imaging.9-11 Fluorescently labeled nanoparticles can be injected
intravenously into the CAM vasculature and imaged over time. As investigated
previously in vitro, we examined mMSNP cores as well as EISA and mMSNP
protocells to assess the influence of the SLB and polydispersity on biodistribution
in this more complex ex ovo CAM environment. The influence of the SLB on

Figure 4.3 – Fluorescence Microscopy of Non-Specific Binding
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Figure 4.3 – Differential binding of Hexagonal mMSNPs and protocells
observed after 4 hours incubation in complete medium. A) Bare Hexagonal
mMSNPs (red) bind non-specifically to EA.hy926 (blue – DAPI stained nuclei,
green – phalloidin stained actin), while B) protocells (red) do not interact with
cells in culture. Scale bar = 50 µm. Adapted and reproduced with
permission.3 © 2016, The American Chemical Society.
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nanoparticle flow dynamics and non-specific binding was immediately evident as
bare mMSNP cores bound to endothelial cells and arrested in the vessels of the
CAM within 5 minutes of injection (Figure 4.4A) and were largely taken up by
phagocytic white blood cells after 30 minutes, reducing correspondingly the
concentration of circulating mMSNPs (Figure 4.4B). By comparison, monosized
protocells exhibited significantly lower non-specific binding and uptake by white
blood cells leading to greatly improved circulation characteristics (Figures 4.5A
and 4.5B). A representative video of stable monosized protocell circulation is
reported in the Supporting Information, Video S1, by Durfee et.al.3 Striking was
the contrast between mMSNP and EISA protocells. Even though the in vitro
outcomes were nearly identical, rapid sequestration of EISA protocells by
immune cells, aggregation, and diminished circulation was noted within 5
minutes in the vascular CAM system (Figure 4.6A), with a more pronounced
effect after 30 minutes (Figure 4.6B). The rapid uptake and reduced circulation
are likely due to polydispersity leading to the majority of particles falling within a
size range that either encourages immune cell uptake or advances unpredictable
systemic circulation and distribution.12 The CAM results highlight the need for
reduced size polydispersity to maintain circulation within highly vascularized
networks and elucidate a major limitation of in vitro models in predicting in vivo
results. In this regard, we view the vascularized CAM model to improve greatly
on in vitro models of specific and non-specific binding and more realistically
assess the behavior of nanoparticles designed for in vivo use.9

Figure 4.4 – Hexagonal mMSNP Flow in the CAM
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Figure 4.4 – Fluorescently-labelled nanoparticle flow patterns observed using
ex ovo CAM model. Representative panels highlight differential flow
characteristics between A) Hexagonal mMSNPs 5 minutes post injection and
B) 30 minutes post injection. Red: mMSNP; Blue: autofluorescence from
tissue. Scale bar = 50 µm. Adapted and reproduced with permission.3 © 2016,
The American Chemical Society.
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Figure 4.5 – Monosized Protocell Flow in the CAM

Figure 4.5 – Fluorescent monosized Hexagonal mMSNP protocell flow
patterns observed using ex ovo CAM model. Representative panels highlight
differential flow characteristics between A) monosized protocells 5 minutes
post injection and B) 30 minutes post injection. Scale bar = 50 µm. Adapted
and reproduced with permission.3 © 2016, The American Chemical Society.
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Figure 4.6 – EISA Protocell Flow in the CAM

Figure 4.6 – Fluorescent EISA protocell flow patterns observed using ex ovo
CAM model. Representative panels highlight differential flow characteristics
between A) EISA protocells 5 minutes post injection and B) 30 minutes post
injection. Scale bar = 50 µm. Adapted and reproduced with permission.3 ©
2016, The American Chemical Society.
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4.3 Materials and Methods
4.3.1 Materials
All chemicals and reagents were used as received. See all protocell
synthesis and assembly materials listed in 2.3.1 Materials. Alexa Fluor®488
phalloidin, CellTracker™ Blue CMAC dye, and CellTracker™ green CMFDA dye
were purchased from Life Technologies (Eugene, OR). Triton X-100 and
Formaldehyde were purchased from Sigma-Aldrich (St. Louis, MO). Hoechst
33342 was obtained from Thermo Scientific (Rockford, IL). Heat inactivated fetal
bovine serum (FBS), 10X phosphate buffered saline (PBS), 1X trypsin-EDTA
solution, and penicillin streptomycin (PS) were purchased from Gibco (Logan,
UT). Dulbecco’s Modification of Eagle’s Medium with 4.5 g/L glucose, Lglutamine and sodium pyruvate (DMEM) was obtained from CORNING cellgro
(Manassas, VA).
4.3.2 Endothelial Cell Culture and Nanoparticle Non-Specific Binding and
Uptake Procedure
Human endothelial cells, EA.hy926 (CRL-2922) were purchased from
American Type Culture Center (ATCC, Manassas, VA). We seeded 5×105
EA.hy926 cells in 6-well plates with 2 mL of DMEM + 10 % FBS and 1 % PS at
37 oC in 5 % CO2 humidified atmosphere. After 24 hours, the media was
removed and replaced with 2 mL of fresh complete media supplemented with 20
µg/mL of bare mMSNPs or protocells for 4 hours at 37 oC under 5 % CO2. After
nanoparticle incubation, the media was removed and the cells were gently
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washed twice with PBS. For imaging purposes, the nanoparticle treated cells
were fixed in 3.7 % formaldehyde (in PBS) at room temperature for 10 minutes,
washed with PBS, then treated with 0.1 % Triton X-100 for another 10 minutes.
The fixed cells were washed with PBS and stored in 1 mL of PBS. The cell
nuclei and F-actin were stained with 1 mL of Hoechst 33342 (3.2 µM in PBS) and
0.5 mL of Alexa Fluor®488 phalloidin (20 nM in PBS) for 20 minutes,
respectively. After staining, the cells were washed with PBS twice and stored in
PBS prior to fluorescence microscope imaging. For preparation of flow cytometry
samples, the control and nanoparticle treated cells were removed from plate
bottom using Trypsin-EDTA (0.25 %). The suspended cells were centrifuged,
washed with PBS, and suspended in PBS for flow cytometry measurements.
4.3.3 Nanoparticle Characterization and Non-Specific Binding Analyses and
Fluorescence Microscopy
TEM images were acquired on a JEOL 2010 (Tokyo, Japan) equipped
with a Gatan Orius digital camera system (Warrendale, PA) under a 200 kV
voltage. Hydrodynamic size data were acquired on a Malvern Zetasizer NanoZS equipped with a He-Ne laser (633 nm) and Non-Invasive Backscatter optics
(NIBS). All samples for DLS measurements were suspended in D.I. water or
PBS at 1 mg/mL. Measurements were acquired at 25 oC. DLS measurements
for each sample were obtained in triplicate. The Z-average diameter was used for
all reported hydrodynamic size measurements. All reported values correspond to
the average of at least three independent samples. Flow cytometry data were
performed on a Becton-Dickinson FACScalibur flow cytometer (Sunnyvale, CA).
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The raw data obtained from the flow cytometer was processed with FlowJo
software (Tree Star, Inc. Ashland, OR). The fluorescence images were captured
with a Zeiss AxioExaminer fixed stage microscope (Gottingen, Germany).
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CHAPTER 5
PROTOCELL TARGETING AND CARGO DELIVERY TO INDIVIDUAL CELLS
IN VITRO, EX OVO, AND IN VIVO
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5.1 Overview
It is now widely recognized that nanoparticle based drug delivery provides
a new ability to package poorly soluble and/or highly toxic drugs, protect drugs
and molecular cargos from enzymatic degradation, and enhance their circulation
and biodistribution compared to free drug. Furthermore ‘passive’ or ‘active’
targeted delivery promises precise administration of therapeutic cargos to
specific cells or tissues, while sparing collateral damage to healthy cells and
tissues and potentially overcoming multiple drug resistance mechanisms. 1-3 Socalled passive targeting occurs through the EPR effect resulting from 200 – 2000
nm fenestrations in the tumor vasculature that are permeable to blood
components including nanoparticles.1 Nanoparticles are retained because the
lymphatic function of the tumor may be defective and does not support
convective flow back into the interstitial fluid,4 and because diffusion of
nanoparticles may be highly limited due to their dimensions.5 Arguably all
nanoparticle therapeutics smaller than several micrometers could accumulate in
tumor microenvironments according to the EPR effect; but their efficiency is
strongly dependent on physicochemical factors such as size, shape, surface
charge, and hydrophobicity, which control colloidal stability, and accordingly
circulation time, non-specific binding, opsonization, and uptake by the
mononuclear phagocyte system.1, 6 Active targeting relies on modifying the
nanocarrier with ligands that bind to receptors that are over expressed or
uniquely expressed on targeted cancer cells versus normal cells.7 Typically,
active targeting also relies upon the EPR effect, and its efficiency is governed by
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the same physicochemical factors as those for passive targeting.8, 9 The
difference is that targeting ligands can enhance binding and, therefore, retention
by the targeted cell and can often promote internalization via receptor-mediated
endocytotic pathways.1, 8 Targeting ligands, however, increase size, complexity,
and cost and potentially alter the same physicochemical parameters that govern
the EPR effect, requiring re-optimization of the surface chemistry.1 For this
reason, the benefits of active targeting are often not clear-cut, and consequently
considerably fewer actively targeted nanoparticle therapeutics are used
clinically.10, 11 A major exception is targeted delivery to individual or small groups
of cells or circulating cells, for which the EPR effect is likely inoperative. Here,
nanoparticle delivery to leukemias is an important case in point. Because
conventional anticancer drugs used for leukemia therapy are systemic and nontargeted, they may result in significant acute and long term toxic side effects to
normal tissues. Thus, there is a critical need to increase the efficacy and reduce
toxicity of therapeutic interventions by direct targeting of specific sites or cells. 12,
13

Individual cell targeting, however, remains a significant challenge in cancer

nanomedicine and has yet to be thoroughly demonstrated. 14 In the case of
leukemia therapeutics, active targeting is required to allow specific delivery to
leukemic cells in circulation and those in organ reservoirs such as bone marrow
and spleen. It should be emphasized that targeting cannot be achieved at the
expense of colloidal stability because increased circulation half-life has been
shown to increase delivery to bone marrow, spleen, and liver disease sites,
where leukemia cells may frequently home.15
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To date, protocell based nanocarriers have shown to be effective for the
delivery of multiple classes of cargos and cargo combinations to various cell
types.16 The majority of studies conducted have reported efficacy in vitro,17-19 but
numerous recent reports also show excellent in vivo results, where passive and
active targeting to solid tumors via the EPR effect have been demonstrated.20-23
However, the targeting of individual cells in vivo or in living systems has yet to be
reported, and there have been no direct observations/determinations of in vivo
colloidal stability. Here, based on our hypothesis that in vivo colloidal stability is
paramount to achieving effective targeting, we explore how synthetic factors
(e.g., the lipid/silica ratio and ionic strength during SLB formation) and variation
of modular protocell components (i.e., MSNP size, shape, and pore size, lipid
bilayer fluidity, extent of PEGylation, and surface display of targeting ligands)
influence colloidal stability as judged in vitro and in vivo by particle size stability
and polydispersity and by direct observation ex ovo in a CAM model. We
establish processing conditions whereby we achieve particle size monodispersity
and size stability for protocells with differing size, shape, and pore morphology.
Using optimized processing conditions, we further demonstrate long circulation
times, avoidance of non-specific binding and minimal opsonization ex ovo and in
vivo. Having achieved in vivo colloidal stability, we finally demonstrate targeted
binding and cargo delivery to individual leukemia cells in vitro and ex ovo by
direct observation in the CAM model.
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5.2 Results and Discussion
5.2.1 Protocell Targeting Specificity In Vitro and Ex Ovo
Once we verified the biological compatibility and in vivo stability of the
monosized protocell platform, we examined receptor specific targeting both in
vitro and ex ovo. As a model system we chose a human B cell precursor ALL
cell line (REH) that was engineered to express the epidermal growth factor
receptor (EGFR) and we compared the performance of these REH-EGFR
leukemia cells to the parental (EGFR-negative) cell line so as to have a matched
negative control for our experiments. Targeting was accomplished using the
NeutrAvidin/biotin conjugation strategy to modify an amine functionalized SLB
(prepared with mol ratio DSPC:chol:DSPE-PEG2000-NH2 = 49:49:2 – Table 2.1)
with anti-EGFR monoclonal antibodies as depicted in Figure 2.1.
To examine targeting specificity, we compared protocell interactions with
both the human REH parental cell line controls and also with a murine B
precursor ALL cell line (Ba/F3) also lacking EGFR. We compared the
performance of these parental EGFR-negative control cell lines to corresponding
REH and Ba/F3 clones engineered to express ectopic human EGFR, designated
REH-EGFR and Ba/F3-EGFR, respectively.24 To assess the kinetics of protocell
binding, we incubated anti-EGFR antibody-labeled fluorescent protocells with
REH parental and REH-EGFR cells for various time points in vitro. We observed
significant binding within 5 minutes and maximal binding at 30 minutes of
incubation in complete media under normal cell culture conditions by both flow
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cytometry (Figure 5.1A) and fluorescence microscopy (Figure 5.2). As
expected, from the absence of non-specific binding shown previously (Figures
4.2 and 4.3), protocell binding was not observed in the REH parental cell line
(Figure 5.1B), nor did we observe non-targeted (anti-EGFR negative) protocell
binding to either REH or REH-EGFR cell lines, as measured by flow cytometry
(Figure 5.3). To confirm that target specific binding is not cell line specific, we
incubated anti-EGFR protocells with Ba/F3 and Ba/F3-EGFR cells for 60 minutes
using previously described conditions for REH and REH-EGFR cells. Using
fluorescence microscopy, we observed minimal non-specific binding of EGFRtargeted protocells to parental Ba/F3 cells; conversely we observed significant
selective binding to Ba/F3-EGFR cells (Figures 5.4A and 5.4B). Flow cytometry
analyses revealed the targeted protocells had a much greater binding affinity to
Ba/F3-EGFR cells compared to the control Ba/F3 parental cell line in vitro
(Figures 5.4C and 5.4D).
To provide an in vivo relevant assessment of targeted binding, we
evaluated the characteristics of the targeted protocell binding using real-time
intravital imaging in the ex ovo CAM model of the vasculature. We injected
green fluorescent labelled REH or REH-EGFR cells into the CAM and allowed
the cells to arrest in the capillary bed (~ 30 minutes). Next, we injected either
anti-EGFR targeted or non-targeted red fluorescent protocells into the CAM and
imaged protocell flow and binding dynamics at 1-hour, 4-hour, and 9-hour time
points. We observed protocells flowing in the blood stream at 1 hour (Figure
5.5A), as well as cell specific binding of the anti-EGFR protocells to the REH-

Figure 5.1 – Flow Cytometry Analysis of EGFR-Targeted Protocell Binding
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Figure 5.1 – Flow cytometry analysis of A) REH-EGFR and B) parental REH
cells incubated with red fluorescent EGFR targeted protocells at multiple time
points. A) This data illustrates rapid specific in vitro protocell binding to REHEGFR in as little as 5 minutes in complete medium, and maximal protocell
accumulation after 30 minutes. Red arrows highlight non-EGFR expressing
population of the engineered REH-EGFR cell line. B) There is minimal nonspecific binding to parental REH cells. Adapted and reproduced with
permission.25 © 2016, The American Chemical Society.
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Figure 5.2 – Fluorescence Microscopy Analysis of EGFR-Targeted Protocell
Binding

Figure 5.2 – Fluorescent microscopy analysis of REH-EGFR cells incubated
with EGFR-targeted protocells at multiple time points, fixed and stained (blue–
nuclei, green–cytoskeleton, red–protocells): A) untreated, B) 5 minutes, C) 15
minutes, D) 30 minutes, and E) 60 minutes. These data illustrate rapid in vitro
protocell binding in as little as 5 minutes in complete medium, and maximal
protocell accumulation after 30 minutes. Scale bar = 5 μm. Adapted and
reproduced with permission.25 © 2016, The American Chemical Society.
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Figure 5.3 – Flow Cytometry Analysis of EGFR-Targeted Protocell Specificity

Figure 5.3 – A) Mean fluorescence intensity graph of REH and REH-EGFR
cells incubated with either non-targeted or EGFR-targeted protocells shows
targeting specificity of EGFR-targeted protocells. B) Flow cytometry analysis
of REH-EGFR cells incubated with red fluorescent non-targeted protocells at
multiple time points. C) Flow cytometry analysis of parental REH cells
incubated with red fluorescent non-targeted protocells at multiple time points.
These data demonstrate the high specific binding of EGFR-targeted protocells
to REH-EGFR and low non-specific binding of both targeted and non-targeted
to protocells. Adapted and reproduced with permission. 25 © 2016, The
American Chemical Society.

Figure 5.4 – Targeted Protocell Specificity for Ba/F3-EGFR Cells
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Figure 5.4 – A) Fluorescent microscopy shows minimal EGFR-targeted
protocell (red) interactions with a non-EGFR expressing BAF cell line after 1hour incubation (blue – DAPI stained nuclei, green – phalloidin stained actin),
while B) targeted protocells (red) exhibit a high degree of binding to an EGFR
expressing BAF cell line. Flow cytometry analysis of protocells incubated with
C) BAF and D) BAF-EGFR confirm fluorescent microscopy analysis (grey = no
protocell control, blue = EGFR-targeted protocells).

Scale bar = 10 µm.

Adapted and reproduced with permission.25 © 2016, The American Chemical
Society. See Appendix B.3 for 20X magnification of Ba/F3 and Ba/F3-EGFR
cells.
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Figure 5.5 – Targeted Protocells bind REH-EGFR Cells in the CAM

Figure 5.5 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model reveal stable circulation of EGFR targeted protocells (red) and
binding to REH-EGFR cells (green) in circulation at A) 1-hour, B) 4-hour, and
C) 9-hour time points. Systemic protocell circulation is diminished after 4
hours, however, protocells remain associated with target cells for up to 9
hours. Scale bar A) = 50 μm, Scale bars B) and C) = 10 μm.

Adapted and

reproduced with permission.25 © 2016, The American Chemical Society. See
additional targeted binding images in Appendix B.4.
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EGFR cells. While flow had diminished at 4-hour and 9-hour time points, we still
observed targeted protocell co-localization with the target cells (Figures 5.5B
and 5.5C). Since we observed a significant targeted protocell binding to REHEGFR cells at 1 hour and our in vitro experiments showed binding within 5
minutes, we sought to capture targeted protocell binding within a vascularized
system in real time; thus, we performed intravital imaging in the CAM
immediately after protocell injection and observed several binding events on
multiple cells (Figure 5.6 and reported in the Supporting Information, Video S2,
by Durfee et.al.25) within 5 to 10 minutes post protocell injection. To verify that
protocell binding was indeed EGFR specific, we tested anti-EGFR targeted
protocells with REH cells and non-targeted protocells with REH and REH-EGFR
cells lines and found similar flow patterns for the protocells at 1-hour time points;
however, the protocells did not interact with the leukemia cells (Figures 5.7, 5.8,
and 5.9) providing further support for our targeting methodology. As a final step,
we investigated whether EGFR-targeted protocell binding was influenced by the
particular engineered cell line. We injected Ba/F3-EGFR cells ex ovo, followed
by anti-EGFR protocell injection, and observed target cell specific binding at 10
minutes and 20 hours (Figure 5.10). Based on these findings, we are confident
that we have engineered biologically stable protocells with a high degree of
specificity evaluated both in vitro and by intravital imaging in the CAM model to
bind to individual target cells.

Figure 5.6 – Still frames which capture red fluorescent targeted protocell binding to green fluorescent
labeled REH-EGFR cells captured in successive frames from Video S2 (reported in the Supporting
Information, by Durfee et.al.25) with arrows indicating points where red fluorescent protocells appear to bind
and remain associated with the cells. Frame rate = 4.35 seconds. Scale bar = 20 µm. Adapted and
reproduced with permission.25 © 2016, The American Chemical Society.

Figure 5.6 – Still Frames Capture Protocell Binding Events in CAM
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Figure 5.7 – Targeted Protocells Avoid REH Cells in the CAM
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Figure 5.7 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model reveal stable circulation of EGFR-targeted protocells (red) but no
association with parental REH cells (green) in circulation at A) 1-hour, B) 4hour, and C) 9-hour time points. Scale bar (left) = 50 μm, Scale bars (right top
and bottom) = 10 μm. Adapted and reproduced with permission.25 © 2016,
The American Chemical Society.

Figure 5.8 – Non-targeted Protocells Avoid REH Cells in the CAM
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Figure 5.8 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model reveal stable circulation of non-targeted protocells (red) but no
association with parental REH cells (green) in circulation at A) 1-hour, B) 4hour, and C) 9-hour time points. Scale bar (left) = 50 μm, Scale bars (right top
and bottom) = 10 μm. Adapted and reproduced with permission.25 © 2016,
The American Chemical Society.

Figure 5.9 – Non-targeted Protocells Avoid REH-EGFR Cells in the CAM

143

Figure 5.9 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model reveal stable circulation of non-targeted protocells (red) but no
association with REH-EGFR cells (green) in circulation at A) 1-hour, B) 4-hour,
and C) 9-hour time points. Scale bar (left) = 50 μm, Scale bars (right top and
bottom) = 10 μm. Adapted and reproduced with permission.25 © 2016, The
American Chemical Society.

Figure 5.10 – Targeted Protocells bind Ba/F3-EGFR Cells in the CAM
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Figure 5.10 – Intravital fluorescent microscopy images acquired in the CAM
model show: A) stable circulation of EGFR-targeted protocells (red) and the
initial stages binding to Ba/F3-EGFR (green) 10 minutes post injection; B)
maintained association of EGFR-targeted protocells (yellow, due to merged
green and red) with Ba/F3-EGFR (green) 20 hours post-injection. Scale bar =
10 µm. Adapted and reproduced with permission.25 © 2016, The American
Chemical Society.
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5.2.2 Protocell Cargo Loading and Delivery to Targeted Cells
Next, we evaluated the cargo loading and targeted delivery characteristics
of monosized protocells both in vitro and ex ovo. As a surrogate for a true drug,
we chose YO-PRO®-1, a green fluorescent membrane impermeable molecular
cargo. We added YO-PRO®-1 to red-fluorescent mMSNPs, fused liposomes,
and conjugated anti-EGFR targeting components to the surface following the
steps illustrated in Figure 2.1. Anti-EGFR targeted protocells loaded with YOPRO®-1 exhibited similar size and zeta potential characteristics to unloaded
protocells assembled under identical conditions (Table 5.1). We calculated a 25
% loading efficiency by disrupting the SLB of loaded protocells with a detergent
and measuring the fluorescence intensity of YO-PRO®-1 extracted in DMSO
(Details in – 5.3.8 Cargo loading and release kinetics and Appendix A.4).
Next, we assayed targeted protocell internalization as a measure of time using
an acid wash technique to remove surface bound protocells at specific time
points. Using flow cytometry and fluorescence microscopy, we found that antiEGFR targeted protocell binding and internalization occurs within 1 hour
(Figures 5.11A and 5.12); however, cargo release as measured by intracellular
green fluorescent cargo diffusion, occurred more slowly (Figures 5.11B, and
5.12). To assess protocell targeted cell specific killing, in vitro, we chose
gemcitabine (GEM) as a model anti-cancer cytotoxic agent due to its low
molecular weight, which allows it to access and adsorb to the high surface area
mMSNP mesostructure, as well as its relative membrane impermeability,26, 27
which allows the SLB to essentially seal the cargo in the protocells and to
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Table 5.1 – Unloaded and Loaded Protocell Size and Zeta Potential Analysis

Table

5.1

–

Hydrodynamic

size

characteristics

and

zeta

potential

measurements of loaded and unloaded targeted protocells. Multiple batches
were synthesized, superscript (* and **) denotes mMSNP cores prepared from
the identical batches.

Data represent mean ± SD, n = 3.

Adapted and

reproduced with permission.25 © 2016, The American Chemical Society.
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Figure 5.11 – Flow Cytometry Analysis of EGFR-Targeted Protocell
Internalization

Figure 5.11 – Flow cytometry analysis to assess internalization of A) red
fluorescent EGFR-targeted protocells by REH-EGFR cells in vitro at multiple
time points and B) delivery of model drug, YO-PRO®-1, a green cell
impermeant dye.

After each time-point, cells were acid washed to strip

surface bound protocells then fixed. These data show an increase in the
internalization of protocells and release of cargo with increasing incubation
time.

Adapted and reproduced with permission. 25 © 2016, The American

Chemical Society.

148
Figure 5.12 – Fluorescence Microscopy of Internalization and Cargo Release

Figure 5.12 – Fluorescence microscopy analysis to assess delivery of model
drug, YO-PRO®-1 a green cell impermeant dye, via targeted protocells to
REH-EGFR cells at multiple time points. After each time-point, cells were acid
washed to strip surface bound protocells then fixed. REH-EGFR cells (DIC–
cell structure, red–protocells, green–YO-PRO®-1) at A) untreated, B) 1-hour,
C) 8-hour, D) 16-hour, and E) 24-hour incubation times. These data illustrate
internalization of protocells within 1 hour and the release of YO-PRO®-1 cargo
which appears to localize in the nucleus of the target cells at later time points.
Scale bar = 25μm. Adapted and reproduced with permission. 25 © 2016, The
American Chemical Society.
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prevent off-target effects due to drug leakage. Moreover, GEM requires a
nucleoside transporter to cross the cell membrane, and reduced expression of
the nucleoside transporter is known to be associated with gemcitabine
resistance.26, 27 Furthermore, the plasma half-life of GEM is only 8-17 minutes
due to rapid conversion to an inactive form that is excreted by the kidneys; 26
therefore, GEM requires frequent doses to overcome this clearance
rate. Thus, encapsulation of GEM within a targeted protocell may overcome
many of the challenges associated with conventional GEM-based therapy.
We assessed cargo delivery using REH and REH-EGFR cells incubated
with GEM loaded anti-EGFR protocells in vitro. To prepare GEM loaded, antiEGFR targeted protocells, we suspended mMSNPs in a solution of GEM
prepared in H2O then assembled protocells by fusing GEM-soaked mMSNPs
with liposomes following the steps illustrated in Figure 2.1. The supernatant
from each step was collected and combined; the GEM content was determined
by measuring the absorbance (265 nm) using a microplate reader. Our
described GEM loading strategy resulted in a calculated 15 wt. % GEM
encapsulation (Details in – 5.3.8 Cargo loading and release kinetics and
Appendix A.4). We found cargo loading did not influence the final targeted
protocell size (Table 5.1), a result consistent with GEM loading of the internal
mesoporosity. To examine the drug release profile under simulated lysosomal
conditions, we prepared GEM loaded protocells in PBS, then dialyzed the
samples in either PBS (pH 7.4) or 1 M citrate buffer (pH 5.0) for 72 hours at 37
°C. We measured the absorbance (265 nm) of supernatant collected at several
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time points to determine the quantity of GEM released under these conditions.
We observed a greater total drug release percentage at pH 5.0 (~ 30 %)
compared to pH 7.4 (~ 14 %) after 72 hours (Figure 5.13). We also observed a
significant hydrodynamic size increase at 48 hours in pH 5.0, correlating with the
increase in drug release observed at the same time point, while protocells
maintain size stability at pH 7.4 under the same experimental conditions (Figure
5.13). These data suggest that drug release is increased at a lower pH primarily
due to SLB destabilization as evidenced by aggregation. However, we are only
examining the influence of a single variable (pH), while other conditions exist in
the lysosomal pathway including degradative enzymes, for example
phospholipase A2,28 which could affect drug release. Therefore, we next
examined the functional release of GEM as a measure of cell viability in vitro. To
evaluate the target specific drug delivery, we incubated REH and REH-EGFR
cells with increasing concentrations of anti-EGFR GEM-loaded protocells in
complete media under normal culturing conditions. We observed a distinct
EGFR-target specific decrease in viability correlating to an increase in targeted
protocell concentration (Figure 5.14A). Finally, we assessed the killing
specificity of free-GEM, and observed decreased cell viability with increasing
GEM concentration in a non-specific manner (Figure 5.14B). To verify that the
cargo is responsible for the killing as opposed to the protocell itself, we incubated
anti-EGFR targeted protocells with REH and REH-EGFR cells with increasing
concentrations and observed no loss in viability for up to 200 µg/mL of protocells
(Figure 5.14C). Worth mentioning, a subset of REH-EGFR engineered cells

Figure 5.13 – Size Stability and GEM Release at pH 7.4 and pH 5.0
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Figure 5.13 – Comparison of drug release percentage (left axis) and protocell
size change (right axis) for GEM-loaded protocells maintained in extracellular
physiological conditions (PBS, pH 7.4) and simulated lysosomal conditions
(citrate buffer, pH 5.0) for 72 hours at 37 °C. We observe increased GEM
release at pH 5.0 and significant size increase at 48 hours with a 228-fold size
increase at 72 hours suggesting protocell destabilization and aggregation due
to lower pH conditions. Drug release at pH 5.0 correlates with protocell size
increase over time. Protocells maintain size stability at pH 7.4 for 72 hours at
37 °C, however they do appear to release ~ 14 % GEM after 72 hours.
Adapted and reproduced with permission.25 © 2016, The American Chemical
Society.

Figure 5.14 – EGFR-Targeted Drug Delivery and Cell Viability Assessment
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Figure 5.14 – A) Maintained viability of REH cells and decrease in viability of
REH-EGFR cells with increasing concentration of GEM loaded EGFR-targeted
protocells. REH and REH-EGFR cells incubated with protocells from 0 to 50
ug/ml for 1 hour, then washed to remove unbound protocells. Viability was
assessed at 24 hours. B) Loss in cell viability of REH and REH-EGFR cells
with exposure to increasing concentration of free GEM. Both cell lines were
incubated with free GEM from 0 to 30 uM for 1 hour, then washed to remove
unassociated free drug. Viability was assessed at 24 hours. Viability data
highlights target specific delivery of cytotoxic cargo using monosized protocell
platform and the non-specific cytotoxicity of free drug under the same
conditions. C) Cell viability of parental REH and REH-EGFR cells incubated
with increasing concentrations of cargo-free anti-EGFR protocells for 1 hour
followed by washing to remove unbound protocells. Viability was assessed at
24 hours. Viability data supports the biocompatibility of the monosized
protocell platform. Data represents mean ± SD, n = 3.
Adapted and
25
reproduced with permission. © 2016, The American Chemical Society.
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appear to lose EGFR expression over time (Figure 5.15 and Figure 5.1A – red
arrow); therefore, the remaining viable cells in the maximum dose tested (50 µg
protocells / 30 µM GEM) (Figure 5.14A) are likely to be EGFR negative.
To test targeted binding and cargo delivery in a complex living system, we
injected the CAM with fluorescent labelled REH-EGFR cells followed after 30
minutes by injection of YO-PRO®-1 loaded anti-EGFR protocells. Prior to
intravital imaging a lectin vascular stain was injected to provide contrast in the
blood vessels. Intravital fluorescent imaging of the steps of binding,
internalization, and cargo release was performed at 4 hours and 16 hours post ex
ovo injection based on in vitro experiments that showed binding in as little as five
minutes (Figures 5.1A and 5.2B) but YO-PRO®-1 delivery and release to the
cytosol to occur between 1 hour and 8 hours (Figure 5.12). Figure 5.16A shows
target specific binding to an individual REH-EGFR cell trapped within the CAM
vasculature 4 hours post injection with no evidence of cargo release. Figure
5.16B shows targeted binding to an individual REH-EGFR cell 16 hours post
injection, where YO-PRO®-1 is dispersed throughout the cell similar to the in
vitro results (Figure 5.12). Additional figures in Appendix B.5 illustrate further
evidence supporting targeted delivery ex ovo. To better illustrate the targeted
protocell binding, internalization, and cargo release at 16 hours, we imaged 0.25
µm sections of a targeted cell and stacked the images into a video (Video S3)
reported in the Supporting Information, by Durfee et.al.25
We recognize the need to assess the targeted killing of REH-EGFR cells
by anti-EGFR GEM-loaded protocells in an animal model; however, determining

Figure 5.15 – Evidence of EGFR Expression Loss in REH-EGFR Cells
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Figure 5.15 – Flow cytometry analysis of EGFR expression in REH-EGFR
cells as detected by binding of a PE-conjugated anti-EGFR antibody. Rightshifted histogram (blue) shows a majority of the population to be expressing
EGFR.

However, a minority population (red arrow) does not shift

correspondingly likely due to REH-EGFR cells that have lost EGFR
expression.

Adapted and reproduced with permission.25

American Chemical Society.

© 2016, The

Figure 5.16 – Targeted Cargo Delivery Ex Ovo
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Figure 5.16 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model showing green YO-PRO®-1 cell impermeant cargo loaded, red
fluorescent EGFR-targeted protocells binding to and releasing cargo within
REH-EGFR cells in a live animal model. A1) Fluorescent overlay of (blue)
REH-EGFR cell, (red) protocell, (green) YO-PRO®-1 cargo, (lavender) lectin
vascular stain at 4 hours post injection. A2) Red channel shows protocell
fluorescence, and A3) green channel shows YO-PRO®-1 fluorescence
associated with the protocells.

However, after 16 hours, B1) fluorescent

overlay shows release of YO-PRO®-1 cargo within the cell. B2) Red channel
shows protocell fluorescence at 16 hours and B3) green channel shows YOPRO®-1 release into the cell. Images acquired at 63x magnification, Scale
bar = 5 μm.

Adapted and reproduced with permission. 25

American Chemical Society.

© 2016, The

See Appendix B.5 for more images of YO-

PRO®-1 delivery to REH-EGFR cells in the CAM.
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conclusively that protocells are directly responsible for killing target cells in the ex
ovo system is difficult, since many of the cells are eliminated by the chick
immune system and possess a limited life-span in this host. Further targeted
delivery studies in a murine leukemia model to test protocell co-localization and
disease elimination must be evaluated. Nonetheless, our demonstrated highly
specific targeted drug delivery in vitro combined with surrogate drug delivery ex
ovo provide compelling evidence for the single-cell targeting utility of the
monosized protocell therapeutic delivery platform.
5.2.3 Testing the “Plug-and-Play” Capability of Our Cell-Targeting Strategy
After confirmation that our targeting strategy was not influenced by the
type of cell line used, we were interested in determining the ease of switching
cell-targets, in an effort to engineer a disease agnostic nanocarrier platform. To
achieve this goal, as a model system, we chose a human T cell leukemia cell line
(MOLT4) that was engineered to express the CD19 receptor (MOLT4-CD19) and
we compared protocell interactions with MOLT4-CD19 cells to the parental
(CD19-negative) cell line so as to have a matched negative control for our
experiments. In addition, we tested binding on a native CD19 expressing human
B cell precursor leukemia (NALM6).
We used the same NeutrAvidin/biotin targeting chemistry illustrated in
Figure 2.1 and the same amine functionalized SLB described earlier (Table 2.1),
however, we substituted Biotin Anti-Human CD19 Antibody (Biolegend, CA) or
custom synthesized Biotin Anti-CD19 single chain variable fragment (scFv)
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(GenScript, NJ) in place of the Biotin Anti-EGFR Antibody. To examine targeting
specificity, we compared protocell interactions with MOLT4 parental cell line
controls, MOLT4-CD19, and NALM6 cell lines.
To assess the kinetics of CD19-targeted protocell binding, we incubated
either anti-CD19 antibody-labelled protocells or anti-CD19-scFv-labelled
protocells with MOLT4 parental and MOLT4-CD19 cells for various time points in
vitro. We observed detectable binding of the antibody-labelled protocells within 5
minutes and maximal binding at 240 minutes of incubation in complete media
under normal cell culture conditions as assessed by flow cytometry (Figure
5.17). By fluorescence microscopy, we observed comparable cell-specific binding
in vitro of both antibody- and scFv-labelled protocells (Figure 5.18). Similar to
the non-specific binding profile shown previously (Figures 4.2 and 4.3), protocell
binding was not observed in the MOLT4 parental cell line (Figure 5.19). We also
observed cell-specific targeting using antibody-labelled protocells incubated with
NALM6 cells for 1 hour in complete media, under normal cell culture conditions
(Figure 5.20). Therefore, we have demonstrated in vitro targeted binding in
multiple cell lines, with multiple targeting ligands.
Next, we loaded untargeted, antibody-labelled, and scFv-labelled
protocells with YO-PRO®-1 and evaluated targeting and delivery in vitro by
incubating with MOLT4-CD19 cells at multiple time-points. We loaded protocells
with YO-PRO®-1 as described previously in 5.2.2 Protocell Cargo Loading and
Delivery to Targeted Cells. Next, we incubated protocells with MOLT4-CD19
cells in complete media under normal cell culture conditions for 1 hour, 2 hours, 4
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Figure 5.17 – Flow Cytometry Analysis of CD19-Targeted Protocell Specificity

Figure 5.17 – Flow cytometry analysis of A) parental MOLT4 and B) MOLT4CD19 cells incubated with red fluorescent CD19 targeted protocells at multiple
time points. This data illustrates rapid specific in vitro protocell binding to
MOLT4-CD19 in as little as 5 minutes in complete medium, and maximal
protocell accumulation after 240 minutes. C) Mean fluorescence intensity
graph of protocell bind further illustrates CD19-targeted protocell specificity.

Figure 5.18 – Fluorescent microscopy analysis of MOLT4-CD19 cells incubated with either CD19
untargeted, antibody-targeted, or scFv-targeted protocells at multiple time points, fixed and
stained (blue–cells, red–protocells). These data illustrate rapid in vitro protocell binding in
complete medium with a high degree of specificity.
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Figure 5.18 – Comparable Antibody- and scFv-modified Protocell Binding to
MOLT4-CD19 Cells In Vitro

Figure 5.19 – CD19-Targeted Protocell Binding to MOLT4-CD19 Cells

Figure 5.19 – A) Fluorescent microscopy shows absent CD19-targeted
protocell (red) interactions with parental MOLT4 cell line after 1-hour
incubation (blue – CMFDA live cell stain – false colored blue), while B)
targeted protocells (red) exhibit a high degree of binding to MOLT4-CD19 cell
line.
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Figure 5.20 – CD19-Targeted Protocell Binding to NALM6 Cells

Figure 5.20 – A) Fluorescent microscopy shows absent untargeted protocell
(red) interactions with NALM6 cell line (green) after 1-hour incubation 20x
magnification, B) 63x magnification, while C) CD19-targeted protocells (red)
exhibit a high degree of binding to NALM6 cell line at 20x magnification and D)
63x magnification.
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hours, 8 hours, 12 hours, and 24 hours, then fixed and imaged the cells. We
observed no binding, nor cargo delivery in the untargeted protocell control, and
CD19 target-specific delivery of the membrane impermeable cargo, YO-PRO®-1,
after 8 hours of incubation, with more significant cargo release at 12 hours
(Figure 5.21 – See Appendix B.6 for more detailed images of cargo release).
Following the steps described previously, we evaluated the targeted
binding characteristics of the CD19-targeted protocell binding using real-time
intravital imaging in the ex ovo CAM model. We injected blue fluorescent
labelled MOLT4, MOLT4-CD19, or NALM6 cells into the CAM and allowed the
cells to arrest in the capillary bed (~ 30 minutes). Next, we injected (either
antibody- or scFv-labelled) CD19-targeted protocells into the CAM and imaged
protocell flow and binding dynamics after 4 hours in circulation. We observed
protocells flowing in the blood stream but not interacting with the parental MOLT4
cells (Figures 5.22A and B), however, we detect significant binding to the
MOLT4-CD19 cells (Figures 5.22C and D) and NALM6 cells (Figures 5.22E
and F) in the CAM.
Next, we assessed protocell targeted cell specific killing, in vitro. We used
GEM as our cytotoxic agent as described previously, and incubated MOLT4,
MOLT4-CD19, and NALM6 cells with increasing concentrations of CD19-targeted
GEM-loaded protocells in complete media under normal cell culture conditions.
Similar to EGFR-targeted GEM delivery (Figure 5.14A), we detect a CD19-target
specific decrease in cell viability correlating to an increase in CD19-targeted
protocell concentration in both antibody- and scFv-labelled systems (Figure

Figure 5.21 – Fluorescent microscopy analysis of MOLT4-CD19 cells incubated with either CD19
untargeted, antibody-targeted, or scFv-targeted protocells at multiple time points, fixed, and
stained (blue–cells, red–protocells, green- YO-PRO®-1). We observe protocell binding at 1 hour in
complete medium, with cargo release occurring between 8 and 24 hours. See Appendix B.6 for
more select detailed images.
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Figure 5.21 – Comparable Antibody- and scFv-modified Protocell Binding and
Cargo Delivery to MOLT4-CD19 Cells In Vitro
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Figure 5.22 – Targeted Protocells bind MOLT40CD19 and NALM6 Cells in the
CAM

Figure 5.22 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model reveal stable circulation of CD19 targeted antibody- and scFvmodified protocells (red) avoiding MOLT4 cells and binding to CD19 positive
cells MOLT4-CD19 and NALM6 (blue) in circulation at 4 hours. Additional flow
and binding images in Appendix B.7.
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5.23). Since we had already verified GEM was responsible for the cell killing as
opposed to the protocell itself, using EGFR-targeted protocells with REH and
REH-EGFR cells (Figure 5.14C), we did not examine the effect of the unloadedprotocell on MOLT4, MOLT4-CD19, and NALM6 cell lines.
Next, we loaded the protocells with YO-PRO®-1 and evaluated targeting
and delivery in an ex ovo system. We injected the CAM with fluorescent labelled
MOLT4-CD19 cells, then 30 minutes later, injected YO-PRO®-1 loaded antibodyor scFv-labelled CD19-targeted protocells. We used intravital imaging a lectin
vascular stain to provide contrast in the blood vessels. Intravital fluorescent
imaging of binding, internalization, and cargo release were taken at 30 hours
(MOLT4-CD19) and 20 hours (NALM6) post ex ovo injection. After 30 hours, we
observe YO-PRO®-1 dispersed throughout MOLT4-CD19 cells (Figure 5.24)
and 20 hours with NALM6 cells (Figure 5.25), similar to the EGFR-targeted
cargo release in the CAM (Figure 5.16). The differences in cargo release
between the two cell lines may be due to the artificial expression of CD19 on the
MOLT4 cell line, since NALM6 has native CD19 expression, it is likely to possess
a more complete CD19-mediated internalization system, therefore more rapid
internalization and cargo release.
These results demonstrate the “plug-and-play” simplicity of target
modification to the protocell platform, and further support the advantages of the
SLB to prevent non-specific cell interactions that are paramount to a disease
agnostic drug-delivery nanocarrier platform.

Figure 5.23 – CD19-Targeted Drug Delivery and Cell Viability Assessment
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Figure 5.23 - Maintained viability of CD19 negative MOLT4 cells and
decrease in viability of MOLT4-CD19 and NALM6 cells with increasing
concentration of GEM loaded CD19-targeted protocells.

Viability was

assessed at 48 hours. Viability data supports EGFR-targeted killing described
in Figure 5.14 and further highlights target specific delivery of cytotoxic cargo
using the monosized protocell platform. Data represents mean ± SD, n = 3.

167
Figure 5.24 – CD19-Targeted Cargo Delivery to MOLT4-CD19 Cells Ex Ovo

Figure 5.24 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model showing green YO-PRO®-1 cell impermeant cargo loaded, red
fluorescent CD19 antibody- and scFv-targeted protocells binding to and
releasing cargo within MOLT4-CD19 cells in a live animal model. A) and B)
Green channel shows YO-PRO®-1 fluorescence associated with the
protocells, C) and D) Red channel shows protocell fluorescence, and E) and
F) show fluorescent overlay of (blue) MOLT4-CD19 cell, (red) protocell,
(green) YO-PRO®-1 cargo, (lavender) lectin vascular stain at 30 hours post
injection. Images acquired at 63x magnification.

Figure 5.25 – CD19-Targeted Cargo Delivery to NALM6 Cells Ex Ovo
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Figure 5.25 – Intravital fluorescent microscopy images acquired ex ovo in the
CAM model showing green YO-PRO®-1 cell impermeant cargo loaded, red
fluorescent CD19 antibody- and scFv-targeted protocells binding to and
releasing cargo within NALM6 cells in a live animal model. A) and B) Green
channel shows YO-PRO®-1 fluorescence associated with the protocells, C)
and D) Red channel shows protocell fluorescence, and E) and F) show
fluorescent overlay of (blue) NALM6 cell, (red) protocell, (green) YO-PRO®-1
cargo, (lavender) lectin vascular stain at 20 hours post injection. Images
acquired at 63x magnification.
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5.3 Materials and Methods
5.3.1 Materials
All chemicals and reagents were used as received. See all protocell
synthesis and assembly materials listed in 2.3.1 Materials. All chemicals and
reagents were used as received. Ammonium hydroxide (NH4OH, 28 – 30 %), 3aminopropyltriethoxysilane (98 %, APTES), ammonium nitrate (NH4NO3),
benyldimethylhexadecylammonium chloride (BDHAC), ncetyltrimethylammonium bromide (CTAB), N,N-dimethyl formamide (DMF),
dimethyl sulfoxide (DMSO), rhodamine B isothiocyanate (RITC), tetraethyl
orthosilicate (TEOS), Triton X-100, and Buffer solution pH 5.0 (citrate buffer)
were purchased from Sigma-Aldrich (St. Louis, MO). Hydrochloric acid (36.5 – 38
%, HCl) was purchased from EMD Chemicals (Gibbstown, NJ). Absolute (99.5
%) and 95 % ethanol were obtained from PHARMCO-AAPER (Brookfield, CT).
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-snglycero-3phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000] (ammonium salt) (DOPE-PEG2000), 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (ammonium salt) (DSPE-PEG2000), 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2000-NH2)
phospholipids and cholesterol (chol, ovine wool, > 98 %) were purchased from
Avanti Polar Lipids (Birmingham, AL). Hoechst 33342, Traut’s reagent, YOPRO®-1, and maleimide-activated NeutrAvidin protein were obtained from
Thermo Scientific (Rockford, IL). Alexa Fluor®488 phalloidin, CellTracker™ Blue
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CMAC dye, and CellTracker™ green CMFDA dye were purchased from Life
Technologies (Eugene, OR). Heat inactivated fetal bovine serum (FBS), 10X
phosphate buffered saline (PBS), 1X trypsin-EDTA solution, and penicillin
streptomycin (PS) were purchased from Gibco (Logan, UT). Dulbecco’s
Modification of Eagle’s Medium with 4.5 g/L glucose, L-glutamine and sodium
pyruvate (DMEM) and RPMI-1640 medium were obtained from CORNING
cellgro (Manassas, VA). Gemcitabine (GEM) was purchased from LC
Laboratories (Woburn, MA). Anti-EGFR antibody [EGFR1] (Biotin) (ab24293)
was purchased from Abcam (Cambridge, MA). Biotin Anti-Human CD19 Antibody
[HIB19] was purchased from Biolegend (San Diego, CA) and Biotin Anti-CD19
single chain variable fragment (scFv) (GenScript, NJ). CellTiter-Glo® 2.0 Assay
was purchased from Promega (Madison, WI). DyLight 649 Lens Culinaris
Agglutinin was purchased from Vector Laboratories (Burlingame, CA). SpectraPor® Float-A-Lyzer® G2 Dialysis Device MWCO: 3.5 – 5 kD was purchased from
Spectrum Laboratories Inc. (Rancho Dominguez, CA).
5.3.2 Anti-EGFR / Anti-CD19 Protocell Preparation
First, DSPC:chol:DSPE-PEG-NH2 liposomes were prepared according to
the method described previously. Next, a ratio (2:1, w:w) of DSPC:chol:DSPEPEG2000-NH2 liposomes to bare fluorescent-labeled Hexagonal mMSNP were
combined in a conical tube at room temperature for 30 minutes. The excess
liposomes were removed by centrifugation (15,000 x g, 10 minutes). The pelleted
protocells were redispersed in 1 mL of PBS with bath sonication. To convert the
surface -NH2 to -SH groups, 50 µL of freshly prepared Traut’s reagent (250 mM
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in PBS) was added to the protocells. After 1 hour, the particles were centrifuged,
and the supernatant was removed. The particles were again redispersed in 1 mL
of PBS. Then, 0.15 mg of maleimide-activated NeutrAvidin protein was added to
0.25 mL of thiolated protocells and incubated at room temperature for 12 hours.
The NeutrAvidin conjugated protocells were washed with PBS via centrifugation
and suspended in 0.25 mL of PBS. Then, 50 µL of biotinlyated EGFR antibody
(0.1 mg/mL) or 10 µL biotinylated CD19 antibody (0.5 mg/mL) was mixed with 50
µL of NeutrAvidin conjugated protocells for at least 30 minutes. Finally, the
antibody conjugated protocells were pelleted and redispersed in 100 µL PBS for
in vitro targeting experiments.
5.3.3 Targeted Protocell Biocompatibility Assessment
To examine the biocompatibility of anti-EGFR targeted protocells in vitro,
we incubated ~ 1.5 x 105 cells/mL of REH and REH-EGFR cell lines with either
12.5, 25, 50, 100, and 200 µg/mL of anti-EGFR targeted protocells in complete
medium for 1 hour at 37 °C. Cells were washed twice in complete media and
transferred to a 96-well plate for 24 hours at 37 °C. Cell viability was assessed by
CellTiter-Glo® 2.0 Assay as measured by BioTek microplate reader. The cell
viability was calculated as a percentage of non-protocell treated sample.
5.3.4 In Vitro Targeting Comparison of REH and REH-EGFR Cell Lines
The human leukemia cell lines, REH and REH-EGFR24 were a kind gift
from Professor David F. Stern, Yale University. The REH and REH-EGFR cells
were suspended in RPMI 1640 supplemented with 10 % FBS media at a
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concentration of ~ 5 x 105 cells/mL. Then one mL of cells was incubated with
either NeutrAvidin terminated protocells or anti-EGFR protocells at 10 µg/mL for
5, 15, 30, and 60 minutes respectively at 37 oC under 5 % CO2. The
nanoparticle-treated cells were pelleted using a benchtop centrifuge, washed
with PBS twice. Cells were fixed in 4 % paraformaldehyde for 5 minutes, then
washed in PBS, then permeabilized with 0.1 % Triton X100 for 5 minutes. The
cell cytoskeleton and nuclei were stained by 0.1 mM of Alexa Fluor®488
phalloidin in PBS for 15 minutes, then washed in PBS, followed by 1.6 µM
Hoechst 33342 in PBS for 10 minutes, followed by a final wash in PBS. Stained
cells were imaged on a glass slide using the Zeiss AxioExaminer upright
microscope. Binding quantification of targeted protocells was determined by a
fluorescence shift measured by a BD Accuri™ C6 flow cytometer.
5.3.5 Single Cell Targeting and Model Drug Delivery in the CAM
First, ~ 1 x 107 of either REH or REH-EGFR cells were suspended in 1 mL
PBS and incubated with 2 µL of CellTracker™ green CMFDA dye (2.7 mM in
DMSO) for 10 minutes at 37 oC. The stained cells were centrifuged, washed, and
suspended in 500 µL of PBS. Next, 50 µL of cell solution was administered to ex
ovo avian embryos via the previously described procedure. After 30 minutes cell
circulation, the anti-EGFR protocells (100 µL, 0.2 mg/mL) were injected into
embryos intravenously. Binding of targeted protocells was assessed by
fluorescence microscopy at 1 hour, 4 hours, and 9 hours using the Zeiss
AxioExaminer upright microscope. To assess internalization and cargo delivery,
REH-EGFR cells were stained with CellTracker™ Blue CMAC dye and injected
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as described above, followed by injection of YO-PRO®-1 loaded RITC labelled
protocells (50 µL, 1 mg/mL). Prior to imaging of we injected with DyLight 645 Len
Culinaris Agglutin lectin stain to visualize the vasculature, we then imaged the
binding, internalization, and cargo release by fluorescence microscopy at 4 hours
and 16 hours using the Zeiss AxioExaminer upright microscope. We used the
same conditions to image CD19-targeted protocell binding using MOLT4,
MOLT4-CD19, and NALM6 cell lines.
5.3.6 Characterization
TEM images were acquired on a JEOL 2010 (Tokyo, Japan) equipped
with a Gatan Orius digital camera system (Warrendale, PA) under a 200 kV
voltage. Flow cytometry data were performed on a Becton-Dickinson
FACScalibur flow cytometer (Sunnyvale, CA). The raw data obtained from the
flow cytometer was processed with FlowJo software (Tree Star, Inc. Ashland,
OR). Hydrodynamic size and zeta potential data were acquired on a Malvern
Zetasizer Nano-ZS equipped with a He-Ne laser (633 nm) and Non-Invasive
Backscatter optics (NIBS). All samples for DLS measurements were suspended
in various media (D.I. water, PBS, and DMEM + 10 % FBS) at 1 mg/mL.
Measurements were acquired at 25 oC or 37 oC. DLS measurements for each
sample were obtained in triplicate. The Z-average diameter was used for all
reported hydrodynamic size measurements. The zeta potential of each sample
was measured in 1xPBS using monomodal analysis. All reported values
correspond to the average of at least three independent samples. The
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fluorescence images were captured with a Zeiss AxioExaminer fixed stage
microscope (Gottingen, Germany).
5.3.7 In Vitro Targeting Comparison of Ba/F3 and Ba/F3-EGFR Cell Lines
The murine precursor B cell ALL cell lines, Ba/F3 and Ba/F3-EGFR24 were
a kind gift from Professor David F. Stern, Yale University. The Ba/F3 and Ba/F3EGFR cells were suspended in RPMI 1640 supplemented with 10 % FBS media
at a concentration of ~ 1 x 106 cells/mL. Then one mL of cells was incubated with
anti-EGFR protocells at 5 µg/mL for 1 hour at 37 oC under 5 % CO2. The cell
nuclei and membrane were stained by 1 µL of Hoechst 33342 (1.6 mM in DI) and
2 µL of CellTracker™ green CMFDA dye (2.7 mM in DMSO) for 10 minutes. The
nanoparticle-treated cells were pelleted using a benchtop centrifuge, washed
with PBS twice, and dispersed in PBS. The live cells were imaged on a glass
slide using the Zeiss AxioExaminer upright microscope. To further examine the
specificity of targeted protocells, the binding of particles was determined by a
fluorescence shift measured by a Becton-Dickinson FACScalibur flow cytometer.
5.3.8 Cargo Loading and Release Kinetics
Model drug loading was achieved by adding 1 % volume YO-PRO®-1 (1
mM in DMSO) to mMSNPs (1 mg/mL in H2O) and stored for 12 hours at 4 °C.
After loading, targeted protocells were prepared using method described earlier
in Anti-EGFR targeted protocell preparation. We observed a color change in the
pelleted YO-PRO®-1 loaded protocells and did not observe any color in the
supernatant during protocell assembly. We suspect that the interaction between
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YO-PRO®-1 and mMSNPs to be largely driven by electrostatics, since YOPRO®-1 carries a positive charge. Moreover, YO-PRO®-1 is membrane
impermeable, therefore, it should remain encapsulated by the SLB of the
protocell until it is broken down in the intracellular environment. To quantify YOPRO®-1 loading, protocells were pelleted by centrifugation and resuspended in
DMSO with bath sonication, this step was repeated twice. Supernatants were
pooled and concentration was determined using a microplate reader
fluorescence measurement at 480/510 nm. We used a 3.5 – 5 kDa MWCO
Float-A-Lyzer to evaluate GEM release kinetics in either PBS (pH 7.4) or citrate
buffer (pH 5.0). GEM was encapsulated into protocells as described above, then
protocells were loaded into Float-A-lyzers and sealed in 50 mL conical tubes
containing either PBS or citrate buffer, and stored at 37 °C while stirring. We
removed 0.5 mL of dialysate for 265 nm absorbance analysis on a BioTek
microplate reader at multiple time points, then added 0.5 mL of fresh dialysate
solution to the conical tube. To assess protocell size at 24 hours and 72 hours
we removed sample from the Float-a-Lyzer, and measured the hydrodynamic
size on Malvern Zetasizer Nano ZS, then placed back inside the Float-a-Lyzer
and stored at 37 °C while stirring. Consistent with findings reported by Meng
et.al,20 we did not see evidence of drug precipitation and we determined the
effective release of GEM by cell viability analysis, in addition, our loaded and
targeted protocell maintained monodispersity.
5.3.9 Targeted Protocell GEM Delivery and Cytotoxicity Assessment
We incubated ~ 1.5 x 105 cells/mL of REH and REH-EGFR cell lines with
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either 0, 1, 5, 10, 25, or 50 µg/mL of GEM loaded (~ 15 % w/w) anti-EGFR
targeted protocells in complete medium for 1 hour at 37 °C. We used the same
conditions for CD19-targeted delivery to MOLT4, MOLT4-CD19, and NALM6
cells. Cells were centrifuged (500 x g, 3 minutes) and washed twice in complete
media and transferred to a white 96-well plate for 24 hours at 37 °C. In
comparison, we incubated ~ 1.5 x 105 cells/mL of REH and REH-EGFR cell lines
with either 0, 0.6, 3, 6, 15, or 30 µM of free GEM, the equivalent doses based on
15 % (w/w) GEM loading into protocells, under identical experimental conditions.
Cell viability was assessed by CellTiter-Glo® 2.0 Assay as measured by BioTek
microplate reader. The cell viability was calculated as a percentage of nonprotocell treated sample.
5.3.10 In Vitro Internalization and Cargo Release Assay
REH-EGFR cells were suspended in RPMI 1640 supplemented with 10 %
FBS media at a concentration of 5 x 105 cells/mL. Then one mL of cells was
incubated with YO-PRO®-1 loaded, RITC-labelled anti-EGFR protocells at 10
µg/mL for 60 minutes at 37 °C, washed twice in media to remove unbound
protocells, and incubated for 1, 8, 16, and 24 hours respectively at 37 °C under 5
% CO2. The protocell-treated cells were pelleted using a benchtop centrifuge, at
each time point, and resuspended in an acid wash solution (0.2 M acetic acid,
0.5 M NaCl, pH 2.8) and incubated on ice for 5 minutes. Cells were then washed
twice with PBS by centrifugation and protocell internalization was assessed by a
red fluorescence shift and cargo release was assessed by a green fluorescence
shift as measured by a BD Accuri™ C6 flow cytometer. Additionally, live cells
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were imaged on a glass slide using the Leica DMI3000 B inverted microscope.
We used the same conditions for CD19-targeted delivery to MOLT4, MOLT4CD19, and NALM6 cells.
5.3.11 In Vitro Targeting Comparison of MOLT4, MOLT4-CD19, and NALM6
Cell Lines
The MOLT4, MOLT4-CD19, and NALM6 cells were suspended in RPMI
1640 supplemented with 10 % FBS media at a concentration of ~ 5 x 105
cells/mL. Then ~ 5 x 105 cells were incubated with either NeutrAvidin terminated
(untargeted) protocells, CD19-targeted antibody-, or scFv-modified protocells at
10 µg/mL for 5, 10, 15, 30, 60 minutes, 2, 4, 8, 12, or 24 hours respectively at 37
oC

under 5 % CO2. The nanoparticle-treated cells were pelleted using a

benchtop centrifuge, washed with PBS twice. Cells were stained with CMAC
(live cell stain) then fixed in 4 % paraformaldehyde for 5 minutes, then washed in
PBS. Stained cells were imaged on a glass slide using the Zeiss AxioExaminer
upright microscope. Binding quantification of targeted protocells was determined
by a fluorescence shift measured by a BD Accuri™ C6 flow cytometer and
analyzed using FlowJo software.
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CONCLUSIONS AND FUTURE DIRECTIONS
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6.1 Conclusions
The modular design of protocell constructs promises a new drug and
disease agnostic platform for customized delivery and controlled release of
multiple types of cargos and cargo combinations. Packaging drugs within MSNP
core protected by the SLB may enable the re-purposing of drugs that have to
date failed clinical trials due to poor solubility, high toxicity, and/or susceptibility to
degradation. The supported bilayer can retain and protect fragile and/or highly
soluble cargos and enable triggered release of the cargo upon acidification within
the tumor or tumor microenvironment. The ability to add imaging agents to the
core of the protocells gives rise to the potential for more specific imaging agents
and even the development of theranostics which can provide both imaging and
therapy simultaneously. The modularity of the protocell size, shape, pore
architecture and surface chemistry further suggest applications in personalized
medicine requiring individualized cargo combinations, targeting, and release
profiles. However, the modularity and versatility of protocell technology means
that there are many factors which must be accounted for in assessing
biocompatibility, toxicity, drug release, and utility in vivo before protocell
technology can be applied in patient populations.
Here, by systematically evaluating the influence of SAlipid:SAsilica and ionic
strength on vesicle fusion to MSNPs, we established a robust processing
protocol to prepare colloidally stable mMSNP supported lipid bilayers aka
protocells characterized by size uniformity (PdI < 0.1) and long-term stability in
biologically relevant media. The protocol we developed (SA lipid:SAsilica ≈ 2:1 and
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ionic strength = 40 mM) using prismatic Hexagonal mMSNPs was shown to be
transferable to MSNPs of differing size, shape, and pore morphology. Only for
mMSNPs prepared with the largest pores (~ 18 nm) did we find fusion not to
occur – presumably due to reduced van der Waals and electrostatic interactions
and/or surface roughness arrested bilayer spreading.
Having established a robust process to prepare monosized protocells, we
evaluated their long-term stability in biologically relevant media in vitro as well as
in ex ovo and in vivo models and systems. We found that zwitterionic SLBs
prepared with or without PEG conferred excellent stability to the protocells
compared to the parent mMSNP. DSPC-based SLBs were shown to have longerterm stability than DOPC-based protocells in PBS at 37°C. However, DOPCbased protocell stability was restored by the removal of soluble oxygen.
Furthermore, protocells prepared with both unsaturated DOPC and saturated
DSPC SLBs were stable for over 72 hours in FBS enriched media suggesting
that preparation and storage in de-oxygenated buffer or exposure to proteins
prior to use would allow either formulation to be implemented in vivo depending
on the desired characteristics of the specific application. While saturated SLBs,
with demonstrated stability in standard PBS are easier to prepare and store, we
believe protocells prepared with unsaturated SLBs could be used for in vivo
targeting, where the fluid bilayer could support lateral diffusion of targeting
ligands, enabling high avidity binding with low targeting ligand density, as
previously reported in vitro.1
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The behavior of DSPC-PEG-based protocells was assessed ex ovo in the
CAM model whose diverging and converging vasculature recapitulates features
of the liver and spleen and whose immune system is replete with professional
phagocytic cells including Kupffer cells and sinusoidal macrophages. High-speed
intravital imaging of protocells and target cells injected into the vasculature of the
CAM model allowed direct observation of circulation, non-specific binding to the
endothelium, uptake by white blood cells, and binding to target cells in a complex
setting, containing blood proteins and a developing immune system. While in
vitro assessment is standard practice and provides important information, we
contend it lacks the complexity to accurately forecast in vivo outcomes. For
example, by comparing monosized protocells with highly size polydisperse
protocells, we demonstrated size monodispersity to be important for avoiding
arrest in the capillary bed and uptake by immune cells. Monosized DSPC-PEGbased protocells, shown to be stable within complex CAM and in vivo mouse
models, were conjugated with anti-EGFR antibodies while maintaining size
monodispersity.
Flow cytometry combined with fluorescence microscopy showed a high
degree of binding specificity of EGFR-targeted protocells to REH-EGFR and
Ba/F3-EGFR ALL cells compared to EGFR-negative parental control cells. Using
intravital imaging in the CAM, we directly observed selective binding of EGFRtargeted protocells to individual leukemic cells followed by delivery of a
membrane impermeant cargo, while avoiding non-specific binding to endothelial
cells and uptake by immune cells. Overall, we demonstrate that zwitterionic
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monosized protocells prepared by vesicle fusion on mMSNP cores have longterm stability in complex biological media as judged by intravital imaging in the
experimentally accessible CAM model. Colloidal stability is crucial to achieving
targeting to individual (leukemic) distributed cells, where the EPR effect is
inoperative.
Finally, we demonstrated the highly specific therapeutic efficacy of
targeted protocells by delivery of the cytotoxic anti-cancer drug cargo
gemcitabine to an engineered EGFR-expressing leukemic cell line, while sparing
EGFR-negative parental cells from off-target effects. Further, we confirmed the
biocompatibility of the protocell platform. We believe our optimized monosized
protocell design has great potential for the active targeting, detection and
treatment of highly disseminated metastatic cells including difficult to target
circulating leukemia cells as well as combined passive and active tumor targeting
employing the EPR effect. The logical next steps will include identifying the size
limitations of the protocell platform, testing of alternative targeting conjugation
chemistries, identifying unique targeting ligands for important diseases, and
examining a large array of therapeutic cargo types to be evaluated in vitro, ex
ovo, and ultimately in in vivo models of leukemia, including xenograft and
primagraft model systems.
6.2 Preliminary In Vivo Targeting Experiments
With the success of monosized protocell development and evaluation in a
complex embryonic CAM system, we have started to evaluate the targeted
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binding of protocells in vivo, using MOLT4-CD19 and antibody-labelled protocells
in a leukemia mouse model through a collaboration with the Children’s Hospital
of Philadelphia (CHOP), and funded through a grant from the Leukemia and
Lymphoma Society (LLS). Our preliminary in vitro and ex ovo CD19 targeting
studies are outlined in Chapter 5. The next aim is to undertake in vivo studies of
ALL-targeted protocell and evaluate stability, biodistribution, uptake in normal
and leukemic cells and tissues, and preliminary determinations of pharmacologic
dose range, toxicology, and therapeutic efficacy in ALL xenograft models.
To examine biodistribution and ALL-targeted binding, we injected MOLT4CD19 (cell line expresses green fluorescent marker) xenograft mice with either 1
mg of non-targeted or CD19-targeted protocells and imaged the mice using IVIS
Lumina live animal imaging system at 4 hours post-injection. We detected the
fluorescence of the cells and the protocells in circulation (Figure 6.1). While the
number of mice used in this experiment is not sufficient, the biodistribution profile
of targeted protocells appears more systemic than the untargeted protocells.
The wider biodistribution of targeted protocells could be due to binding with
MOLT4-CD19 cells in circulation; however, a larger study with more mice is
needed to accurately assess the biodistribution of protocells in vivo.
At 48 hours post-injection, mice were sacrificed, blood and tissues were
harvested to assess co-localization of protocells with MOLT4-CD19 cells.
Interestingly, in the ex vivo fluorescence analysis of the long bones, we see a
higher intensity of protocell fluorescence co-localized with the MOLT4-CD19 cells

Figure 6.1 – Live Animal Imaging of Protocell Biodistribution
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Figure 6.1 – IVIS live animal imaging system used to image differential
biodistribution of CD19-targeted and untargeted protocells (red) in the CHOP
MOLT4-CD19 (green) xenograft model. Protocell/MOLT4+CD19 overlay
image shows targeted protocells more systemic than untargeted protocells,
with higher targeted protocell signal in the extremities.
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(Figure 6.2). These preliminary results offer promising insight into the targeting
potential for protocells in vivo. Larger scale experiments are planned in the near
future and will require careful preparation of large batches of protocells to be
loaded with therapeutic cargo to be shipped to CHOP for in vivo validation.
6.3 Future Directions
The modular design of the protocell platform has led to rapid advancement
in this field; however, there are still many areas in which improvements can be
made. For example, modifications can be made to the MSNP core, the external
lipid layer, the targeting chemistry, and the cargo to create unique protocells for
specific applications. Although the protocell has demonstrated utility in
therapeutic delivery for cancer using both in ex ovo2 and in vivo systems,3-5
technological improvements could still be utilized to increase the therapeutic
efficiency. In the case of Leukemia, we created monosized protocells with a
prolonged circulation profile, with the addition of targeting chemistry to target
cells in circulation,2 however, we could use the same size control to optimize
delivery of cancer therapeutics using the EPR effect. Size control could effect or
direct site specific dissemination of protocells to differing body tissues in addition
to the peripheral vasculature and other tissues (liver, spleen, bone marrow)
which may harbor leukemic cells, or, protected tissues which serve as
sanctuaries for leukemic cells (testes, brain) and are frequent sites of recurrent or
relapsed disease following systemic chemotherapy treatment. For example, to
target the bone marrow, a nanoparticle size range of 70 – 200 nm and spherical
or rod shape is desirable; to target the brain and testicular region requires

Figure 6.2 - Ex vivo IVIS analysis 48 hours post-injection of long bones shows protocells/MOLT4-CD19
cells co-localization with higher fluorescent intensity in the targeted protocells in regions containing target
cells, highlighted by red dashed circles. Untargeted protocells also co-localize with MOLT4-CD19 cells,
however the protocell intensity is much lower than that of targeted protocells (yellow dashed circles).
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Figure 6.2 – Ex Vivo Co-localization Imaging
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smaller 40 – 50 nm nanoparticles; to target the spleen and liver spherical
nanoparticles greater than 100 nm in diameter are most effective. 6
In addition to core MSNP size / shape modifications, the multitude of lipid
formulations available for protocell assembly (Table 3.5) allows for a large variety
of surface chemistries which can be used add functional targeting ligands. With
the emergence of new chemical reactions more commonly known as clickchemistry combined with the ability to custom manufacture peptide, single chain
variable fragment antibodies (scFv), antibodies, and other targeting ligands,
many conjugation chemistry options are available to protocell modification.7 In
particular, copper-catalyzed or copper-free click chemistries are of particular
interest for the conjugation of targeted ligands, as they possess the potential to
reach quantitative yields and avoid immunogenicity due to strictly click-reactive
lipids, while still allowing the addition of a wide variety of targeting ligands
(Figure 6.3). While click-chemistry targeting modifications have yet to be
reported in protocell research, they have the potential to greatly increase the
utility of the protocell for in vivo applications.
Although the targeting modification reported in this dissertation has been
shown to be highly specific, and can be used across multiple cell and target
types, some limitations exist with this method. For example, using multiple steps
to modify the lipid head groups with the targeting ligands including centrifugation,
and bath sonication could potentially disrupt the SLB and cause cargo to leak
during the process. In addition, NeutrAvidin is a large globular protein, as are full
length antibodies and both can be recognized by the immune system and could

Figure 6.3 – Targeting Chemistry Strategies Schematic
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Figure 6.3 – New chemistry approaches for coupling ligands to the lipid
bilayer of the protocell. Schematic shows a cross section of a lipid bilayer
containing functional groups that form the basis for: copper (I)-catalyzed
Huisgen 1,3-dipolar cycloaddition ligation (a and b), copper-free click
chemistry ligation (c), Staudinger ligation (d), and tetrazine/trans-cyclooctene
inverse electron demand Diels-Alder cycloaddition (e). Coupling ligands for
each reaction are represented by a red star. Adapted and reproduced with
permission.7 © 2014, The Authors.
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potentially limit the repeated use of the protocell platform due to an adaptive
immune response. Regardless of the success demonstrated using the
NeutrAvidin/Biotin “plug-and-play” targeting strategy, decreasing the size and
number of targeting ligands on the surface would be highly beneficial to a
reusable nanocarrier platform.
In addition to improved targeting chemistry, a comprehensive study in the
delivery of a wide range of therapeutic cargo is needed. The protocell platform,
may provide a second-life for drugs that have failed trials due to insolubility, nonspecific cytotoxicity, and other undesirable side-effects, by sequestering drugs
within the highly porous MSNP surface and sealing cargo within a SLB envelope
until they can be delivered to the target destination. While the delivery of many
cargos by protocells have been demonstrated in vitro, many have yet to be
translated to in vivo systems. Therefore, further studies are needed to examine
the loading, stability, and delivery of a wide variety of therapeutic cargos
including: small molecules (hydrophilic, hydrophobic, neutral, and charged),
proteins (enzymes and toxins), nucleic acids (DNA, mRNA, siRNA, and shRNA),
and aptamers. These cargo-types can be evaluated in vitro, and using ex ovo
methods described in this dissertation, we can rapidly evaluate the potential
behavior of cargo delivery in a complex animal system prior to expensive and
time-intensive in vivo animal experiments.
In addition to the evaluation of different cargo classes, a comprehensive
examination of cargo release or leakage which can lead to toxicity and limit
therapeutic effectiveness must be implemented. A simple method to prevent
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premature leakage from the protocell would be to use a hydrophobic modification
of the MSNP surface, then soaking these hydrophobic cores in an organic
solvent with hydrophobic cargo, followed by the addition of a lipid monolayer and
transferred to an aqueous phase, thereby sealing hydrophilic drugs within a
hybrid-bilayer protocell.8, 9 Another method for controlled drug release which
could allow the protocells to react to the tumor microenvironment is the use of
lipids covalently attached to the MSNP surface through disulfide bonds. This
method provides a controlled release mechanism for cargo only in the presence
of disulfide reducing conditions likely to be present in tumors and endocytic
vesicles.10 Other potential agents such as complex nanomachines or molecular
valves can be incorporated to increase the specificity of drug release from the
MSNP core.11 These technologies have only been tested in in vitro systems, but
have the potential to greatly reduce the toxicity of therapeutic chemotherapy
delivered by the protocell. Although, as we increase the complexity of the
protocell platform, we create more potential failure points, therefore a less
complicated method such as, electrostatic attraction and/or hydrophobic
interactions will likely lead to greater success.
Perhaps the most attractive feature of the protocell is the MSNP core in
which we have fine control over the synthesis and incorporation of diagnostic
components, making protocells ideal imaging and theranostic agents.
Fluorescent-labelled protocells have been used in vivo to examine biodistribution
in a tumor model.3 Further studies varying the size, shape, and SLB composition
have yet to be examined and are crucial in the development of disease specific
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protocells. Moreover, theranostic protocells allow for real-time assessment of the
biodistribution in both normal and diseased tissue, providing invaluable
information for the development and monitoring of protocells in a clinical setting.
The ability to synthesize MSNP cores that incorporate a metallic or magnetic
core,11-14 fluorophores,3-5 positron emission tomography (PET) imaging agents,15
or even other nanoparticles such as quantum dots1 would allow the development
of protocells as imaging agents for a variety of imaging technologies.
While this dissertation focuses on the optimization, characterization, and
application of targeted protocells for use in cancer therapeutics, many of the
protocell features discussed have potential for several other applications,
including antiviral and antibacterial therapy, vaccine development, synthetic red
blood cells (i.e. oxygen carriers), diagnostic devices, as well as other nonmedical material applications including energy and surface coating.
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APPENDIX A
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Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual
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A.1 – Calculations to Identify Optimal Liposome to mMSNP Surface Area
Ratio
To estimate the number of particles in solution (n), we employed a shape
applicable model to calculate mMSNP exterior surface area (SA) and volume
(VmMSNP) from dimensional measurements obtained from TEM image analysis (n
= 50), pore volume (Vpore) measurements from nitrogen adsorption–desorption
isotherms, a mesoporous silica density (𝜌) of 2 g/cm3, and a sample mass (m).
The equations below were used to estimate the number of particles in solution
per unit concentration (mg/mL) and the external particle surface areas (nm2)
used in determination of the lipid:silica surface area ratio.
A.1.1 Hexagonal mMSNP Calculations
𝑆𝐴𝑚𝑀𝑆𝑁𝑃 = 6𝑎ℎ + 3√3 ∗ 𝑎2
𝑉𝑚𝑀𝑆𝑁𝑃 =

𝑛𝑚𝑀𝑆𝑁𝑃 =

3√3 2
𝑎 ℎ
2

(𝑚⁄𝜌) + (𝑚 ∗ 𝑉𝑝𝑜𝑟𝑒 )
𝑉𝑚𝑀𝑆𝑁𝑃

For example – a = 44.80 nm, h = 50.68 nm, m = 0.1 g, 𝜌 = 2 g/cm3, Vpore = 0.83
cm3/g
SAmMSNP = 2.41 x 104 nm2, VmMSNP = 2.64 x 105 nm3, nmMSNP = 4.99 x 1014
mMSNPs
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A.1.2 Spherical mMSNP Calculations
𝑆𝐴𝑚𝑀𝑆𝑁𝑃 = 4𝜋(𝑑⁄2)2
𝑉𝑚𝑀𝑆𝑁𝑃 =

𝑛𝑚𝑀𝑆𝑁𝑃 =

4
𝜋(𝑑⁄2)3
3

(𝑚⁄𝜌) + (𝑚 ∗ 𝑉𝑝𝑜𝑟𝑒 )
𝑉𝑚𝑀𝑆𝑁𝑃

For example, (5 nm pore mMSNP) – d = 99.32 nm, m = 0.1 g, 𝜌 = 2 g/cm3, Vpore
= 0.86 cm3/g
SAmMSNP = 3.11 x 104 nm2, VmMSNP = 5.17 x 105 nm3, nmMSNP = 2.69 x 1014
mMSNs
A.1.3 Rod-like mMSNP Calculations
𝑆𝐴𝑚𝑀𝑆𝑁𝑃 = 2𝜋(𝑤 ⁄2)(𝑙) + 2𝜋(𝑤 ⁄2)2
𝑉𝑚𝑀𝑆𝑁𝑃 = 𝜋(𝑤)2 𝑙
𝑛𝑚𝑀𝑆𝑁𝑃 =

(𝑚⁄𝜌) + (𝑚 ∗ 𝑉𝑝𝑜𝑟𝑒 )
𝑉𝑚𝑀𝑆𝑁𝑃

For example – w = 81.97 nm, l = 176.68 nm, m = 0.1 g, 𝜌 = 2 g/cm3, Vpore = 0.87
cm3/g
SAmMSNP = 5.69 x 104 nm2, VmMSNP = 9.77 x 105 nm3, nmMSNP = 1.42 x 1014
mMSNPs
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Next we estimated the surface area (SA) of liposomes by calculating the
number of lipid molecules per unit mass (m) and assumed 0.59 nm2 to represent
the area of a single lipid head group. We also assume cholesterol area does not
contribute to the external surface area of liposomes. Finally, we assume the
internal surface area (SAinnner) is equal to half the total SA of the liposomes per
unit mass.

𝑀𝑜𝑙𝑒𝑠𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡 =

𝑚𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡
𝑁
𝑀𝑊𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡 𝐴

𝑛

𝑆𝐴𝑖𝑛𝑛𝑒𝑟 = (0.59 ∗ ∑ 𝑀𝑜𝑙𝑒𝑠𝑖 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡 )/2
𝑖=1

For example – DSPC:chol:DSPE-PEG2000 liposomes – mol ratio (49:49:2)
DSPC MW = 790.145 g/mol, DSPE-PEG2000 MW = 2805.497 g/mol, m = 0.2 g
SAinnner = 2.54 x 1019 nm2

To estimate the interior liposome surface area to total exterior mMSNP
surface area, we multiplied the SAmMSN by the number of mMSNPs (n) per unit
mass, then we divided liposomes interior SA by mMSNPs surface area per unit
mass at the 2:1 mass ratio experimentally determined as optimal (See Figure
3.3).
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𝑆𝐴𝑡𝑜𝑡𝑎𝑙 𝑚𝑀𝑆𝑁𝑃𝑠 = 𝑛𝑚𝑀𝑆𝑁𝑃 ∗ 𝑆𝐴𝑚𝑀𝑆𝑁𝑃
𝑆𝐴 𝑟𝑎𝑡𝑖𝑜 = 𝑆𝐴𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒 𝑖𝑛𝑛𝑒𝑟 ⁄𝑆𝐴𝑡𝑜𝑡𝑎𝑙 𝑚𝑀𝑆𝑁𝑃𝑠
For example – Hexagonal mMSNPs (calculated above) m = 0.1 g, SAmMSN = 2.41
x 104 nm2, nmMSN = 4.99 x 1014 mMSNPs, Liposomes (calculated above) SAinnner
= 2.54 x 1019 nm2
SA ratio = 2.11 : 1
The calculated mass of fluorescent liposome (DSPC:chol:DSPEPEG2000:22-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-23,24-Bisnor-5Cholen-3β-Ol (NBD-Chol) – 54:43:2:1 mol %) to mMSNP (118.7 nm) is 0.263 to
1. The experimental quantification of mass of fluorescent labeled liposome to
mMSN is 0.276 to 1, as measured from fluorescence intensity of unbound
liposomes in the supernatant following centrifugation of the protocells compared
to a standard curve generated from known fluorescent liposome concentration.
The calculated and experimental values are within 4.7 % of each other, which is
supportive of our method of surface area ratio calculations.
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A.2 – Calculations to Quantify Surface Area and Pore Volume
The surface area and pore size of MSNPs described in this dissertation
were calculated following the Brunauer-Emmet-Teller (BET) equation and
standard Barrett-Joyer-Halenda (BJH) method.
Example calculations for SA and pore size for Hexagonal mMSNPs below:
First, we generate the data obtained from the adsorption isotherm as a straight
line using quantity adsorbed (Q) in cm³/g at STP, and relative pressure (p/p0)
from 0.05 to 0.1

𝑦=

1
𝑄[(𝑝⁄𝑝0 ) − 1]
𝑥 = 𝑝⁄𝑝0
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Next we use the trendline equation to calculate the monolayer adsorbed
gas quantity (vm) and the BET constant (c). We use the value of the slope (A)
and the y-intercept (I) in the equations below.

𝑣𝑚 =

1
1
=
= 𝟐𝟏𝟒. 𝟐𝟕 𝒄𝒎³/𝒈 𝑺𝑻𝑷
−3
(𝐴 + 𝐼)
(4.63 × 10 + 3.7 × 10−5 )
𝐴
4.63 × 10−3
𝑐 = 1+ = 1+
= 𝟏𝟐𝟔. 𝟏𝟒
𝐼
3.7 × 10−5

To calculate the surface area (SA), we use the values vm, Avogadro’s
Number (NA), the adsorption cross section of N2 (s) = 0.162 nm2, the molar
volume of the adsorbate gas (V) = 34.65 cm3mol−1 at 77K, and a total of mass of
mMSNPs (a) = 0.183 g.

𝑆𝐴 =

(𝑣𝑚 ∙ 𝑁𝐴 ∙ 𝑠 ∙ 𝑎)
(214.27 ∙ 𝑁𝐴 ∙ 1.62 × 10−19 𝑚2 ∙ 0.0183 𝑔)
=
= 𝟏𝟏𝟎𝟑 𝒎𝟐
𝑉
34.65

BET values are typically calculated by the software used to run the
program. Pore size determination uses a modified Kelvin equation to relate the
amount of adsorbate removed as the p/p0 is decreased. Solving pore size using
BJH equations contains many variables and is complicated to solve manually but
can simply be tabulated by the same software used to run the program.
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A.3 – Calculations to Quantify Percent Hemolysis
Whole human blood (5 mL) stabilized in K2EDTA tubes (BD Biosciences)
and purified by centrifugation at 500 x g for 10 minutes to isolate RBCs from
serum. This step was repeated five times, then RBCs were diluted in 50 mL
PBS. Next, either bare mMSNPs or protocells were added the diluted RBCs and
stored at 37 oC for 3 hours. Samples were centrifuged at 300 x g for 3 minutes,
then 100 µL of supernatant from each sample was transferred to a 96-well plate.
Hemoglobin absorbance was measured using a BioTek microplate reader
(Winooski, VT) at 541 nm. Percent hemolysis was calculated using equation
below. Where negative control = RBCs diluted in PBS, and positive control =
RBCs diluted in D.I. water.

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 = (

𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑏𝑠541 𝑛𝑚 − 𝑁𝑒𝑔. 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑏𝑠541 𝑛𝑚
) × 100%
𝑃𝑜𝑠. 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑏𝑠541 𝑛𝑚 − 𝑁𝑒𝑔. 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑏𝑠541 𝑛𝑚

For example – 100 µg of MSNPs (n = 2) were incubated with RBCs and the
average measurement Abs541 nm = 0.446, the Positive control average Abs541 nm
= 0.5745 and the Negative control average Abs541 nm = 0.034.

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠𝑀𝑆𝑁𝑃 = (

0.446 − 0.034
) × 100% = 𝟕𝟔. 𝟐𝟐 %
0.5745 − 0.034

For example – 100 µg of protocells (n = 2) were incubated with RBCs and the
average measurement Abs541 nm = 0.04, the Positive control average Abs541 nm =
0.5745 and the Negative control average Abs541 nm = 0.034.
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0.04 − 0.034
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠𝑃𝑟𝑜𝑡𝑜𝑐𝑒𝑙𝑙 = (
) × 100% = 𝟏. 𝟏𝟏 %
0.5745 − 0.034
Percent hemolysis experiments were performed using three independent
experiments with (n = 2) for each MSNP / protocell formulation. Values obtained
using equations above were averaged and the mean ± SD were plotted on the
graph in Figure 3.10.
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A.4 – Calculations to Quantify Loading Efficiency of YO-PRO®-1 and GEM
To quantify YO-PRO®-1 loading, protocells were pelleted by centrifugation
and resuspended in DMSO with bath sonication, this step was repeated twice.
Since YO-PRO®-1 is more soluble in DMSO and the SLB is unstable, the wash
steps destabilize the protocell membrane and extract the YO-PRO®-1 from the
pores. Supernatants were pooled and concentration was determined using a
microplate reader fluorescence measurement at 480/510 nm. The fluorescence
numbers obtained were compared to a standard curve generated using a serial
dilution YO-PRO®-1. We calculated a mean 25 % loading efficiency of YOPRO®-1 for protocells used in the model drug delivery experiments in vitro and
ex ovo.
To load and quantify GEM, 0.5 mg of Hexagonal mMSNPs (mmMSNP) were
suspended in 50 µL of GEM dissolved in D.I. water at 10 mg/mL (m0 = 0.5 mg)
and stored for 12 hours at 4 °C. After drug loading, targeted protocells were
prepared using method described earlier in Anti-EGFR targeted protocell
preparation (Details in – 5.3.2 Anti-EGFR protocell preparation). At each
step, supernatant was collected, pooled (v1 = 2.55 mL), and GEM loading was
determined using a microplate reader absorbance measurement at 265 nm. A
standard curve generated from a serial dilution of GEM in PBS (n = 3) was used
to calculate the concentration of GEM in the supernatant. To account for
absorbance signal from non-GEM components in the supernatant, unloaded
protocells were prepared simultaneously under identical conditions and
measured at 265 nm. This absorbance value (Abscontrol) was subtracted from the
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value obtained from supernatant containing GEM (AbsGEM) prior to calculation of
GEM concentration based on standard curve (equation below).

𝑐1 =

(𝐴𝑏𝑠 − 0.0507)
7.7115

For example, we used (mmMSNP = 0.5 mg), and (m0 = 0.5 mg) and we obtained
(AbsGEM = 2.51) and (Abscontrol = 1.18).

𝑐1 =

(2.51 − 1.18) − 0.0507
= 𝟎. 𝟏𝟕 𝒎𝒈/𝒎𝑳
7.7115

The total volume of the pooled supernatant is used to calculate the
amount of GEM in the supernatant where c1 = 0.17 mg/mL and v1 = 2.55 mL (see
equation below).
𝑚1 = 𝑐1 × 𝑣1
𝑚1 = 0.17 × 2.55 = 𝟎. 𝟒𝟑 𝒎𝒈
The supernatant amount (m1) was then subtracted from the starting GEM
amount (m0) to estimate the total amount loaded into protocells (see equation
below)
𝑚𝑙𝑜𝑎𝑑𝑒𝑑 = 𝑚0 − 𝑚1
𝑚𝑙𝑜𝑎𝑑𝑒𝑑 = 0.5 − 0.43 = 𝟎. 𝟎𝟕 𝒎𝒈
To estimate the loading capacity as a percentage of weight we use the
formula below.
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𝑚𝑙𝑜𝑎𝑑𝑒𝑑
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 = (
) × 100 %
𝑚𝑚𝑀𝑆𝑁𝑃
0.07
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 = (
) × 100 % = 𝟏𝟒 % (𝒘/𝒘)
0.5
This experiment was repeated 4 times with different Hexagonal mMSNP
preparations and we determined the average GEM loading capacity of protocell =
15.25 % ± 1.6 % (mean ± SD). While the loading percentage of our protocells is
lower than what was reported by Dr. Nel’s group, our loading conditions contain
half the amount of GEM that was described by the Meng et.al.20 Since GEM is
neutral at physiological pH, and mMSNPs are negatively charged, we do not
suspect an electrostatic interaction to play a significant role in loading, instead
suspect the GEM and mMSNPs will reach an equilibrium state where the small
molecule drug will occupy the high internal space of the pores and will then be
encapsulated with the addition of the lipid bilayer in protocell assembly.
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APPENDIX B
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B.1 – Example TEM Measurements of MSNP Dimensional Features

B.1 – Example image analyzed in ImageJ software, I draw a line along the scale
bar provided by the TEM software, then draw several lines across the long-axis
and short axis of the Hexagonal MSNPs. I used 50 measurements of each
MSNP and calculated the mean ± SD for each particle, and used these
measurements in the size and SA ratio analyses in Table 3.1 and Figure 3.3.
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B.2 – Example TEM Measurements of Bilayer Thickness

B.2 – Example image analyzed in ImageJ software, I draw a line along the scale
bar provided by the TEM software, then draw several lines across the edge of the
high contrast MSNPs across the slightly lower contrast SLB perimeter around the
MSNP. I highlighted 5 regions to show the yellow measurement lines. I used 33
measurements of each protocell shape and calculated the mean ± SD for each
particle, and used these measurements in the bilayer thickness analyses in
Figure 3.4.
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B.3 – Fluorescent Microscopy Imaging of Ba/F3 and Ba/F3-EGFR Cells

B.3 - A) Fluorescent microscopy shows minimal EGFR-targeted protocell (red)
interactions with a non-EGFR expressing BAF cell line after 1-hour incubation
(blue – DAPI stained nuclei, green – phalloidin stained actin), while B) targeted
protocells (red) exhibit a high degree of binding to an EGFR expressing BAF
cell line. Flow cytometry analysis of protocells incubated with C) BAF and D)
BAF-EGFR confirm fluorescent microscopy analysis (grey = no protocell
control, blue = EGFR-targeted protocells). These images correspond to
Figure 5.4.
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B.4 – Additional REH-EGFR Targeted Binding in the CAM Images

B.4 – Intravital fluorescent microscopy images acquired ex ovo in the CAM
model reveal stable circulation of EGFR targeted protocells (red) and binding to
REH-EGFR cells (green) in circulation. Both A) and B) were taken 1-hour post
injection. Highlighted region shows individual protocells in flow and magnifies the
protocell/cell interactions. These images correspond to Figure 5.5.
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B.5 – Additional REH-EGFR Targeted YO-PRO®-1 Delivery CAM Images

B.5 - Intravital fluorescent microscopy images acquired ex ovo in the CAM model
showing YO-PRO®-1 cell impermeant cargo (green) loaded, fluorescent EGFRtargeted protocells (red) binding to and releasing cargo within REH-EGFR cells
(blue) in a live animal model. Lectin vascular stain (lavender) added and
targeting was imaged at 16 hours post injection. Images acquired at 63x
magnification, Scale bar = 5 μm. Figures C) and D) are the same cell imaged in
different focal planes. These images correspond to Figure 5.16.
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B.6 – High Resolution Images of YO-PRO®-1 Delivery to MOLT4-CD19 cells
In Vitro.

B.6 – High resolution imaging of MOLT4 and MOLT4-CD19 (blue) cells
incubated with YO-PRO®-1 loaded CD19 antibody-targeted protocells at 4 and
12-hour time points. There is no significant binding by CD19 targeted protocells
in the parental MOLT4 cell line, however we see significant binding at 4 hours
and 12 hours with YO-PRO®-1 release in the targeted cells only. Inset (bottom
right) highlights a cluster of cells with a high degree of YO-PRO®-1 release.
These images correspond to Figure 5.21.
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B.7 – Additional CD19-targeted Protocells and MOLT4, MOLT4-CD19, and
NALM6 Cell in the CAM

B.7 - Intravital fluorescent microscopy images acquired ex ovo in the CAM
model showing red fluorescent CD19-targeted protocells circulating 4 hours
post-injection not binding to A) parental MOLT4 cells but binding specifically to
B) MOLT4-CD19, and C) NALM6 cells. Lectin vascular stain (lavender)
highlight the CAM vasculature. Images A) and B) acquired at 20x and C) at
63x magnification. Images correspond to Figure 5.22.

